ࡱ> 35./012c :bjbjZZ Ɏ8b\8b\?`33PAPAAAA$AAAPB0DA`D^2EHEHEHER"R Rz0-ARR@ZR@RRPAPAHEHE ZZZRPA8HEAHEZRZZk}XASHE9X~(ב00`~hPYPSSAG RRZRRRRRZRRR`RRRRRRRRRRRRR3> @: MEMORANDUM TO: Arkansas Medicaid Prescribers and Interested Parties  FROM: Suzette Bridges, P.D., Division of Medical Services Pharmacy Program DATE: November 26, 2014 SUBJ: AR Medicaid DUR Board Edits Approved at the October 15, 2014 Meeting: Changes to Existing Prior Authorization (PA) Criteria or Edits; Clinical Edits through the Manual Review PA Process; AEVCS Edits, including Dose-Op Edits, Cumulative Quantity, Daily Dose Edits, Age Edits, or Gender Edits. All criteria for the point of sale (POS) clinical edits can be viewed on the Magellan Medicaid website at HYPERLINK "https://arkansas.magellanrx.com/provider/docs/rxinfo/PACriteria.pdf"https://arkansas.magellanrx.com/provider/docs/rxinfo/PACriteria.pdf. All drug claim edits, such as quantity edits, dose edits, age edits, or gender edits, can be viewed on the Magellan Medicaid website at HYPERLINK "https://arkansas.magellanrx.com/provider/docs/rxinfo/ClaimEdits.pdf"https://arkansas.magellanrx.com/provider/docs/rxinfo/ClaimEdits.pdf. (Reimbursement rates stated in this memo are current as of the writing of this memo; the rates are approximate as they have been rounded to 2 decimals.) The following edits will be effective January 13, 2015 unless otherwise stated. CHANGES TO EXISTING PRIOR AUTHORIZATION (PA) CRITERIA OR EDITS: Kalydeco (ivacaftor) 150 mg tablets: Kalydeco is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. Limitations of use: not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. The FDA approved dose for adults and pediatric patients age 6 years and older is one 150 mg tablet taken orally every 12 hours (300 mg total daily dose) with fat-containing food. The dose of Kalydeco should be reduced to 150 mg once daily for patients with moderate hepatic impairment. See package insert for dose adjustments when prescribing with CYP3A inhibitors. The reimbursement rate is $440.37 per tablet; $880.74/day; $26,422.20/30-day supply; $321,470/yr. Kalydeco will continue to be covered through a manual review PA on a case-by-case basis. The approval criteria have been revised as follows: PA Approval Criteria: Beneficiary must have a diagnosis of cystic fibrosis with gene testing positive for gene mutation in one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; AND Beneficiary must be established on the evidence-based standard of care for the treatment of cystic fibrosis; AND The transaminases, alanine transaminase (ALT) and aspartate transaminase (AST), tests are required at baseline and every 3 months during the 1st year of treatment and then annually thereafter; AND Beneficiary must not use tobacco products; AND Beneficiary must be 6 years of age or older; AND Daily dose edit not to exceed 2:1; cumulative quantity edit 60/30 days supply. PA Renewal Criteria for Continuation of Ivacaftor Therapy: The beneficiary has been compliant with ivacaftor therapy, as determined by refill claims history or as reported by requestor; AND Beneficiary must remain tobacco free; AND Documentation submitted to substantiate the following: Stabilization or improvement in lung function (FEV1); Stabilization or improvement in weight gain; Reduction in exacerbations/hospitalizations. Magellan Pharmacy Call Center at 800-424-7895. Advair Diskus (fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder) 100/50 inhaler: Advair Diskus, all strengths, and Advair HFA are now non-preferred drugs on the AR Medicaid Prescription Drug Preferred Drug List (PDL) program. Advair Diskus 100/50 is indicated for pediatric patients aged 4 to 11 years with asthma who are not controlled on an inhaled corticosteroid. The dosage is one inhalation of Advair Diskus 100/50 twice daily, approximately 12 hours apart. The ICS/LABA agents recently selected for preferred status, Dulera and Symbicort, are indicated in patients aged 12 years and older. The PA approval criteria below were developed to fill the gap for children age 4 years through 11 years of age because the two preferred agents on the PDL are indicated for age 12 years and older. No point-of-sale PA approval criteria were developed for beyond 11 years of age because the preferred agents, Dulera and Symbicort, are indicated for patients 12 years of age and older. The reimbursement rate for Advair Diskus 100/50, 60 inhalation container, is $235.80 per container; 12 months supply is $2,829.60. Advair Diskus 100/50 is covered on the PDL as a non-preferred drug with criteria. Point-of-sale (POS) PA approval criteria for Advair Diskus 100/50 are as follows: Criterion 1: Beneficiary is between 4 years through 11 years of age; AND A paid drug claim is found in Medicaid drug history in the last 6 months for a preferred ICS/LABA agent (Dulera or Symbicort) or a paid drug claim in Medicaid history for Advair Diskus (any strength) or Advair HFA (any strength); OR Criterion 2: Beneficiary is between 4 years through 11 years of age; AND One of the following paid claim scenarios is found in Medicaid drug claims history: e" Three inhaled corticosteroid claims in the last 120 days; OR e" Three oral steroid claims in the last 120 days; OR Combination for e" three claims (as defined below) in the last 120 days: One inhaled corticosteroid + 2 oral steroids Two inhaled corticosteroids + 1 oral steroids EBRx PA Call Center Local at 501-526-4200 or Long Distance Toll Free at 1-866-250-2518. Veramyst 27.5 mcg Nasal Spray (fluticasone furoate) and Nasonex 50 mcg Nasal Spray (mometasone furoate): The nasal corticosteroids drug class is a drug class that is included on the AR Medicaid Prescription Drug PDL program. Due to changes in the marketplace, the remaining preferred drug in this drug class is fluticasone propionate 0.05% nasal spray (generic Flonase 0.05% Nasal Spray), which is indicated for the management of the nasal symptoms of seasonal and perennial allergic and non-allergic rhinitis in adults and pediatric patients 4 years of age and older. The PA approval criteria below were developed to fill the gap and replace a previous preferred drug, Nasacort AQ Nasal Spray, which was indicated for children age 2 years and older and is no longer covered by AR Medicaid Prescription Drug program. No point-of-sale PA approval criteria were developed for beyond 3 years of age because the preferred agent, fluticasone propionate, is indicated for adults and pediatric patients 4 years of age and older. The reimbursement rate is as follows: Veramyst Nasal Spray inhaler = $133.80 per inhaler; Nasonex Nasal Spray = $178.52 per inhaler; and fluticasone 0.05% propionate nasal spray = $10.40 per inhaler. Fluticasone propionate nasal spray does not require a PA. Veramyst 27.5 mcg Nasal Spray and Nasonex 50 mcg Nasal Spray are covered on the PDL as non-preferred drugs with criteria. POS PA approval criterion for Veramyst 27.5 mcg Nasal Spray (fluticasone furoate) and Nasonex 50 mcg Nasal Spray (mometasone furoate) is as follows: Beneficiary is between 2 years through 3 years of age. EBRx PA Call Center Local at 501-526-4200 or Long Distance Toll Free at 1-866-250-2518. Prolia (denosumab) 60 mg/ml syringe for subcutaneous use: Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer; treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. The dose is 60 mg every 6 months administered by a healthcare professional as a subcutaneous injection in the upper arm, upper thigh, or abdomen. The reimbursement rate is $909.66 per injection, or $1,819.52 per year. Prolia will continue to be covered through a manual review PA on a case-by-case basis for the initial dose. POS PA continuation approval criteria for Prolia will apply as follows: 1 Prolia claim is found in Medicaid drug history in the previous 12 months. In addition, a therapeutic duplication edit will reject an incoming Prolia claim if an Xgeva (denosumab) claim is found in the medical claims history in previous 6 months. A quantity edit for Prolia of 1 injection per 175 days will be implemented. Magellan Pharmacy Call Center at 800-424-7895. CLINICAL EDITS THROUGH MANUAL REVIEW PRIOR APPROVAL (PA) PROCESS: Treatment of Gaucher disease type 1 (GD1): The enzyme replacement therapies (ERT) given as IV infusions are covered through the Medicaid medical side. Cerdelga (eliglustat) 84 mg capsule: Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test. Limitations of use: Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of Cerdelga to achieve a therapeutic effect; a specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers). The recommended dosage of Cerdelga is 84 mg twice daily in CYP2D6 EMs and IMs. The recommended dosage in CYP2D6 PMs is 84 mg once daily; appropriate adverse event monitoring is recommended. Some inhibitors of CYP2D6 and CYP3A are contraindicated with Cerdelga depending on the patients metabolizer status. Please refer to the manufacturers drug package insert for complete information regarding other CYP2D6 and CYP3A inhibitors that may require dosage adjustment depending on the patients CYP2D6 metabolizer status to reduce the risk of potentially significant adverse reactions. The reimbursement rate is $438.60 per capsule; $877.20/day; $26,316/30-day supply; $320,178/yr. Cerdelga 84 mg capsule is covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, and criteria used in the clinical trials. Magellan Pharmacy Call Center at 800-424-7895. Zavesca (mig lustat) 100 mg capsule: Zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access). The recommended dose for the treatment of adult patients with type-1 Gaucher disease is one 100 mg capsule administered orally three times a day at regular intervals. If a dose is missed, the next Zavesca capsule should be taken at the next scheduled time. It may be necessary to reduce the dose to one 100 mg capsule once or twice a day in some patients due to adverse reactions, such as tremor or diarrhea. The reimbursement rate is $251.12 each capsule; $753.36/day; $22,600.80/30 days; $274,976.40/yr. Zavesca 100 mg capsule is covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, and criteria used in the clinical trials. Magellan Pharmacy Call Center at 800-424-7895. Sutent (sunitinib malate) capsules12.5 mg, 25 mg, 37.5 mg, 50 mg: Sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate; advanced renal cell carcinoma (RCC); progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. The FDA-approved dose for GIST and RCC is 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off; pNET 37.5 mg orally once daily, with or without food, continuously without a scheduled off-treatment period. Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability. The reimbursement rate is as follows: 12.5 mg = $126.85 each capsule; $3,551.80 for 4 week (28 day) supply; 25 mg = $253.71 each capsule; $7,103.88.28 for 4 week (28 day) supply; 37.5 mg = $380.56 each capsule; $10,655.68 for 4 week (28 day) supply; 50 mg = $441.67 each capsule; $12,366.76.10 for 4 week (28 day) day supply. Sutent (sunitinib malate) capsule is covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, and criteria used in the clinical trials. Magellan Pharmacy Call Center at 800-424-7895. Northera (droxidopa) capsules100 mg, 200 mg, 300 mg: Northera is indicated for the treatment of orthostatic dizziness, lightheadedness, or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been demonstrated. Clinical studies examined the efficacy of Northera in the short-term (1 to 2 weeks) and over longer-term periods (8 weeks; 3 months). Studies showed a treatment effect of Northera at week 1, but none of the studies demonstrated continued efficacy beyond 2 weeks of treatment. The starting dose is 100 mg three times during the day. Titrate by 100 mg three times daily, up to a maximum dose of 600 mg three times daily. Take consistently with or without food. The reimbursement rate is as follows: 100 mg = $16.16 per capsule; $1,454.40/30-day supply; 200 mg = $32.31 per capsule; $2,907.90/30-day supply; 300 mg = $48.47 per capsule; $4,362.30/30-day supply. Northera is covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, and criteria used in the clinical trials. Magellan Pharmacy Call Center at 800-424-7895. Zydelig (idelalisib) 100 mg and 150 mg tablets: Zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. Improvement in patient survival or disease related symptoms has not been established. The reimbursement rate for both strengths is $123.84 per tablet; $7,430.40 for 30 day supply. Zydelig is covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, and criteria used in the clinical trials. Magellan Pharmacy Call Center at 800-424-7895. Topical and systemic treatment of onychomycosis of the toenail or fingernail: Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. The use of topical agents should be limited to cases involving less than half of the distal nail plate or for patients unable to tolerate systemic treatment. Topical treatments alone are generally unable to cure onychomycosis because of insufficient nail plate penetration. Daily application and a long duration of treatment (48 wk) are required for topical agents. Ciclopirox is the only topical nail antifungal agent that has been reported to penetrate through all nail layers, but it still has low efficacy when used as monotherapy. The newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis. They offer shorter treatment regimens, higher cure rates, and fewer adverse effects. The efficacy of the newer antifungal agents lies in their ability to penetrate the nail plate within days of starting therapy. Evidence shows better efficacy with terbinafine than with other oral agents. TOPICAL ANTIFUNGAL AGENTS: Jublia (efinaconazole) 10% Topical Solution Nail Lacquer The reimbursement rate is $463 per a 4 ml bottle. If 1 container is filled every 4 weeks, the cost is approximately $5,556 for 48 weeks of therapy. Kerydin (tavaborole) 5% Topical Solution Nail Lacquer The reimbursement rate is $1,158.90 per 10 ml bottle or $463.56 per 4 ml bottle. If one 4 ml bottle is filled every 4 weeks, the cost is approximately $5,556 for 48 weeks of therapy; if one 10 ml container is filled every 4 weeks, the cost is approximately $13,906.80 for 48 weeks of therapy. Generic Ciclopirox 8% Topical Solution Nail Lacquer The reimbursement rate is $42.65 per 6.6 ml bottle. If one 6.6 ml bottle is filled every 4 weeks, the cost is approximately $511.80 for 48 weeks of therapy. ORAL ANTIFUNGAL AGENTS: Terbinafine hydrochloride tablets 250 mg The recommended dose for fingernail onychomycosis is one 250 mg tablet once daily for 6 weeks; toenail onychomycosis is one 250 mg tablet once daily for 12 weeks. The reimbursement rate is $0.24 each tablet; 4 week (28 day) supply = $6.72; 6 week supply = $10.08; 12 week supply = $20.16. Itraconazole 100 mg capsule The recommended dose of itraconazole is 200 mg (2 x 100 mg capsules) once daily for 12 consecutive weeks for toenails with or without fingernail involvement; for fingernails only, the recommended dosing regimen is 2 treatment pulses, each consisting of 200 mg (2 x 100 mg capsules) twice daily (400 mg/day) for 1 week. The pulses are separated by a 3-week period without itraconazole. The reimbursement rate is $6.76 per 100 mg capsule; 400 mg daily x 7 day supply = $189.28; 200 mg daily x 4 week (28 day) supply = $378.56; 200 mg daily x 12 week supply = $1,135.68. The oral antifungal agents, terbinafine 250 mg tablets and itraconazole 100 mg capsules, are available without a PA. The three topical agents, Jublia 10% Topical Solution Nail Lacquer, Kerydin 5% Topical Solution Nail Lacquer, and Ciclopirox 8% Topical Solution Nail Lacquer, are covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, criteria used in the clinical trials, current guidelines, and comparative effectiveness data. Magellan Pharmacy Call Center at 800-424-7895. Purixan (mercaptopurine) 20 mg/ml oral suspension: Purixam (mercaptopurine) is indicated for the treatment of patients with acute lymphoblastic leukemia as part of a combination regimen. The reimbursement rate is $10.84 per 20 mg (per ml). It is available as a 100 ml bottle = $1,083.60 per bottle. The reimbursement rate for mercaptopurine 50 mg tablet is $1.42 per 50 mg tablet. The mercaptopurine 50 mg tablets are available without a PA. Purixan is covered through a manual review PA on a case-by-case basis. In addition, a quantity limit of 1 bottle per claim has been added since the bottle must be used within 6 weeks after being opened. Magellan Pharmacy Call Center at 800-424-7895. Sprycel (dasatinib) Tablet20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg: Sprycel is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. The dose for chronic phase CML is 100 mg once daily. The dose for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL is 140 mg once daily. The reimbursement rate for each strength tablet is as follows: 20 mg = $87.65 each tablet; 50 mg = $175.30 each tablet; 70 mg = $175.30 each tablet; 80 mg = $315.94 each tablet; 100 mg = $315.94 each tablet; 30 day supply = $9,478; 140 mg = $315.94 each tablet; 30 day supply = $9,478. Sprycel is covered through a manual review PA on a case-by-case basis based on data in package insert for indications, dose, and criteria used in the clinical trials. Magellan Pharmacy Call Center at 800-424-7895. PROPOSED AEVCS EDITS, INCLUDING DOSE-OP OR QUANTITY EDITS: Sivextro (tedizolid phosphate) 200 mg tablet and 200 mg vial: Sivextro is an oxazolidinone-class antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillinsusceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. The recommended dosage of Sivextro is 200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 18 years of age or older. Safety and effectiveness in pediatric patients below the age of 18 have not been established. The reimbursement rate for the 200 mg tablet is $304.44 per each tablet; 6 day supply = $1,826.64. The reimbursement rate for the 200 mg vial = $242.52 each vial; 6 day supply = $1,455.12. Sivextro is covered with a cumulative quantity edit not to exceed 6 tablets or 6 vials per claim and per month. In addition, there is a therapeutic duplication edit between a claim of the tablets and claim of the vials that will not allow both dispensed within the same month. An age edit has been added that requires the beneficiary to be age 18 years or older. Magellan Pharmacy Call Center at 800-424-7895. Ribavirin 200 mg tablets and capsules: The reimbursement rate for both tablets and capsules is $1.27 each. A cumulative quantity edit of 196 tablets or capsules for a 28 days supply and a daily dose edit not to exceed 7 tablets or capsules per day will be implemented to prevent duplicate billing from 2 different pharmacies within the same month. Magellan Pharmacy Call Center at 800-424-7895. FRIENDLY REMINDERS:  INCARCERATED PERSONS: The Medicaid Pharmacy Program is prohibited by federal regulations, 42 C.F.R. 435.1009 and 435.1010, from paying for drug claims for Medicaid beneficiaries who, on the date the prescription is filled, are incarceratedin a correctional or holding facility for individuals who are prisoners, including juvenile correctional facilities; are detained pending disposition of charges; or are held under court order as material witnesses. If medications are requested for incarcerated Medicaid beneficiaries, the medications cannot be billed to Medicaid Pharmacy Program and are subject to recoupment. Pharmacists should contact the correctional facility regarding the facilitys reimbursement procedures for the requested medications. ANTIPSYCHOTIC AGENTS CRITERIA FOR CHILDREN < 18 YOA have an ongoing requirement for labs for metabolic monitoring. When any provider sends a patient who is less than 18 years of age for the metabolic labs that are required for the antipsychotic agents, the provider must include the PCPs name and Medicaid ID number on the lab order request form. It does not have to be the PCP ordering the labs. Please refer to the Physician/Independent Lab/CRNA/Radiation Therapy Center Provider Manual, Section II, 245.000 B. CHANGES TO INFORMED CONSENT FORM FOR ANTIPSYCHOTIC AGENT PA FOR CHILDREN < 18 YOA: For those providers who have not had their own version of the Informed Consent form approved for use with Medicaid PA requests and who use the Medicaid Informed Consent form for antipsychotic agents, the form has been updated (v010914) and is posted on the Magellan Medicaid website. As the form is updated and posted on the Magellan Medicaid website, providers are required to use the most current form. Effective, Dec. 10, 2013, the old versions will no longer be accepted. FOR PDL REQUESTS AND FOR REQUESTS FOR ANTIPSYCHOTIC DRUGS: Providers requesting a Prior Authorization (PA) for a drug on the PDL or requesting a Prior Authorization (PA) for an antipsychotic medication should contact the Evidence-based Prescription Drug Program (EBRx) PA Call Center Toll Free 1-866-250-2518 or Local 501-526-4200 or fax 501-526-4188. Please include any supporting documentation for the request with the fax and include beneficiary ID number, beneficiary name, and Medicaid Provider ID with your request. FOR NON-PDL DRUGS AND FOR NON-ANTIPYSCHOTIC DRUG REQUESTS: Providers requesting a Prior Authorization (PA) should call the Magellan Pharmacy Call Center at 800-424-7895. For Prior Authorization (PA) requests requiring manual review, you may fax your request to the Magellan Pharmacy Call Center Fax 800-424-7976 or to the state office fax at 501-683-4124. Please include any supporting documentation for the request with the fax and include beneficiary ID number, beneficiary name, and Medicaid provider ID with your request. An approval, denial, or request for additional information will be returned by the close of business the following business day. THE AR MEDICAID PHARMACY PROGRAM REIMBURSES FOR COVERED OUTPATIENT DRUGS FOR MEDICAID BENEFICIARIES WITH PRESCRIPTION DRUG BENEFITS. Only medications prescribed to that beneficiary can be billed using the beneficiarys Medicaid ID. Sanctions may be imposed against a provider for engaging in conduct that defrauds or abuses the Medicaid program. This could include billing a childs medication to a parents Medicaid ID number and vice-versa. EMERGENCY OVERRIDE: In an emergency, for those drugs for which a five-day supply can be dispensed, a pharmacy may dispense up to a five-day supply of a drug that requires clinical criteria or is non-preferred. This provision applies only in an emergency situation and when the Magellan Pharmacy Call Center is unavailable, Evidence Based Prescription Drug Program Help Desk is unavailable, and the pharmacist is not able to contact the prescribing physician. To file a claim using this emergency provision, the pharmacy provider will submit a 03 in the Level of Service (418-DI) field. Frequency of the emergency override is limited to once per year per class of drugs for non-LTC-eligible beneficiaries and once per 60 days per class for LTC-eligible beneficiaries. For any Schedule-II controlled substance filled using the Medicaid Emergency Override process, please refer to the Arkansas State Board of Pharmacy regulations regarding partial fill of a Schedule-II controlled substance. ANY REIMBURSEMENT RATES STATED IN THIS MEMORANDUM (OR ANY PREVIOUS MEMORANDUMS) ARE FOR REFERENCE PURPOSES ONLY AND SUBJECT TO CHANGE and are in no way a contractual obligation by Arkansas Medicaid. Current Generic Upper Limits (GUL) or Maximum Allowable Cost (MAC) that have been issued at the State and or Federal level, along with State issued Capped Upper Limits (CAP), can be found on the Magellan Medicaid website:  HYPERLINK "https://arkansas.magellanrx.com/provider/documents/" https://arkansas.magellanrx.com/provider/documents/ EAC is Estimated Acquisition Cost, and, in the absence of a federal or state GUL or MAC, this reimbursement methodology is calculated using AWP-14% for brand agents and AWP-20% for generic agents. MANUAL REVIEW PA REQUESTS AND EXCEPTIONS TO ESTABLISHED CRITERIA ARE REVIEWED ON A CASE-BY-CASE BASIS. Prescribers must provide a letter explaining the medical necessity of the request along with written documentation, e.g., chart notes, to substantiate the medical necessity of the request. THE ANTENATAL & NEONATAL GUIDELINES, EDUCATION, AND LEARNING SYSTEM (ANGELS) PROGRAM HAS DEVELOPED A PEDIATRIC GUIDELINE FOR STRONG-WILLED PRESCHOOLERS (YOUNG CHILDRENS STRONG-WILLED/NONCOMPLIANT/DISRUPTIVE BEHAVIOR) THAT HAS BEEN PEER REVIEWED AND FINALIZED. The guideline covers the problems, etiology, and prevalence of children who have disruptive behavior problems or oppositional defiant disorder (ODD). The guideline indicates that early intervention is important to effectively address disruptive behavior problems and prevent escalation of the problem into the school-aged years. The guideline points out that no medications are indicated for the treatment of disruptive behavior disorders. The most thoroughly researched and validated types of interventions to treat young childrens disruptive behavior are often collectively referred to as parent management training (PMT), behavioral parent training (BPT), or sometimes just as parent training (PT). PMT approaches typically involve working with both the parent and child, teaching parents specific parenting skills to improve the parent-child relationship, improve compliance, and decrease disruptive behavior. The complete guideline is available at this link:  HYPERLINK "http://www.uams.edu/cdh1/peds_guidelines.aspx" http://www.uams.edu/cdh1/peds_guidelines.aspx? Providers are asked to create a user name and password to log in to view any of the available pediatric guidelines on the website. This advance notice is to provide you the opportunity to contact, counsel, and change patients prescriptions. If you need this material in an alternative format, such as large print, please contact the Program Development and Quality Assurance Unit at 501-320-6429. If you have questions regarding this transmittal, or you need this material in an alternative format, such as large print, please contact the Provider Assistance Center at 18004574454 (TollFree) within Arkansas or locally and out-of-state at (501) 3762211. Arkansas Medicaid provider manuals (including update transmittals), official notices and remittance advice (RA) messages are available for downloading from the Arkansas Medicaid website: HYPERLINK "https://medicaid.mmis.arkansas.gov/default.aspx"medicaid.mmis.arkansas.gov ONGOING REMINDER FROM PREVIOUS COMMUNICATIONS: Prescribers are required to monitor children < 18 years of age for metabolic changes every 6 months on an outpatient basis when the child is receiving any antipsychotic agent. Acceptable CPT codes for the metabolic monitoring criteria are listed below [reminder, criteria requires CPT codes monitoring for both glucose (group-1) and lipids (group-2)]: Group-1 (glucose codes): Criteria require one of the following CPT codes that contain glucose monitoring in the previous 9 months from claim date of in-process claim: 83036 (HbA1c), OR 80050 (General Health Panel), OR 80069 (Renal Function Panel), OR 80047 (Basic Metabolic Panel), OR 80048 (Basic Metabolic Panel), OR 80053 (Comprehensive metabolic panel), OR 82962 (Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use), OR 82948 (Glucose; blood, reagent strip), OR 82947 (Glucose; quantitative, blood). AND, criteria require one of the following lipid panel tests or all of the individual lipid test monitoring codes in previous 9 months from claim date of the in-process claim: Group-2 (lipid codes): 80061 (Lipid panel), OR 83701 (High resolution fractionation and quantitation of lipoproteins panel), OR 82465 (Cholesterol, serum or whole blood, total), AND 83718 (HDL cholesterol), AND 84478 (Triglycerides), AND 83721 (LDL Cholesterol). Please Note: When any provider sends a patient who is less than 18 years of age for the metabolic labs required for the antipsychotic agents, the provider must include the PCPs name and Medicaid ID number in the lab order request form. It does not have to be the PCP ordering the labs. Please refer to the Physician/Independent Lab/CRNA/Radiation Therapy Center Provider Manual, Section II, 245.000 B for detailed information, pasted below: B. The referring physicians individual provider identification number must also accompany the order. If the clients PCP referred the client to the physician ordering the tests, the ordering physician must include with the order the PCPs individual provider identification number, in addition to his or her own individual provider identification number. The reference facility retains the ordering physicians provider information with the clients medical record for the medical necessity audit trail. The reference facility enters the PCPs provider identification number on its claim(s) to certify PCP referral. If the Medicaid client is exempt from PCP Program requirements, the reference facility submits the individual provider identification number of the ordering physician on its Medicaid claim.     AR Medicaid DUR Board Meeting October 15, 2014 Page  PAGE 9 of 9  Division of Medical Services Arkansas Medicaid Pharmacy Program P.O. Box 1437, Slot S295 Little Rock, AR 72203-1437 501-683-4120 Fax: 501-683-4124 TDD/TTY: 501-682-6789 humanservices.arkansas.gov Protecting the vulnerable, fostering independence and promoting better health ProvMem-005-14 ICD-10 implementation deadline has been postponed by CMS to Oct. 1, 2015. Will you be ready?   EFGίtbbSbSbDbh~5CJOJQJ^JaJhV*5CJOJQJ^JaJ#hMFhz"5CJOJQJ^JaJhCJOJQJ^JaJh@CJOJQJ^JaJjhCUmHnHu hWhz"CJOJQJ^JaJ hMFhz"CJOJQJ^JaJhWCJOJQJ^JaJhV*CJOJQJ^JaJ hzEhz"CJOJQJ^JaJ#hV*hz"5CJOJQJ^JaJ  FH> ? t u  `^``gd- r ^gd- r `^``gd, `^``gdz" p@ Pgdz"gdz" x^x`gdz"$x^x`a$gdz"  4 5 < = > ? ۾}i}iWF8h- rCJOJQJ^JaJ h$)h6UCJOJQJ^JaJ#hV*hV*5CJOJQJ^JaJ&h- rh,5>*CJOJQJ^JaJ hV*5>*CJOJQJ^JaJ h$)5>*CJOJQJ^JaJ hMFh,CJOJQJ^JaJh,CJOJQJ^JaJhz"CJOJQJ^JaJhV*5CJOJQJ^JaJ#hMFhz"5CJOJQJ^JaJ#hMFhg5CJOJQJ^JaJ? H I N O r s t u { | , 5 I 컩ۆۆۆۆۆۆtfUGUhjd}CJOJQJ^JaJ hMFhz"CJOJQJ^JaJh- rCJOJQJ^JaJ#hV*h- r5CJOJQJ^JaJ&h- rh- r5>*CJOJQJ^JaJh- r5CJOJQJ^JaJ#h- rh *5CJOJQJ^JaJhV*5CJOJQJ^JaJ hJX{5>*CJOJQJ^JaJ hV*5>*CJOJQJ^JaJ&h- rhz"5>*CJOJQJ^JaJI J M V j k   0 > I f r ĽĬp^L^p#hyEhKZ5CJOJQJ^JaJ#hyEh`5CJOJQJ^JaJ#hyEh:g5CJOJQJ^JaJ h/bh~CJOJQJ^JaJjhjd}Uhjd}CJOJQJ^JaJ hMFhz"CJOJQJ^JaJ hMFhz"'jh0JCJOJQJU^JaJhjd}0JCJOJQJ^JaJjhjd}Uhjd}jhU   / 0 V ^_Q!8^8gd,[!8^8gd`[! & Fgd7%!gdu%! & Fgd7%$a$gd84# !7$8$H$^gd84#!$7$8$H$^a$gd7!h^hgd/b^gdz"h^hgdz"r ۽{iZH:h CJOJQJ^JaJ#h:gh84#5CJOJQJ^JaJh84#5CJOJQJ^JaJ#hMFh84#5CJOJQJ^JaJ#hMFh,[5CJOJQJ^JaJh,[5CJOJQJ^JaJh@5CJOJQJ^JaJ#hMFh84#5CJOJQJ^JaJh:g5CJOJQJ^JaJhV*5CJOJQJ^JaJ#hyEh:g5CJOJQJ^JaJ#hyEh75CJOJQJ^JaJ   - . / 0 8 9 J U V W ^ <=̻}o^P^B^4^4^h-CJOJQJ^JaJhrCJOJQJ^JaJhY>CJOJQJ^JaJ h,[h,[CJOJQJ^JaJh`[CJOJQJ^JaJ#h,[h,[5CJOJQJ^JaJhM5CJOJQJ^JaJh/5CJOJQJ^JaJhu%CJOJQJ^JaJ hu%h84#CJOJQJ^JaJhr5CJOJQJ^JaJ h84#5>*CJOJQJ^JaJ&hMFh84#5>*CJOJQJ^JaJ L\]^_´¦ӊ|||m_Q_Q_hL-CJOJQJ^JaJhyxCJOJQJ^JaJhyx5CJOJQJ^JaJh*CJOJQJ^JaJhfJCJOJQJ^JaJh,[CJOJQJ^JaJhY>CJOJQJ^JaJh-CJOJQJ^JaJ hO"GhO"GCJOJQJ^JaJhO"GCJOJQJ^JaJ h,[h,[CJOJQJ^JaJhRCJOJQJ^JaJ58QRU^_fgӷudVdHdHdh~R@CJOJQJ^JaJhrCJOJQJ^JaJ h,[h,[CJOJQJ^JaJ#hJXh,[5CJOJQJ^JaJh#cy5CJOJQJ^JaJ#h,[h,[5CJOJQJ^JaJhO"G5CJOJQJ^JaJh,[CJOJQJ^JaJh#cyCJOJQJ^JaJhyxCJOJQJ^JaJ hyxhyxCJOJQJ^JaJh*CJOJQJ^JaJQRhJ01lT! ^ gdm! & Fgd/^gd!^gd/! & Fgd/! & Fgd/!gd,[! & Fgd7%!^gd,[!gdu%./14<=DIJYZcdjkl|n`n`nOA`h/CJOJQJ^JaJ h,[h/CJOJQJ^JaJh/CJOJQJ^JaJ h/h/CJOJQJ^JaJh,[5CJOJQJ^JaJ#hlzhlz5CJOJQJ^JaJht5CJOJQJ^JaJ#hlzh,[5CJOJQJ^JaJ#hlzhO"G5CJOJQJ^JaJh4#oCJOJQJ^JaJ h,[h,[CJOJQJ^JaJh;8CJOJQJ^JaJT)oʹvgXJ8&#hYhY5CJOJQJ^JaJ#h,[h,[5CJOJQJ^JaJh>$CJOJQJ^JaJh j5CJOJQJ^JaJh 5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJ hu%h8CJOJQJ^JaJ# *h8hmCJOJQJ^JaJh*RCJOJQJ^JaJ h,[h,[CJOJQJ^JaJ hh,[CJOJQJ^JaJ#hlzh/5CJOJQJ^JaJ#h/h/5CJOJQJ^JaJ 9:Gmp ! G^gdU ! G^gd`[ ! & F Ggd7% ! G8^8gd`[ ! G8^8gdz8 ! G8^8gdO ! & F Ggd7%!^gd>$! GgdE!^gd joxy"):;DEMNZ[ϾuggggggYggh* CJOJQJ^JaJhCCJOJQJ^JaJhYCJOJQJ^JaJ hYhYCJOJQJ^JaJhOCJOJQJ^JaJh;,CJOJQJ^JaJh(CJOJQJ^JaJ h`[h`[CJOJQJ^JaJh,[5CJOJQJ^JaJh{5CJOJQJ^JaJ#h,[h,[5CJOJQJ^JaJ"&NPQ $%4LVbs´´¦˜˜xgYKYY=hfJCJOJQJ^JaJhO"GCJOJQJ^JaJhCJOJQJ^JaJ hO"GhO"GCJOJQJ^JaJ hhmCJOJQJ^JaJh,[5CJOJQJ^JaJhOCJOJQJ^JaJhbCJOJQJ^JaJh;,CJOJQJ^JaJh?CJOJQJ^JaJ h(h?CJOJQJ^JaJhYCJOJQJ^JaJ hYhYCJOJQJ^JaJsu|}(),ȷ{jYH7 h jh(CJOJQJ^JaJ h*h(CJOJQJ^JaJ h*h* CJOJQJ^JaJ h jh`[CJOJQJ^JaJhmCJOJQJ^JaJhlCJOJQJ^JaJhbCJOJQJ^JaJ#h*h*5CJOJQJ^JaJ hO"GhO"GCJOJQJ^JaJhO"GCJOJQJ^JaJhfJCJOJQJ^JaJh*CJOJQJ^JaJhyxCJOJQJ^JaJ,789:EF_`fmpq%17lm°ŸrdŸVEd h`[h(CJOJQJ^JaJhSCJOJQJ^JaJh`[CJOJQJ^JaJ h(h`[CJOJQJ^JaJh;,CJOJQJ^JaJh* CJOJQJ^JaJ h`[h`[CJOJQJ^JaJ#hmyhmy>*CJOJQJ^JaJhmyCJOJQJ^JaJ h jh`[CJOJQJ^JaJ h jhmyCJOJQJ^JaJhsBCJOJQJ^JaJmp{|}ʻ}kZZLZ>ZhSCJOJQJ^JaJhmyCJOJQJ^JaJ h`[h`[CJOJQJ^JaJ#h(hmy>*CJOJQJ^JaJ h(hmyCJOJQJ^JaJh;,CJOJQJ^JaJh* CJOJQJ^JaJ h`[hmyCJOJQJ^JaJhmy>*CJOJQJ^JaJ h*hmyCJOJQJ^JaJ#hmyhmy>*CJOJQJ^JaJ#hUh`[5CJOJQJ^JaJp}' ( $$R%S% ! G8^8gd h ! & F Ggd7%!gdE ! G8^8gdz8 ! & F Ggd7% ! & F Ggd7% ! G^gdmy ! & F Ggd7% ! GG^Ggdmy&(      ' ( 4 5 B D ޿ЮЮЮЮЮЮЮЮ}l}X&hh 5CJOJQJ\^JaJ hw7h7CJOJQJ^JaJ&hw7h75CJOJQJ\^JaJh`[5CJOJQJ^JaJhmyCJOJQJ^JaJ h`[h`[CJOJQJ^JaJ h!hmyCJOJQJ^JaJhCJOJQJ^JaJ h!h`[CJOJQJ^JaJ h!h(CJOJQJ^JaJ!D E Q b c l m o ~  D!W!ʹʔsasasRA3h;,CJOJQJ^JaJ h hh hCJOJQJ^JaJhyE5CJOJQJ^JaJ#hEh* 5CJOJQJ^JaJ#h hh h5CJOJQJ^JaJh`[5CJOJQJ^JaJ hw7h7CJOJQJ^JaJ&hh 5CJOJQJ\^JaJ h%5CJOJQJ\^JaJ h75CJOJQJ\^JaJ&hw7h75CJOJQJ\^JaJ h 5CJOJQJ\^JaJW!Z!b!e!!!!!!!""""p"q""""",#-#7#C#D#G#R#e#######M$Y$$῱ჟuguuuh#:CJOJQJ^JaJhOCJOJQJ^JaJhsBCJOJQJ^JaJh{CJOJQJ^JaJ#hEh* 5CJOJQJ^JaJhCJOJQJ^JaJ h;,h;,CJOJQJ^JaJ h hh hCJOJQJ^JaJh;,CJOJQJ^JaJ h hh;,CJOJQJ^JaJ$$$$$$$$$$$$$% %%%D%P%Q%S%^%u%v%%ŷťŗťŗʼnŗweVE hNhNCJOJQJ^JaJhN5CJOJQJ^JaJ#hEhE5CJOJQJ^JaJ#hEhN5CJOJQJ^JaJh!uCJOJQJ^JaJhfJCJOJQJ^JaJ#hEh* 5CJOJQJ^JaJhrCJOJQJ^JaJhCJOJQJ^JaJ hh{CJOJQJ^JaJhsBCJOJQJ^JaJh hCJOJQJ^JaJ%%%%%%%%%%% &&"&$&%&1&2&i&j&&ϯϞqcqRARR h*hOCJOJQJ^JaJ h*hsBCJOJQJ^JaJh#:CJOJQJ^JaJ h jhsBCJOJQJ^JaJhlCJOJQJ^JaJh.SCJOJQJ^JaJ hsBh*CJOJQJ^JaJ#hEh* 5CJOJQJ^JaJh*CJOJQJ^JaJ#hEh*5CJOJQJ^JaJhfJCJOJQJ^JaJ hNhECJOJQJ^JaJS%%%&&&&3'4'o'))8*9**=++8,9, ! G8^8gd! ! G8^8gdO"G ! & F Ggd7% Ggd!gdE ! G^gd ! & F Ggd7% ! G8^8gd h&&&&&&&&&&&&&&&&&&&&&&'''ӷӷӛvbQ@ h5CJOJQJ\^JaJ hy5CJOJQJ\^JaJ&hhy5CJOJQJ\^JaJ hw7hCJOJQJ^JaJ&hw7h5CJOJQJ\^JaJhCJOJQJ^JaJhHCJOJQJ^JaJh* CJOJQJ^JaJh*CJOJQJ^JaJhsBCJOJQJ^JaJh#:CJOJQJ^JaJ hsBhsBCJOJQJ^JaJ' '"'1'2'3'4'X']'m'n'o'u'v''ǶsaRA/A#hEh* 5CJOJQJ^JaJ h!h!CJOJQJ^JaJh!5CJOJQJ^JaJ#hquhqu5CJOJQJ^JaJhqu5CJOJQJ^JaJ#h!h!5CJOJQJ^JaJ hhCJOJQJ^JaJ hw7hCJOJQJ^JaJ h5CJOJQJ\^JaJ&hw7h5CJOJQJ\^JaJ&hhy5CJOJQJ\^JaJ hy5CJOJQJ\^JaJ''''+(L(((((G)~)))))))))9*@*A*g*h*±•ᄣrdVHh*CJOJQJ^JaJhyxCJOJQJ^JaJhquCJOJQJ^JaJ#hyxhqu5CJOJQJ^JaJ hh]jCJOJQJ^JaJhrCJOJQJ^JaJhlCJOJQJ^JaJ h!hlCJOJQJ^JaJ h!hO"GCJOJQJ^JaJhO"GCJOJQJ^JaJ h!h!CJOJQJ^JaJhCJOJQJ^JaJh**************%+)+<+=+u+++++++++++++ŷŘŘӊӊӊyyk]OhrCJOJQJ^JaJh.SCJOJQJ^JaJhCJOJQJ^JaJ hquhquCJOJQJ^JaJhquCJOJQJ^JaJhfJCJOJQJ^JaJ h*hECJOJQJ^JaJhECJOJQJ^JaJhlCJOJQJ^JaJh*CJOJQJ^JaJhyxCJOJQJ^JaJ hyxhyxCJOJQJ^JaJ++,7,8,9,f,g,h,i,,,,,,ųraO>0hk6CJOJQJ^JaJ h h84#CJOJQJ^JaJ#h*h84#5CJOJQJ^JaJ h84#5>*CJOJQJ^JaJ&hKh84#5>*CJOJQJ^JaJh`[5CJOJQJ^JaJh:g5CJOJQJ^JaJh]j5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJhsBCJOJQJ^JaJ h!h!CJOJQJ^JaJhfJCJOJQJ^JaJhquCJOJQJ^JaJ9,h,i,,,D-j-1152622233D3 G^gd= ! G8^8gd= ! G8^8gdqu ! & F Ggd7% ! & F Ggd7% ! G8^8gdmd! & Fgd7% ! G8^8gdz8 G^gd:g,,,,,,,D-h-i-j-r-s-=.]._.n.oaPB4BhCJOJQJ^JaJhCJOJQJ^JaJ hquhquCJOJQJ^JaJh`CJOJQJ^JaJ hquh`CJOJQJ^JaJh,[5CJOJQJ^JaJh]j5CJOJQJ^JaJ#hquhqu5CJOJQJ^JaJ hOQ@h7%CJOJQJ^JaJh7%CJOJQJ^JaJhl5CJOJQJ^JaJ#h7%h7%5CJOJQJ^JaJh7%5CJOJQJ^JaJn.o.s.t....//////////E0H000001;1@1111112´䦕´´䕇ykZy hhHCJOJQJ^JaJhHCJOJQJ^JaJh CJOJQJ^JaJhrCJOJQJ^JaJ hhCJOJQJ^JaJhY}CJOJQJ^JaJh`CJOJQJ^JaJ hquh`CJOJQJ^JaJ hquhquCJOJQJ^JaJhCJOJQJ^JaJhlCJOJQJ^JaJ22222&2425262?2M2N2P2c2d22222233ǵvvhYG8hk5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJh=5CJOJQJ^JaJh=CJOJQJ^JaJ hyxhyxCJOJQJ^JaJh*CJOJQJ^JaJhtCJOJQJ^JaJ#hyxhyx5CJOJQJ^JaJ#h`h`5CJOJQJ^JaJht5CJOJQJ^JaJh CJOJQJ^JaJh2ECJOJQJ^JaJhyxCJOJQJ^JaJ333C3D3_4`4a444445 5d5e5556]6^6`6i6w66ͻ}o}a}o}o}PaoaA͜ht5CJOJQJ^JaJ hh.CJOJQJ^JaJh2ECJOJQJ^JaJh.CJOJQJ^JaJ h2Eh2ECJOJQJ^JaJhn%CJOJQJ^JaJhtCJOJQJ^JaJ hthtCJOJQJ^JaJ#hthyx5CJOJQJ^JaJ#htht5CJOJQJ^JaJhECJOJQJ^JaJ#h=hE5CJOJQJ^JaJD355_6`677G7H77J:K:q:::E;;;T<U<< G^gd\7 ! G8^8gd\78^8gd\7! & F ! G8^8gdmd G^gd2E ! G8^8gdt6666777E7F7G7H7k7l7777°paO=, h\7h`CJOJQJ^JaJ#hMhd:i5CJOJQJ^JaJ#hMhrfO5CJOJQJ^JaJh* 5CJOJQJ^JaJ#hrfOhrfO5CJOJQJ^JaJh,[CJOJQJ^JaJ hEh2ECJOJQJ^JaJhk5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJ hth2ECJOJQJ^JaJhtCJOJQJ^JaJ hyxhtCJOJQJ^JaJh*CJOJQJ^JaJ777777778182858:8;8@8A8E8F8V8W8w8x88888888889M9m9n9r999K:p::::::::::| hhCJOJQJ^JaJh`CJOJQJ^JaJhHCJOJQJ^JaJh* CJOJQJ^JaJh.CJOJQJ^JaJh7%CJOJQJ^JaJhYCJOJQJ^JaJh\7CJOJQJ^JaJ h\7h\7CJOJQJ^JaJ0:::::::::::::::;;;;;(;-;7;;;<;D;U;W;a;b;d;m;u;;;;;;;´´´ᘇugh\7CJOJQJ^JaJ#hrfOh\75CJOJQJ^JaJ h\7hrfOCJOJQJ^JaJh.CJOJQJ^JaJh7%CJOJQJ^JaJhCJOJQJ^JaJh`CJOJQJ^JaJ h\7h`CJOJQJ^JaJ h\7h\7CJOJQJ^JaJh^CJOJQJ^JaJ&;;;;S<T<U<<<<<<<<<<<C>IJĀq_P_?. hHhHCJOJQJ^JaJ hHhclpCJOJQJ^JaJh^5CJOJQJ^JaJ#hMhH5CJOJQJ^JaJh* 5CJOJQJ^JaJ#hHhH5CJOJQJ^JaJ hEh\7CJOJQJ^JaJhr5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJhrfO5CJOJQJ^JaJh\7CJOJQJ^JaJ hyxh\7CJOJQJ^JaJh*CJOJQJ^JaJ<<<\@]@^@@@@&A'AAABB2BtDuDDD!8^8gdU! & F gd7% Ggd5 G^gdU ! G8^8gdH!8^8gdH! & F gdrfOC>E>>>>>>??8?@?E?F?????3@4@]@^@w@@@@@@@@@@@@@@@@@@@@@@@||nnhrCJOJQJ^JaJhCJOJQJ^JaJhCJOJQJ^JaJh* CJOJQJ^JaJh+CJOJQJ^JaJh:$CJOJQJ^JaJhclpCJOJQJ^JaJ hHhclpCJOJQJ^JaJ hHhHCJOJQJ^JaJhHCJOJQJ^JaJ+@@@ A AA'A0A1AGAiAoAAAAAABBаААЂpaRA h5hUCJOJQJ^JaJhU5CJOJQJ^JaJh55CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJhUCJOJQJ^JaJ hyxhHCJOJQJ^JaJhH5CJOJQJ^JaJ#hHhH5CJOJQJ^JaJhCJOJQJ^JaJhHCJOJQJ^JaJ h }KhHCJOJQJ^JaJ hHhHCJOJQJ^JaJBB B0B2B9B:B}B~BBC4C5CCCCDDDsDuDzDDDDDDDDDDEE{E}EEͿͱͱͱͣͱ̈́ͱޱssa#hjd}hjd}5CJOJQJ^JaJ hyxhUCJOJQJ^JaJhCJOJQJ^JaJ hhCJOJQJ^JaJhGqCJOJQJ^JaJhUCJOJQJ^JaJhFCJOJQJ^JaJ hUhUCJOJQJ^JaJhU5CJOJQJ^JaJ#hUhU5CJOJQJ^JaJ#D|E}EEEEFFHHcJdJJJNKOKKLLLMMM8^8gd!8^8gd! & F gd7% G^gdU!8^8gdU ! G8^8gdUEEEEEEEEEEEEEEEEEFF2G3G4GGGGHH¡qcUqGqcUhBCJOJQJ^JaJhGqCJOJQJ^JaJh`U]CJOJQJ^JaJ h`U]h`U]CJOJQJ^JaJh"?CJOJQJ^JaJ hUhUCJOJQJ^JaJhH5CJOJQJ^JaJ#hUhU5CJOJQJ^JaJhU5CJOJQJ^JaJhUCJOJQJ^JaJ hEhUCJOJQJ^JaJhGq5CJOJQJ^JaJHH@HBHCHvHwH|HHHHHHHH?I@IIIJJbJcJdJlJwJJJӴykyY#hh5CJOJQJ^JaJhCJOJQJ^JaJ hhCJOJQJ^JaJh`U]CJOJQJ^JaJhBCJOJQJ^JaJhCJOJQJ^JaJ h`U]h`U]CJOJQJ^JaJhGqCJOJQJ^JaJh"?CJOJQJ^JaJh$KCJOJQJ^JaJ h`U]h"?CJOJQJ^JaJJJJJJJJ&K-KAKBKDKMKNKOKhKKKKKKKKKKKKKKKKKKLLLLLLL˽ˬ~oˬh5CJOJQJ^JaJ#hh5CJOJQJ^JaJhUCJOJQJ^JaJhaCJOJQJ^JaJ hhCJOJQJ^JaJhCJOJQJ^JaJ hhaCJOJQJ^JaJ hUhCJOJQJ^JaJ#hh"?5CJOJQJ^JaJ'LLLLLLLLLL_M~MMMMMMMμ༭q`R`D3 hhCJOJQJ^JaJhCJOJQJ^JaJhCJOJQJ^JaJ hh"?CJOJQJ^JaJhaCJOJQJ^JaJhCJOJQJ^JaJ hhaCJOJQJ^JaJhrfO5CJOJQJ^JaJha5CJOJQJ^JaJ#hh"?5CJOJQJ^JaJ#hh5CJOJQJ^JaJh"?5CJOJQJ^JaJ hhrfOCJOJQJ^JaJMMMMMMMMMN N!N(N:NbNdNiN~NNNNNNNNNNNNNNпппппЏЁseeS#h"?hZc5CJOJQJ^JaJhZcCJOJQJ^JaJhaCJOJQJ^JaJhCJOJQJ^JaJ h"?hFCJOJQJ^JaJ hhaCJOJQJ^JaJh"?CJOJQJ^JaJ h"?h"?CJOJQJ^JaJhFCJOJQJ^JaJh"?5CJOJQJ^JaJ#h"?h"?5CJOJQJ^JaJMMdNNNNP8Q9QQQ$S%STSUSSTTTTTT!8^8gd<O!8^8gd! & F gd7% G^gd<O n8^8gd8^8gdZc8^8gd"?NNO$O0O9OHOIOgOmO}OOOOPPP$P>P?PrPsPPPPPPPPPPPPPPPPPQ Q QQ.Q8Q9QSQTQUQѲѤhMCJOJQJ^JaJhCJOJQJ^JaJh"?CJOJQJ^JaJ hhCJOJQJ^JaJhCJOJQJ^JaJhZcCJOJQJ^JaJ h"?hZcCJOJQJ^JaJhZc5CJOJQJ^JaJ/UQ`QaQoQtQQQQQQQQQQR#R0RNRORgRRRRSS#S$S%SаퟑЀЀrdrVHh<OCJOJQJ^JaJhrfOCJOJQJ^JaJh<|CJOJQJ^JaJhFCJOJQJ^JaJ hyxhCJOJQJ^JaJhCJOJQJ^JaJ hhCJOJQJ^JaJ h"?hCJOJQJ^JaJhM5CJOJQJ^JaJhCJOJQJ^JaJh5CJOJQJ^JaJ#hh5CJOJQJ^JaJ%SRSSSTSUSSSSSTT-T8TCTETHTITNTTTTTTTTTUͿqqqcqUqUqqGqhCJOJQJ^JaJhACJOJQJ^JaJh)CJOJQJ^JaJh<OCJOJQJ^JaJh5CJOJQJ^JaJ h<Oh<OCJOJQJ^JaJh5CJOJQJ^JaJ#hh5CJOJQJ^JaJhCJOJQJ^JaJ hEh<OCJOJQJ^JaJh5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJTUUUUVV\VXX Y%YBY_Y|YYYYZZZ G^gd k n8^8gd ! n8^8gd<O! & F G^gd<O!8^8gd<O ! G8^8gd<OUUUUU5UWUnUUUUUVVVV/V0Vថ~o^L=h75CJOJQJ^JaJ#h<Oh<O5CJOJQJ^JaJ hEh<OCJOJQJ^JaJh)5CJOJQJ^JaJ#hjd}hjd}5CJOJQJ^JaJhyECJOJQJ^JaJ h<Oh<OCJOJQJ^JaJ hyxh<OCJOJQJ^JaJh<O5CJOJQJ^JaJ#hh<O5CJOJQJ^JaJh<OCJOJQJ^JaJ hh<OCJOJQJ^JaJ0V5V6V[E[\\N]P]k]r]^^ͻ͘xjx\xNx@x2h-CJOJQJ^JaJhhCJOJQJ^JaJh kCJOJQJ^JaJhlCJOJQJ^JaJha)}CJOJQJ^JaJ h kh kCJOJQJ^JaJh+5CJOJQJ^JaJ#h kh k5CJOJQJ^JaJ h k5>*CJOJQJ^JaJ#h*h k5CJOJQJ^JaJ&h kh k5>*CJOJQJ^JaJhCJOJQJ^JaJ hEh kCJOJQJ^JaJZZZZ=[t^u^^2_`````*CJOJQJ^JaJ hg 5>*CJOJQJ^JaJ&hMFhg5>*CJOJQJ^JaJ hh%phh%pCJOJQJ^JaJhTrCJOJQJ^JaJhH*CJOJQJ^JaJhlCJOJQJ^JaJ hwKhh%pCJOJQJ^JaJ#h*hh%p5CJOJQJ^JaJ&hwKhg 5>*CJOJQJ^JaJh %5CJOJQJ^JaJjhCUmHnHueff\g]grgsgtgggghh iiiiiiiiiijjkпwfXJhUCJOJQJ^JaJhlCJOJQJ^JaJ hwK5>*CJOJQJ^JaJ&hwKhwK5>*CJOJQJ^JaJhjd}CJOJQJ^JaJ#h*hwK5CJOJQJ^JaJ&hMFhwK5>*CJOJQJ^JaJ hwKhwKCJOJQJ^JaJhwKCJOJQJ^JaJ hwKh\ CJOJQJ^JaJ hwKhgCJOJQJ^JaJkk]khktkkkkkkkkkkkkk l/l\l^l_llᱠ|jYHY:YhUCJOJQJ^JaJ hjd}hjd}CJOJQJ^JaJ h=hwKCJOJQJ^JaJ#h'=#hl5CJOJQJ^JaJ#h'=#hwK5CJOJQJ^JaJ#h*hwK5CJOJQJ^JaJ hg 5>*CJOJQJ^JaJ&hMFhwK5>*CJOJQJ^JaJhwKCJOJQJ^JaJhH*CJOJQJ^JaJ hwKhwKCJOJQJ^JaJh,CJOJQJ^JaJllmmmm7momzmmmmmFnGnnnnnnn޿пucQ?#h'=#hUn5CJOJQJ^JaJ#h'=#h%`5CJOJQJ^JaJ#h*h%`5CJOJQJ^JaJ&hH*hg 5>*CJOJQJ^JaJ&hwKhg 5>*CJOJQJ^JaJ&hwKhg5>*CJOJQJ^JaJhH*CJOJQJ^JaJ hwKhwKCJOJQJ^JaJhUCJOJQJ^JaJ h=hwKCJOJQJ^JaJ hjd}hjd}CJOJQJ^JaJnnno#o0o1ooooppppppppppqﱝygVVE h=hz"CJOJQJ^JaJ hwKhz"CJOJQJ^JaJ#h'=#hl5CJOJQJ^JaJ#h'=#hz"5CJOJQJ^JaJ#h{hz"5CJOJQJ^JaJ&hwKhz"5>*CJOJQJ^JaJ&hwKh%`5>*CJOJQJ^JaJhTrCJOJQJ^JaJhUnCJOJQJ^JaJhH*CJOJQJ^JaJ hwKh%`CJOJQJ^JaJq:qqqUrVrrrrrrrr s ssssBtCtptqtt޿п~jVD#h'=#hz"5CJOJQJ^JaJ&hMFhz"5>*CJOJQJ^JaJ&hwKhz"5>*CJOJQJ^JaJ&hwKhg 5>*CJOJQJ^JaJhTrCJOJQJ^JaJhb#CJOJQJ^JaJ hwKhzCJOJQJ^JaJ hwKhz"CJOJQJ^JaJhUnCJOJQJ^JaJ h=hz"CJOJQJ^JaJ hjd}hjd}CJOJQJ^JaJttttttttu uvuuuuuuuuu v v v v-v.vXv_vvv޿ޱޣޑ|i޿X hwKhzCJOJQJ^JaJ$hjd}hjd}0JCJOJQJ^JaJ)j"hjd}CJOJQJU^JaJ#jhjd}CJOJQJU^JaJhlCJOJQJ^JaJhjd}CJOJQJ^JaJ hwKhCJOJQJ^JaJh-}CJOJQJ^JaJ hwKhz"CJOJQJ^JaJ hwKhYCJOJQJ^JaJvvvv7w8w9w:wSwwwwwwww͹rararM9&hwKhNn85>*CJOJQJ^JaJ&h2 hz"5>*CJOJQJ^JaJ h2 hwKCJOJQJ^JaJ h2 hz"CJOJQJ^JaJ#h'=#h-}5CJOJQJ^JaJ#h'=#hg 5CJOJQJ^JaJ#h*hg 5CJOJQJ^JaJ&h2 hg 5>*CJOJQJ^JaJ&hwKhz"5>*CJOJQJ^JaJ hwKhz"CJOJQJ^JaJhTrCJOJQJ^JaJw&x'xQxxxxoypy|y}yyyzzQ{R{X{Y{c{d{s{t{~{{{{{{{{|||ǵtcUhlCJOJQJ^JaJ h&hCJOJQJ^JaJ hhYXCJOJQJ^JaJhYXCJOJQJ^JaJ h2 hCJOJQJ^JaJ h2 hg CJOJQJ^JaJ#h*hg 5CJOJQJ^JaJ&h2 hg 5>*CJOJQJ^JaJ hYX5>*CJOJQJ^JaJ&hwKhg 5>*CJOJQJ^JaJ!|||}}3}4}5}6}}}}}~~ ~)~*~ѽѬ|k]kOk;&hMFhz"6CJOJQJ]^JaJhTrCJOJQJ^JaJhzCJOJQJ^JaJ hMFhz"CJOJQJ^JaJ hMFhNn8CJOJQJ^JaJhTrCJOJQJ^JaJ h2 hCJOJQJ^JaJ hYXhCJOJQJ^JaJ&jh>*CJOJQJU^JaJ#h&h>*CJOJQJ^JaJhjhU h&hCJOJQJ^JaJ}}*~~ŁƁvw1RsKu ! & F7$8$H$gdz" !7$8$H$^gdz"!^gdz"gdz"h^hgdNn8ÀĀŀ߀HꚉxgxTC6(hMFhO^5OJQJ^JhMFhz"OJQJ^J!h*hz"56OJQJ\^J$hMFhz"56>*OJQJ\^J hjd}6CJOJQJ]^JaJ hPn86CJOJQJ]^JaJ hi6CJOJQJ]^JaJ&hMFhz"6CJOJQJ]^JaJ$hd110J6CJOJQJ]^JaJ/jhd116CJOJQJU]^JaJ hd116CJOJQJ]^JaJ)jhd116CJOJQJU]^JaJHJTÁāŁƁHLstwÃEؼtbTFhTrCJOJQJ^JaJhlCJOJQJ^JaJ#h*hz"5CJOJQJ^JaJ&hMFhz"5>*CJOJQJ^JaJ#hMFhz">*CJOJQJ^JaJ hMFhO^CJOJQJ^JaJ hMFhz"CJOJQJ^JaJ hMFhz"CJOJQJ^JaJhTr5OJQJ^JhMFhz"5OJQJ^JhMFhO^5OJQJ^Jh\ 5OJQJ^JEFUpqt{܄߄MbcdRSTVabᘆucQ?#h*hu-5CJOJQJ^JaJ#hMFhu-5CJOJQJ^JaJ#hMFh&5CJOJQJ^JaJ hMFhu-CJOJQJ^JaJ#h*h9x5CJOJQJ^JaJ&hMFhz"5>*CJOJQJ^JaJ#hMFhz">*CJOJQJ^JaJ)hMFhz"56>*CJOJQJ^JaJhTrCJOJQJ^JaJ hMFhz"CJOJQJ^JaJh9xCJOJQJ^JaJLMd|ͅTUVzx };<=gdu-! & Fgd= 8^8`gd7!^gdu- ! & F7$8$H$gdi ! & F7$8$H$gdz" !7$8$H$^gdz" !7$8$H$gdz" !7$8$H$^gdz"bcd%BEvՇևxyz;<>?sbsQMIB hu-hp:hp:hz" h=hu-CJOJQJ^JaJ h*hu-CJOJQJ^JaJ#h=hu-5CJOJQJ^JaJhTrCJOJQJ^JaJh=CJOJQJ^JaJh9xCJOJQJ^JaJ#hMFhu->*CJOJQJ^JaJ#hMFhu-6CJOJQJ^JaJh\ CJOJQJ^JaJhlCJOJQJ^JaJ hMFhu-CJOJQJ^JaJ=>?ABDEGHJK $IfgdZ $IfgdZ $$Ifa$gdZgdu-?@BCEFHIKܒ}yk^O@hZ5CJOJQJ\^JhZCJ OJQJ\^JaJ h JhZOJQJ^JjhCUmHnHuhhZ h*hZCJOJQJ^JaJ'hp:@<B*CJOJQJ^JaJph2hd11@<B*CJOJQJ^JaJmHnHphu6jh*hZ@<B*CJOJQJU^JaJph-h*hZ@<B*CJOJQJ^JaJphhjhU "#'367<QRSTUVW|ufb[WF hZ5CJOJQJ\^JaJh h /hZhZhZOJQJ^JmHnHu hb\hZhb\hZ5CJ\aJh hZ5CJ\aJhZ5CJ\aJhl6hZ5CJ\aJhBhZCJOJQJ\aJhZCJOJQJ\aJhZmHnHu h JhZh JhZOJQJ^JjhCUmHnHu h0hZ<RS $IfgdZ $$Ifa$gdZgkd$$Ifl4OFq/ V' \`*    44 laf4ytZSTUVqӌԌՌ֌׌،ٌ7~n!$7$8$H$^a$gd %gdp:$a$gd$$a$gd /gkdp$$Ifl4Fq/ V' \ *    44 laf4ytZ WqrČ̌ҌӌԌՌ֌׌،ٌ #6789:İ}r}raZ hu-hp: hCc5hZOJQJ^JmH sH hZ5OJQJ^JhCc5hZ5OJQJ^JhhBhp:CJaJ hp:hp:hhBhZCJaJ&hZB*CJOJQJ\^JaJph,hSMhZB*CJOJQJ\^JaJph hZ5CJOJQJ\^JaJ&hBhZ5CJOJQJ\^JaJ789:gdu-? 0 00&P1h:p-/ =!"#$% < 00&P1h:pp:/ =!"#$% Fi0 ̤%-qmJFIF``C    $.' ",#(7),01444'9=82<.342C  2!!222222222222222222222222222222222222222222222222221>" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?_iv3_^̰@䑺(UxBO+,'@"\#,] J+YqmYt{mFiX5:f/4A@j d؀k̎ys/XZ\j/1+Dw,.WhmE0 0FjJeԅ/lvbFApT5@Q@p0L)mw#EQiIw_,:ޣ-3rhlw7E}c\s6qP5qajWdJgp?5h^+o sZ6Orλ )Ni" LiѦؚ"?NRI$f'Gl[Hpu+H#ؤs(]]kB_>H? 6;>k䰺c:f Pv:| ";J+'N/-fYu` (ֵs)SO*ju۝lmS[N } (H3U((((((((٠Fԣ8'0BvS ;Y,Photoshop 3.08BIM,,Tqhttp://ns.adobe.com/xap/1.0/ image/jpeg dhs.tck2c Illustrator 2007-05-21T13:25:11-05:00 2007-05-21T18:25:13Z 2007-05-21T13:25:11-05:00 256 120 JPEG /9j/4AAQSkZJRgABAgEBLAEsAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABABLAAAAAEA AQEsAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAeAEAAwER AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAAAAAQFAwIGAQAHCAkKCwEAAgIDAQEBAQEAAAAAAAAA AQACAwQFBgcICQoLEAACAQMDAgQCBgcDBAIGAnMBAgMRBAAFIRIxQVEGE2EicYEUMpGhBxWxQiPB UtHhMxZi8CRygvElQzRTkqKyY3PCNUQnk6OzNhdUZHTD0uIIJoMJChgZhJRFRqS0VtNVKBry4/PE 1OT0ZXWFlaW1xdXl9WZ2hpamtsbW5vY3R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo+Ck5SVlpeYmZ qbnJ2en5KjpKWmp6ipqqusra6voRAAICAQIDBQUEBQYECAMDbQEAAhEDBCESMUEFURNhIgZxgZEy obHwFMHR4SNCFVJicvEzJDRDghaSUyWiY7LCB3PSNeJEgxdUkwgJChgZJjZFGidkdFU38qOzwygp 0+PzhJSktMTU5PRldYWVpbXF1eX1RlZmdoaWprbG1ub2R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo +DlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+v/aAAwDAQACEQMRAD8AN/8AnMLzcUtdF8owP8U7 HUb1Ad+K1igB70Lcz9AxVIv+cWdeu/Ln5haz5I1OsMl6JEELfs3tizcl3od4/U/4EYq+r8Vdir5w /wCczP8Ajl+Vv+M93/xCLFXzy3PQY9I1LRNcLandRGeeG09SKW0kWQqiO4NGZgOWx+YxV+gvl2e+ uPL+mXGoKVv5rSCS7UjiRM0amQFe3xV2xVMMVeZ/85J/+SV8x/8ARl/1HwYq+QLDzxfaf5A1Hyna VjTV7yO4v5RtyhgQcIh7M/xN/qjxOKvq3/nHP8qE8neWRrGox/8AOw61Gjz1ofQtj8UcI9zsz+9B +zir17FXYq+Tv+cpNdvfMv5jaR5K0us8liscYgU/avb5lopp4R+n8qnFWQ/84e+bvVsNZ8pTv8du 41GyBO5SSkc4HsrBD/sjir6QxV2Kvkr/AJzF/wCU30T/ALZn/YxJirANf/MNvMH5U6N5b1B2fU/L 17wtJGNfUsZIXCj5wsgT/VK4q+qP+cbP/JK+XP8Ao9/6j58VemYqlfmu/v8AT/K2sX+nR+tqFnY3 M9nDTlzmihZ41496sAKYq/P6G/XzDrc975o124gu5gZE1GSJ7smXkCA/F1dE3O6K1OgXFX3N+UYi H5baAI9V/Tf+igyakJJJhJIWJkAeWklEclAGAIApQdMVZfirsVfC/wCdWu3nnf8AM/X7uxrPZaSj wQEdFtbL4Xcf5LSFnH+tir6P/wCcZPN36f8AywtbOZ+V5oTtp8oJ39JQHgPy9Ngg/wBXFXrOKuxV 8Xf85MeZ/MV9+Zt9oupXE0Oi6f6K2VotfT9N40dpghKq7szHf2pXbFXpX/OKlto9tda9HpvmZtVt vThNvpjrLbPECzGSV7Zy8YNeI5Ru3ucVYH+Y3kH81fPn5tX19Bol7Z2lxdLa6df3MUsUENvB+7jl ZwrFFPH1DQVqcVS+T8r/AM5/KH5i2ustp13r+oWNzDey6pZie6juCSGkUzSojsWFVeoxV9oQyiWG OUKyCRQwRwVYVFaMp6HxGKr8VeD/APOVnlLzP5j07y7HoOl3OpvbzXLTrbRtIUDLGFLcelaHFXiq flB+aflu88v69pGhXlzd8EvTCbcyG3uIZmUxTRkd+AYV6q2Kvs7yvrF1rGg2Wo3dhPpd3PGDc2Fy jJJFINnUhgKio+E9xiqaYq8//PzRtV1n8ptd03SrSW+v5/qno2sCl5H4XkLtxUbmiqTir5ftfyE8 9XPka91M6JeQ63Y3sarYSROss9rKgBaND9oxyAdOxPhir6K/5x61PzsPKf8Ah7zdpN7YXejhY7G7 u4nRZrU7InJhTlD9n/Vp4HFXq2KrJ5RDBJMVZxGrOUjBZ24itFUdSewxV8XW/wCVn50+bvzCutY/ R91oGo3txNfJql4J7WOBql0VZokd1IFFSgxVMvy08hfmn5E/NqyvZ9DvLuzgums9Rv7eKWW3lt5i Y5JldlVmUV9QGgO2KvsLFXYq+Z/+cpfIvnHzF5u0m50LRrvUreHT/TlltomkVX9aRuJKjrQ1xVh3 5qfkL5otdQ07VPLOi3V1Z6tZwz3dnDEWktbsRr60bov2QzHkPeo7Yq+ifyD0bVdG/KbQtN1W0lsb +D6361rOpSROd5M68lO4qrA4q9AxVK/NMmsx+W9UbQ4fX1n6rKNOi5KlZyhEfxOQoo1DucVfEGt+ TvzY1e7h02/8pXTapGSWvI9OaKaau3KaeNFjl3/3Y1ST1Y4q+uPyT8j6j5L/AC9sNF1NlOo8pLi7 jQhljeZuXphhseK0BI2rWm2Ks7xVIfPmo6xp3k3V7vRbWa91dLZ10+3t1LyGeT93GwVak8GYMfYY q+QfJn5BfnDqzaibeGTy+wh9Kc6g9xafWo5q84VKI/qA8PjDbdK4qz3/AJxj8v8A5heVPOV3aaxo F/ZaRq9sVluJoXSJJ7eskTMSKbqXUe5GKvp/FXYq+T/z5sfzWufOusSS+Wn1Py9OEh0uT6oL5Yol QKJIZow0kDO/JivJdzuDtiqe/wDOLv5T+bdD1288069Zy6XC1q1naWlwpjnkaR0dnaNviVVEdPiA qT7Yq+k8VdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdi rsVdirsVdir4t/OPXvOcn506xo2laxe2/r3lvbWlvHdTRRK8sUSqAFYKo5Niqv5G/Nj8y/IHn+Ly /wCab25vLOO5Sz1TT72Y3JiEhA9SGQs9CobkOLcWH34q+ufM0jx+XNVkjYpIlncMjqaEERMQQRir 4E07zb5uu52jn833enoFLCa5ur5kJBA4gW6zvXeu60264q+0PyN029svy00l77Un1a6vg94988ks gdZnJj4GcLIFEYXZgN64q+cPz78xea4vzr1nS9O1q8soHksY4Yo7qaGFDLZwb0VgFHJqnbFUV+Tn 5k+fNC/NSz8ralrcms6bc3jadcxtcNeQcmYqstvIxagD71XqK1GKvrPXtZs9E0S/1i9PG10+3kuZ t6ErEhYgV7mlB74q+Dl/Mf8AMQaqPM/6WvjGL/1+BuJfq5mD+v6Xp8uPH/JpSmKvvLQtYs9a0Wx1 ezbla6hBHcwmoPwyqGANO4rQ4q+Tf+cmvM/mXTvzTuLbT9WvbO2FpbMIbe4liSpU1PFGA3xVKfJH nj8xvLP5paVoh8xza1A9/a213bxXct5aTJclBIqeptzUSUrxqGHtir6v/MzTfMGp+RNY0/y6WGtX MIjsykvoMGLrUiSq8aLXvir4oivPzSl82nymmt6gdbF62nGD6/Lx+sJIYmXn6nGnMda0xV9p/lZ5 d1ny/wCRNL0zW55LnWURpNQmmmM7+rK7OV9QlqhAQopttir5J/OT8wPNR/NXzH9Q1q9tra1vTbxQ QXEiRKbVVhICKwX7Ue+3XriqI/OX85Nb8x+YrC40XVLqxs4dMtBLFazSQqbmaMTz8ghWrI0vpn/V xV9Q/kjrk2t/lV5dv55muLg2xgnlkZmdnt5GhJZmJYk+n1OKvnD/AJyP80eZrD829RtLHWLyytRD a8YobiaONeUCEnjG30mgxVnX/OL1lrV9ruraxeeaX16zs7dbZIBPfOiSzuH5sl3HCCQkRAIr1xVM /wDnLfWdY0vy9oEmmX1xYvJdyrI9tK8JYCIEBihWuKvIfLv5za8fyq80eVr7U7ptUpb3ei6h60hu ABdwm4h9WvOnpguN+nLtir17/nEjWdY1Ty9r8mp31xfPHdxLG9zK8xUGIkhS5amKsX/5yd0/8x9L 8xSeZ7G/urLyy621rGbe8aMeuUYn9yjg/snemKob/nG/QPzG1/zJY+adQ1W9uPK9lJOkglvZHElw kdERoWckgGQNuKbYq+q8Vdir5U/P/wDN/wA533nmXyP5Xup7K2tZY7RxaMY57q6lC/D6i0cKGfgF B3O5rtRVhWpXP54flFq9jPqF9dWpu1MsMUlx9btJuHH1EdOToWWoB7iux74q+xfJPme380+U9L8w QIYk1G3WYxE14P8AZkSvfi4IxV8dfm/5q80wfmz5gsrfX72wtFvjGtLm4WGJSF34RFiFXqQqk+Ax V7L/AM4sxahcQ6/qV75jfX6NBbQ/vb144tnd9ruOL4mqv2QaU98VeQ/nLY+ZLb87tY1jT9NuJ2tb 23ubaQQSSRs0MUTLuo3HJd6HFXeTPy+/MT8y/wAxV1rWbG4gt5rtLrV9Snha3iCRlS0cVQoL8VCq q9O+2KvsfzOrP5a1ZVBZms7gKo3JJibYYq/P/R9G1SzuWlvvLFxqcJQqtvLHdxKrEg8+UJjaoAIp Wm+Kvtf8kL3U7v8ALXSZL/Tk0oIrQWdinq1jt4GMUfP1md+R4E79qYq+bPz38satqv57aqkdlctZ 3U2nxG5ihdlCtaW6MwYAr8O+Kvc/y6/5xt8n+S9di10Xdzqmo21fqhnCJFEWUqXCKKlqE0Jbbwri qF/5yl1rVLfyDFoemW09xca3cBJ/QR3K29vSR68AftPwHuK4q+b/APlW35o/8q8Gqfo6X/DP1n6x 6HFfX9fl9W5+lT16dvDvir6R/wCcW9a1S4/L+TRNUt5re50S4aOATxsha2nrLHTkBWj+oPYUxV47 /wA5P6LrN3+a1xNaWFxcQmztgJIondahTUVUEYqlX5fWuufll+a0M2raHNf2lpIbee4W1eUpDMAV urc8TRgjBvGhK98VfbMUscsSSxsGjkUMjDoVIqDir4z07RNaH/OSr3ZsLkWv+Kp5PrBhk9Pgb1yG 5040p3xV9mu6ojOxoqglj7DfFXwfonkjX/N+v+ZLifTbqOaS0v8AVIDLE6EzI3rKnxAAs5PGg8cV Qeifl1rtz5P8ya1Lp1yr6eLOC2haGQO73E45si8angse/scVfTP/ADirJfp+Ws2n31tNbS2OoTJG kyMhMciJKCAwH7btirxb/nJPRdYufzf1G4ttOuLq39G0+KOKR0akCVHJBir0L/nF+/1Rda1bTrfy wmhaS8C3F3O31xneZG4RIpuHYDZ3Jp4Yqjf+cvdO1C98u+X0sraW5ZLyYusKNIQPSG5Cg4q8W8wf lFrEX5Y+WPOFjZXDz3X1i11mzEbmVJEuplgl4U5cWiUKdtqD+bFXtP8AziFp2oWXl3zAl7bS2zPe QlFmRoyR6R3AYDFU8/5yqsry8/LGOG0gkuJf0lbt6cSM7UCS1NFBOKu/5xVsryz/ACxkhu4JLeX9 JXDenKjI1CkVDRgDir2LFXYq+Sf+cgvy1836D+YUnnrQbeeewuJor5Lu3UyNaXcXEn1AASo5oHVi Kb07Yqw3WfMH5q/nRq+m2b2hvntOUVutrCYreIykepLK+6rXgKlmpttir7K8heV18q+TdI8vCQTN p1usUso2V5T8UjKD2LsSPbFXyZ518o3us/8AOQ1xa3enXMukX+u28N1KscgQ28ssaSESKNhxJ+Ku 2KvrHyT5D8s+StKl0vy9bNbWk0zXEiu7SsZGVUJLOSfsoMVZBirsVdirsVdirsVdirsVdirsVdir sVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVfNUn54/mJHI0bXNvyQlT+4Tq DTOiHZuE9D83nD2nmBrZb/yvX8wv+WmD/kQmH+TcXcfmj+VMvkyz8tvP35i+bvMS2cl3DHYW6+tf SrAnL0wQAi1H2nOw8Nz2zF1mlw4oXW/TdzNHq82adbUOb2vNM7hD6hFeTWU8dnOLa7ZCIJyocI/7 JKnqK9RkokA77hEga25vnnUvzk/MzTdQudPu57dLm0kaGZfQQgMh4mh8Ns38Oz8MgCLovP5O0c0Z GJqwhv8Alev5hf8ALTB/yITJfybi7j82H8qZfJ3/ACvX8wv+WmD/AJEJj/JuLuPzX+VMvkyLyB+b /nnV/NVjpt1FFf2104jmSOMRtGhPxTcl7Rjc16jbrmPqtBihjMhsQ5Ol7QyzyCJFgvdc0ju3lv8A zkV588y+SvJNlqvl64S3vZtSitZHeNJQYngnkI4uGH2o13xV87f9DQfnF/1dIP8ApEt/+aMVfXNn rF/L+XcGtPIDqD6Ql40vEU9Y2wkLcacftdsVfI3/AENB+cX/AFdIP+kS3/5oxV6V5b/On8wb78jP Nnm24vYm1vSr22gspxBEFVJZbdWBjC8W2lbqMVea/wDQ0H5xf9XSD/pEt/8AmjFX0v5M8469qn5I p5qvJ1fWm028ujOERV9WH1eB4AcduA2pir5o/wChoPzi/wCrpB/0iW//ADRir6E/ID8xdf8ANf5f 6nr/AJnuVnnsb+eL1UjSICCG2hlpxQKOsjb4q+fJP+cofzfLsU1KBEJJVfqtuaDsK8MVer/846/n d5q84+ZtQ0PzPdR3EhtRc6eyQxwkNE4Ei/uwteSyA7/y4qiP+cjvzo8z+S9Z0nR/LN1Hb3MlvJda gXijmJV3CQijhuP92599sVeP/wDQ0H5xf9XSD/pEt/8AmjFX2ho+oLqOkWOoKKLeW8VwoHSkqB/4 4q8t/wCcjPzW1byJoemRaFMkOtalOxV3RJAtvCv7w8HBG7OgH04q8B/6Gg/OL/q6Qf8ASJb/APNG Kvo//nH/APMm/wDPXkp7rVpUl1uwuHt75kQRhlb95E/FQFFVbjt/LiqB/wCcjfzB80eSPLOl3/l2 4S2ubm99CZniSUFPSd6UcMBuoxV8/f8AQ0H5xf8AV0g/6RLf/mjFX1J+T35jW/nzyXa6qSq6nB/o +qwLQcbhAKsF7LIPiX7u2Kvm/wA1/wDOR/5t6b5o1jTrfUYY4LK+ubeKNrWAsqRTMigkpWoC98Ve pf8AONv5q+dPPN/rsPmO7juY7GK3e2CQxxUMjOGrwVa/ZGKpX51/JzWYp7vVvL7jV9PaaYyQxf70 RMkhWROH7fBwV+Hf2zoNP2hEgRn6S8/quzpWZQ9QeZOjxuyOpV1NGVhQgjsQc2QLqyKe0f8AON91 bCXXbUkC6dbeVR3MaGRW/wCBLj7803awPpPTd3XZEh6h12e3ZpndOxV8pfmpc21z+YOtyWwAjE4j NDUc4kWOQ/S6nOo0QIwxt5XXkHNKmKZlOIyPy3+Xvm7zEVbTdPc2zf8AH3N+6hp4h2py/wBjU5j5 tXjx8zu5WHR5MnIbd7LvK3nfy9+XU15p8Fkut6kzcLzVYZfTjPH/AHTDyRiUU/tbcj7AZiZtPPUU SeEdzmYdTj01xA4pdS9H8i/m9ZebNXOmRaZPazCJpTLyWWMBaV5EBSOuxpmv1OhOKPFYLsdNr45Z cIBDDP8AnMH/AMlppn/bag/6hbrMBznyBir6Ktv+crNOh8mxeXj5dmLx6cunm4+srQlYPR58fT+m lcVfOuKvaPJv/rL/AJ+/7aVl/wAn7TFXi+KvtT8uP/WZo/8Ati6j/wAz8VfFeKvpH8m9VOl/84ze ebxTR1ub6KNttnnsraFTv4M4xV83Yqy/8ovMv+G/zJ0DVWcpAl0sNye3o3FYZCfkshOKov8APDzL /iL80tevlfnbw3Bs7Ujp6dqPRqvszIW+nFWC4q++PyL1T9J/lJ5YuOXIx2YtSfD6ozW9Po9LFXyz /wA5I+b/APEX5o38UTh7LRlXTrehqOURLTHbv6zMPkBirAJfL9/H5at/MJH+g3F5NYKadJYYo5T9 6zfhir1f/nFLzf8Aof8AMN9Fmfjaa/AYQtaL9ZgBlhJ/2PNR7tir0v8A5zF/5QnRP+2l/wAyJMVf JWKvSfyG/MxvI3nWJ7qUroWqcbbVVr8KqT+7n/55Man/ACS2Ksb/ADOYN+ZXmxlNQdZ1AgjoR9ak xV7T/wA4Z/8AHV80f8YLT/icuKvQfLHnb/D/AOaGveXdQk46bqV/LJbu2yxXEx5D5LJyofeh8c2+ bT+JgjMcwPsdTi1PBnlA8ift/aznzf8Alp5W80I0l5b+hfkUS/gokte3Ps4/1h8qZhYNXPFyO3c5 ufSY8vMb97x+78jee/y31mPXtMUahZ25PK4hUlTEftJPEPiUEdSKgeNc20dTi1EeCWx/HJ1B0uXT S44+ofjm9E0X8+PI95aq+oyy6XcgD1IpIpJV5d+Dwq9R8wM1+Ts3KDtuHPx9p4iNzRSjzX+d8V3G 2leSree+1K4+CO7ETUWu1YoiObt4clFPfLcPZxHqyGotebtEH04gZSYj5c/Inzdqzi51iRdKgkPJ zKfVuG5bk8FNAfHkwPtmXl7Sxx2j6vucPF2XklvM1971by1+UPkrQuEotPr94tD9ZvKSUPisdBGv t8NffNXm12SfWh5O1w6HFj5Cz5sa/Of8yxplu/lrR5aahMtL6dP90xMP7tSOjuPuHudsns/R8R45 cujjdo6zgHBH6j9jwa1tbm7uYrW2jaa4nYRwxIKszMaAADxzeSkALPJ0MYmRoc31H+VnlR/LvlG0 gvLOO21eT1HvmXizsWkYoGda14x8RStM5nW5/EyEg3Ho9RosHh4wCPV1eef85g/+S00z/ttQf9Qt 1mI5b5AxVlKflZ+Y72C6gnlvUGsWiFwtyIH4GIrzD8qfZ471xVi2KvafJaO//OMHn4KpY/pGzNAK 7Ca0JP0AYq8WxV9hfl75k0KL/nGOR5L6FPqml39tcKXAZJnM/CMr15PUcR37Yq+PcVexaVqElh/z ixrEJqg1XzKtun+UqwW8367Y4q8m0yJZtStIWXmsk0aFOtQzgU+nFUR5k0ebRfMOp6PMCJNPuprZ uXX91IUr9NK4qpafZ3msazbWcZMl5qNwkKHqWlncKPmSzYqu16zSy1zUbNFKJbXU0Ko3UCOQqAff bFX01+Q3n230D8gNe1OVh6nl64ufRjapBeZI3t1+TzS8cVfLU881xPJPO5kmmZpJZG3LMxqxPzOK vS9S86eRp/yL07ybClyfMlnenUJJTEohMjvIrAPy5U9FwPs9Rirz3RtVu9I1ey1Wzbhd2E8dzAw2 o8TB1/EYq+mf+cptZtNc/K3yprFma2uo3UdzDvWiy2rsAfcVocVfLsLRrNG0qlowwLqOpUHcYqnf nryjqHlHzXqOgXqsHs5SsMhFBLCd4pV2FQ6UOKpLc3M1zO087F5Xpzc9WIFKnxJ7nFX0V/zhn/x1 fNH/ABgtP+Jy4qs/N10b8xtaKLwAkjFPdYUBP0kVzp9B/cx/HV5ftD++l+Oj2b8nvPv+JND+o3sn LWdNUJMWPxSxdEl9z+y/vv3zT6/TeHKx9JdzoNV4sKP1B6DmA57C9e/KDyNrN+l9NZtbTBuUy2je ikvs6gU+laH3zMxa7LAUD83Dy6HFM2QyPRPLmhaHb+hpNjFZxmgb01+JqdObmrN/sjmPkyymbkbc jHijAVEUmOVtjCfzR/MODylpHp27B9avFIsojQhB0Mzg9l7DufauZuj0pyy3+kc3D1urGKO31Hk+ Ybi4nubiS4uJGlnmYvLK5qzMxqWJPUk50gAAoPLykSbPNPfy/s9SuvOmjJpyF7iO7ilJHRUjcM7N /khQa5TqpAY5X3ORo4yOWPD3vrfOUeseGf8AOYP/AJLTTP8AttQf9Qt1ir5AxV+genf+Shtf/AfT /qCGKvz8xV9O/wDONPlu08zflF5u0C7YpDqV08BkAqUZrePhIB3KNRvoxV8+ebvJ/mDylrU+ka5a vbXULEIxB9OVAaCSJujI3YjFUlxVG6Lomr63qUOmaRaSXt/cHjFbwryY+/sB3J2HfFXsv54+Wl8j fln5I8ltIJb4yXeoak6fZM5CA0PcL6pRT3C4q8p8i2hvPO/l60AqbnU7OKlafbuEXr9OKvQ/+cpf LX6J/NKa+jTjb63bxXikdPUUejKPnWLkf9bFUJ/zjP5a/Tf5r6fNInK20eOTUZfDlGAkW/tLIp+j FWJfmjZiz/MnzTbqAETVbwoASaI07soqd9lOKoSz8131r5O1LyxGaWupXltdykf8u6SqVP8ArM6H /Y4qksUUk0qRRKXkkYIiDqWY0AGKvV7v/nF/82LW0mupLW0ZII2ldUuVZiEBYhRTc7Yq8mxV6Lqf m06r+RmmaFM/K50HWiqAmp+r3ME0kf3OJB8qYq86xV9jf85NflevmfyuPM2lxCTWtEjLuEFWnsvt Ou3Ux7uvty8cVfHOKvo7/nDP/jq+aP8AjBaf8TlxVL/zHk9Tz5rrUpS8lX/gW4/wzqtIP3Ufc8pr T++l70B5Y8x6h5d1u21axaksDfHGfsyRn7cbezDJ5sIyRMS14MxxzEg+tNB1uw1zSLXVbB+dtdIH WvVT0ZG/ylbY5y2XGYSMTzD1mPIJxEhyKPytm7FUj84+bdN8raJLqd6eRHwW1uDRpZSPhQfrJ7DL tPglllwhpz544o8RfKnmDXtR17VrjVNQk9S5uGqf5VUbKijsqjYZ1GLEIRERyeVzZTkkZFLssan0 z+Vf5a2nla1GpyTtPqd/bxibYBIlajtGlK1+KlTXemc3rdYcpr+EF6fRaMYhf8RZ/mC5yW6/5a0D zDZpZa5p8GpWkcgmSC5QSIJFVlDgHuFcj6cVSD/lTn5V/wDUq6b/ANI6f0xVlSafZJYLp6QItisQ t1tgPgEQXgEp/Lx2xViv/KnPyr/6lXTf+kdP6Yqnvl/yt5d8u20ltoWnW+m28z+pLFbII1Z6BeRA 70GKr9c8uaDr9n9S1rT7fUbWtRFcxrIAfFeQPE+4xVhL/wDOOv5MvP658toHrWi3N2qbf5AmCfhi rL/Lnk7yt5agMGg6Vbaajf3hgjVXf/Xf7b/7I4qs8weR/KHmKaKfXdHtdSmgUpDJcxLIVUmpCk9N 8VQFj+VX5bWF7Be2flrT7e7tpFmt544EDpIh5KymmxBFRiqY+YfJflPzG0Da9pNrqbWwYW7XMSyF A9OQWvSvEYqt8v8Akjyh5cmmm0LR7TTZZ1CTSW0Sxsyg1AJA6VxVBal+V35d6nfTX+oeXbC6vblu c9xLAjO7HuxI3xVCf8qZ/Kr1Of8AhXTuVKU9Baf8D0xVWt/yk/LG2uIriDyxp0c8LrJFItugKupq rDbqCMVZaQCKHcHqMVYd/wAqc/Kv/qVdN/6R0/piq4flB+VwQxjyvpwRiGZfq6UJWoBIp25HFVv/ ACpz8q/+pV03/pHT+mKsvSONI1jVQI1AVUHQACgGKsRb8nvysZix8q6ZUmp/0aMdfoxVNvL3kryl 5ceaTQdItdMe5CrO1tGsZcJUqGp1pU4q+WfOEwn8263MBQS3904B7BpmNM63TiscfcHkNSbyS/rH 70ny1pfRP5C6DruneXJ7u+kKWOous1jZsNwKUM3t6m1B3ArnP9p5YynQ5jm9H2ZinGFnkeQen5rX ZOxV82/nteatJ55ktbuUtZ28UbafENlVJEBc0/mLggn2zouzIx8Kxz6vOdqSl4tHl0ec5sHWsl8i eR9T82azHaW6sllGwa+vKfDFH336F2/ZX+Fcx9TqY4o2efRytLpZZZV06vrCGJIYUiT7EahFr4KK DOWJt6sL8CoPWNY0zRtMudU1S5S00+0QyXFxIaKqjbtuSTsANydhir5+8w/85jaXBdtDoHl+S9t1 NBd3c4t+QHhEiSmh7Vb6MVTHyj/zlz5Y1S9hs9c0e40l5mWNJ4H+uRc2IA5AJFIB/qq2Kp9+an/O Q9l+X/mddBm0SXUHa2jufXSdYhSRmHHiUfpw8cVYd/0OZpf/AFK0/wD0lp/1SxVPvIn/ADk9b+cP NmneXLPy3NDNqEhX12uVYRoiNI7lREK8UQnFUh/6HM0v/qVp/wDpLT/qlirv+hzNL/6laf8A6S0/ 6pYqzvyb/wA5CeWfN2l6o+k2c669ptrLeLok7Kj3CQipEMq81J6DcA+1N8VYJ/0OZpf/AFK0/wD0 lp/1SxV7x5Z8zWGv+VdP8xw/ubS/tUuyrkfugy8nRm2H7s1Un2xV4VL/AM5laOsjrH5ZndAxCP8A WkHIA7GnpbVxVEX3/OXVpZJaNceVZ0N5ALmNTdqD6bOyqT+6/aCch7HFWaflF+edp+Y+pX9jBpEm mmwhWdpHmWXlyfjQAIlMVTH8zfzr8m+QEEGoSPeaxInOHSrahl4no0jH4Y1Pid/AHFXi8/8AzmVr ZuC0Hlq2S2rtG9xIz8f9cIor/scVegeW/wDnJ3y7rnlzWNRTSbmDVNFtDfXGnFg8bxK6Rnhchafa kH2kX2xVi/8A0OZpf/UrT/8ASWn/AFSxV3/Q5ml/9StP/wBJaf8AVLFXrGi/mtos/wCW8HnzXI/0 Hps6u6wyP60hAkaNAvFVLNJxqqgdMVeRaz/zmVbJdsmi+WmmtVJ4z3dyInYf8Yo0kC/8GcVZP5A/ 5ym8r+ZtWtNH1HS7nSdQvpUgtSjfW4WkkPFVLKsbryJH7FPE4q8e1SX1dTu5dz6k0jb9ficnfOwg KiHjspuZ97Ovyh/LlvM2p/pHUIz+g7Fx6gI2nlFCIh/kjq/3d8wdfq/Djwj6j9jndn6PxDxS+kfa +k1VVUKoAUCgA2AAznXo28VdirxH/nI3SKSaPrCr1ElnM3yPqRj8Xzc9k5Pqj8XS9r4/pl8Hiubl 0j6s/K/ywfLvk+0tHmM0tzS8mPHiFeZFPADrRaUqf7M5fWZvEyE/B6vR4fDxgMszFcp2Kvnz/nMX Ub+HytoNhEzLZXd3K90B0ZoYx6QY/wCzY09vbFXy5o66Q2qWq6w88elmRRePahWnWKvxGMPRS3zx V7f+XP5Y/lnqf5gaDf8AlfzdFqNlaXK3N1o2pRNb31YAZEEYZVSesgXkFAoK9cVSz/nLT/yakf8A 2zbf/icuKvNvJ2m+T7++nj80azNotokXKCeC2a6Z5OQHAqpFBxqa4q+if+ccPIv5dR+Z7/X/ACz5 huNbn023EEkU9m1oIjdk8XBZjyPGF128cVfK+KvRNW/LPSLP8mtF8+LqjLqWp3EsD6XJw4ssc80X KGlH+EQgtWuKrPyAlvI/zg8tG0r6jTyK4H++mhkEtfbhU4qg/wA5fJ/+EvzH1jSo04WbS/WrDw+r 3H7xFH+pUp/scVepeQ/zK+of84y+ZLIylb/TZH020Ffi9PUzVSp8V5zH/Y4q8K8s6DeeYPMOnaJZ j/SdRuI7eM0qF9RgCx9lHxH2xV6F/wA5J6ZZ6V+Y6aZZJ6dnY6ZY29um20cUXBRtTsMVT3/nGDXY tAbztrcq8003RzdGPpyMTFwv+yIpirxvW9a1LW9Xu9X1OY3F/eyNNcSt3ZvDwA6Adhtir1byj/zi 7588xeW4tbNzaad9bjE1jZ3Rk9SRGFUZ+CsIww6dT7YqzDQPyr1jyR+R/wCYFxr9sLfWb6P0QgZZ ALa3KlGV1LCkjyMfoFfZV82Yq9P0/wAl/kneS21svnm9F1cskax/oqSgkcgceRb+Y9cVZp/zlRBP oWm+SvKVqzDRtOsmEQoQJJYQkIdutWCD/hj44q8Q8sR+WpNbto/Ms11b6MxYXU1iqPOvwniVWT4S OVK+2Kve/wAl/wAtPIL/AJladrnlrzXb65p1jHLcDTrhGtr+ObhwjrC4X1FQvyLrShA7Yqzi4/5x xZrhpI9drE0tSj2/xCImp+MSULU/yaZuR2tt9P2uml2RZvi+xn83mfyB5J0yHS3v4LaOzThHZxn1 Zqjc8kjDNyY9S1N8wBhy5pcVXbsJZsWGNEgUwPX/APnIqFeUegaYXP7NzeniP+RUZJ/4cZnYuyj/ ABn5OBl7WH8A+bzvUvzU8+393HcyavLCYnDxwwUiiBU1FUQAOP8AXrmwhosURXC66evyyN294/LT 8xrPzdpvCbhBrVsB9btQdmHT1Ywf2T3H7J+iuj1mkOKX9Eu90erGaP8AS6tfnHo51P8AL/UeKlpb LjeR03p6R+M/RGWx0GThyjz2XX4+LCfLd84eVpbWLzLpUl2kclqt3AZ0lr6ZT1By5UrtT2zoc4Jg a5085pyBkjfKw+xM5J692KuxV5l/zkLe+Srb8vyvm21lu7G4u4YbdbZlS5jmbkfWhLbco4w5odm+ yeuKvlzzR+WGgWfl2fzL5c846ZrWmxcD9Rkb6rqIEjhQv1ZixLLy33GwqMVYDa3VzaXMV1bStDcw OskMyEq6OpqrKR0IOKvUf+cjr65v/OGjX11/vVd6Bp889Bx/eSK7Nt23OKsJ8neUf8T309p+mtK0 T0IvV+sazc/VIn+ILwR+L1fetPDFX0p/zjhoOjeR7vWbO+83+XdSu9cazSwt9M1FJ5GeD1uS8GET Et6w4ha4q+TMVcQQASKA7j3HTFX07/ziJonkmaK/1dGeXzda1hlilK8YraU/DJAo3+OnF2O46bA7 qov/AJzA8n/WNI0jzZAlZLGQ2F6w6+jNV4WPskgYf7PFXzDFqNxHplxpysRb3M0M8qg7FoFlVKj/ AJ7tir3D/nEbycNR83X3ma4StvosPpWxI/4+bkFaiv8ALEHr/rDFUk/5yp/8m3c/8wdr/wAQOKu/ ITRbnW9E/MPS7VS91daGy26CtWkDFkXb+ZgBiryAgg0OxHUYq+u/I/8AzlH+XqeUbKLXnnsNXsoI 4JrWOB5VlaJQvOJkHEBqVoxFOm/XFUX5j/M/R/zC/IzznqemQSWqWiyWrQTlfUoDG6SELUDmrdKn od8VfHOKvVdB/J6K31HTtQl8+eT1ihmhuJI/0sBIFVg5WhiA5UHSuKvcP+cgPMX5Uar5S0b9M3A1 Gzv7x4rDVdJline2KIfWmUqWSRVYoskdd6+IGKvnXzr+Wml6Foseu6N5t0vzBpcsoijjgkMV6OVS C9q3Jlpx+L4qjwxViWhavqOjazZarpsjRX9lMk1u6Eg8lNabdQ3QjuNsVfob5xSeTyjriQBmnbT7 pYlSvIuYWChab1r0y3AR4kb7w1ZwfDlXOi+Sv0Rq3/LFP/yKf+mdV4ke8PJ+FPuPya/RGrf8sU// ACKf+mHxI94XwZ9x+Tv0Rq3/ACxT/wDIp/6Y+JHvC+DPuPyRmkjzLpGowajp8FzBd27B45Fjf6Qd twRsR3GQycExRIpnjGSEuKIN+59LeT/NFt5z8uzR3lq9pdGM2+o2jqyj94pUtGWG6MK08Oh9+cz4 ThnsbHR6XBm8WG4o9Q+cIPKPmdNcFjb6fPJcQXXoB/Scx+oknGrNTjxr49s6E54cNkjk85HTZBOg Dse59dZyj1jsVdirxf8A5yS/LDzt54sNLfy80M8Omes8umu/pSSySBQHRmpGeKrSjEdcVfLd7+WH 5j2VyLa48saosrHigW0mcMdtkZFZW69jir0f8q/+caPNut6tb3vmuzfR9BhdXmhn+G5uApr6Sxfa QN0Zmp7VxVP/APnI/wDLHzxr/wCYMV75f0O4vdOj0+3gWWBV4BkaSqDcdARiryz/AJUf+bX/AFK9 7/wK/wDNWKvSf+cfPya85ad+ZFrq/mTRp9PsdMhmnhkuAArzsvpRqKE7j1C/+xxV5t/yo/8ANr/q V73/AIFf+asVZ95k/IXzZc/lT5RvrLR5v8T2H1qz1XTQAJjBJeTzQSEVp8HLx6MPDFUj/L/yN+d/ krzVZ6/p3li9LwNxuYCoCzQMR6kTb/tAbeBoe2KvrTzboEHnPyJf6RcRPbjVrOiRzrxeGYqHi5rv Ro5ApPyxV8Un8jvzbBI/wve7eCqf+NsVfXH5EeRpvJ35c2FheQ+hql2WvdSjNOSyzUojU7pGqqfc Yq8U/wCcivyy8/eYfzKn1LRNDub+xa1t0W4iUFSyKQw3I6Yqn/8Azi55A85+WPMGtz6/pE+nQ3Fp HHA8wADMJKkChPbFVH86P+cZL3UNTuPMPkdIzJdMZb3RWZYv3jVLPbs1EHI9UJG/Q9sVeFz/AJT/ AJnwzmB/KerF1NCUsp5Er7OiMh+dcVerfl7+U35q6V+X3nWG70sw22uaesVtpruDdyXMUgMbLEKh RwZweRB6bYq83/5Uf+bX/Ur3v/Ar/wA1Yq7/AJUf+bX/AFK97/wK/wDNWKvU/wAxv+cfvzAuvKfl SLQ4oruDRNLWK50oOIp1u5mae6kXmQj8namzV2GxxV4xP+Wf5iwXQtJPLGqi4JoqCynbl7qQhDD3 GKvX/wAlv+cbfMcuvWev+crX9H6ZYyLPDpspBnuJEPJA6CvCMMKsG3PSlDXFX//Z uuid:ED15957E092F11DC89058E734AFD0A4D uuid:082FE9A8093111DC89058E734AFD0A4D uuid:ED15957D092F11DC89058E734AFD0A4D uuid:ED159575092F11DC89058E734AFD0A4D AdobedC.    u!"1A2# QBa$3Rqb%C&4r 5'S6DTsEF7Gc(UVWdte)8fu*9:HIJXYZghijvwxyz?ǿ{{wq|c5:yfwj|+r[;]xitOEUesfwKmR++uT_},5{{e_^߽߽&wG5ބ۝=;u|6;=ux.7pdX2ژ\-X(r@HG{׿{{{{{{{{{{{{{{#ݳ`^N1>CMco]˴KG:(ǀҺJTF҆($`o~z?e_^߽߽/ ?r/d~Zt_nn]D?]vY8>g4uzQFoL.~YI641-0ؚ=v?#;KeP4+6mt=Z@,II*31{{~~~~~~~~~~~~vi&I`?`Bw b{c~XV;aQ}~J }$)0ĉQU@y~K|ܿg{ٸ09}-3}>y"ckQFdTdu6 ~~?+z ?r_fWfw>ONʤi8|cn\aX9 X40O߽ٲOy/G/bG|!ڕR3_ۃqSg.ޝk|e1m%j6YT1mg913~{{{{{{{{{{{{rK< 4Qy%G!#4߽߽b?_CWzu}ټ/RacꍈlNQy\n6pmI +&Io{{ _|#~WL ʛ%,ofSl(h2uiry&6 VkYY߽߽{{{{{{{{{{{{{{Ce_^߽߽?GO}3K ݽ-E}y{?yfaė6Fs1O6uU<5/O,궆:߽طEuʏϒWpuotvW,)[_!,Pw6E5JOA@{߽Ŀ/ ?r/d~lFwOe3v7ovR|.{o׺TX>@`'O!CI_~~~~~~~~~~~~t#fPmeq#׹j%l-&6$?nVMIC̔eHi)}ͺ۫7n탔-X0]]N0c{{+X穷W[o׻nM[O=K&`kh22~~%C4)wW B|w]qPn>ٵ49LXڰQv[7rjFzWtb~{{{{{{{{{{{{{{]wNlo :s7&݃|,Y6\~>z|yodo:tHgP5LYϽ߽-fRM7T,EټQKԹLMM%u;,УAU6;,ȟ'cIMYvճbK*W~yf )r<\pW*x {{{{{¢>g_͟08<9.b&e-+]$p$38וYZ<](b4*'߽OJ|dO gg9Mv'?]WӴI"uЯdϚwp;Wm${߽e6c0uX%C(ejznSUn>t!᪣$*{{iksЊ]x" 8_nvޤUb{pJ(8RJ{{: ?O{{߽뛳| tv'Uﮪ=CYwK-;uEt3pEǶhc Yo,BXf{(߽ӳWS?oo}> tWu7[O}ϟOy߽ ؿ̳GWc{{/~(c{dOdvwUlbeeξdV:ъxOڍ '߽߽>Z$se[-؝ͽ4VGz,=-C%.jaVO\wgmZLV:#TTq)$O߽CT|R|}Voߓ]|_%tgakM56 qږ5xg,/~c/v&x{[/emL$m{[l)&6 Lc(0K6$ܟ{{X{{{{{{{{{{{{K ʇSO !1*mԹ,gŭ{߽߽߽?}v>HAy,DvtjR£onU#t~~?#Gp}r妃j|Y26ZzQܝMxi"_ƢhQ.6&Y->`4Sʧm> 7Wʜw,rUm)RRc{>xC j2~{~*_}߽߽߽߽߽߽߽߽߽߽߽߽߽]wn_/-WYQޏ}iu w|4V1IO.Y]|:R{{7߽߽?#+#bu?& |g9 ׽3<|e,HٔgpQNb{9Cf->?6~e؛WwLd)XE5#rUo۞,NS-@QQJk%)}d~~~~~~~~~~~~~~|z4wFOl:鮟IzɲCkvrXšmYv_{{# O">Q`)m{t6߳:GwݓPɡS$0:`bo7߽su?{u{c7M6\`{p& %,I7Y"fVIf^ ׳Gwu~=htSxjb6Ue*=c~~~~~~~~~~~0Z^?cѻ'3-T;i|9y`Eۻ~-ݸ kd6 ,T>n~z~{{>mJ'o]a%r?&~%|;' ~'N|e L7ᨓwtGXNI=gNn__)MGޛս۷O^uc+u;1ݙ,۴۞qR掃'Q$!{}߽6a,0czR]˶k+PfWmz $V0˧qk{Fٟn˔=͘ g#3Td2lRSWT,ygr>pN^.۵>K|}ed>1U)1{7nKq=6qn"#C5v(K2߽Γ37tec1[TM}؆kF/LJrAfݏ ~{{{{{{{{{{{{{'./f]=B~cC_zu.=#7gElt]M+v:)*vw1}^2V>\˺ݷ{3wF[X=ř^Y76cijīQ3D{{gM7D|evtWkl̔fNev|qyfRTȄ{{ugd>-{Way["{o>iI_!W}߽߽߽߽߽߽߽߽߽߽߽߽߽߽ٔ_&E6-C'mWqchj_Xߵ JKTm< |N*V: ߽O՝:_z:5Q m)NwۙXEi(2et}߽G'QGWUcUP⒦zQQ$-SVp2%$ '߽߽(iE|U~O~~~~~~~~~~~~(%l_\EC}oտ=x|\fmA(vVۏ1cK$=|{dSVdh&`hk~9~u4d>NQT5,qlLW]Ȅ+60pqӆ yqJƫ{_.2n_z7VuwڛG{ۃzvZdda1R8mٷwGuF$5U4{W{{{{{{{{{{{{}<|X_*l7aVlڊyZ}WS-eF ]V}U'?@}$YXol?gSvO[ɼ`vV=߽KZml{U6{v㷌&{UǗČZ_{{o߽߽E?3۽vV_}>#U\UmӽSVp&1㷕&Ei5(#_{{ۓ߽߽߽߽߽߽߽߽߽߽߽߽ &POr=fjٹ#3Mtwv/'횪r5y,m*ZJ|f6zZ,U~4?fhL|O.f^ŃjWnglmul&-2.v[.~:#I'\w$N-wY[4:t={{5{{{{{{{{{{{'./f]=B~go>w}ꯚpñ־Si(43txet>~V?_Þ?Fv;U[۸:javQv5䒢:ETZ YK3rO 6{sXL:9ir6X* Z9b~~࿗g|&L}2>yN5NOb |KmD'ejU3*i'ʷ?P|~A1fb ql cu/Ͽ?åkZmf<*\4͉[ q%\UT "0/;{߽ٱ~~~~~~~~~l;s6N{uip[[hrr뙒c2c.?I$ {_3~J' nn'ݽdlo^m&J=TVb*5=߽G~~~~~V?H)hz;pe#?+ԕMWFVwd{3up CI#tJG{j>i_~~~~~~~~~~~~~{b8d?Gplvbݓ8܎߮h**V)d)iYMŽ?*T)9vMVj*}_^cuG')TqUazyeXF4~K^oEO7?@;O+⯿{{}{{{{{{{{{{{7,/{z1Ζֻ-_{ܯ9l9%vnKST[ 棩EC#_߽߽O?kZv ?BN# e#r>[{J M1^֒|Hdi=Y=++Ee7̖7lah6<^bomTT)i"B(ozn pW ]>Ovj_aVgHZ=Ž18,E1dr~e~~~~~~~~~~~~|lf8헅('/CQCeQPTbmͻrG,lmt*{=߽߽߽߽߽ǟ/7ufV>[`r7An}U.J8$x%?fv7f .jt7߽o=߽߽߽߽߽߽߽߽߽߽߽γ61޿lE4=?#br2Fa Y>*zN&?plݩu8"AMpEǿ{{o_OcuM~Qı}v~wtB <ۀfkRܟ";x~];Sda۷1U]#O<5Ye~fT|P5WOYܽɲh6Tː)U~jǂ"}߽߽߽M?=͇0;Zzp;7u{[# ={{0SRTٷĽs)8ݽKڻ=%nœ,xmlF ~zͿz_97i~~GȯE?%/:ްU=W-OpSn۰f] JCF}UoKG&?'%#>VTnո>2]CE>Cu=Y4*f=]m[]P,G[,I߽>~Exv{|ܻ&hmcz#MA TDdp{{U.oJ67]ސ޶]ߕrݧ(Dck:K]jZvE%L`]G>bQwT_ͫ{55;nYNomM9>=_V77e1O%<@ª~'|~{6u?USǶ:^o۔?l׽ъRnݿu vc3Q}NZ:SI~w{{{{{{{{{{(Q/_~\Orw١!Mі[sۗ3 .qWTWf 1P!DՐ3O{{Ϳz_97i~~|q~LvxiWg~%UڴTۃp=nL+yl3UmN@o{{?og#`vcz%={5q{inWneap,؆jxqE< %;6ro`NHfgbnyz[ݣ󻆗wm̽&}Gޡ͉$KEs~~~~~~~~~~~~6ro=? c@uw@YYn=ѹv[l Jե5>Y~亹@=?͇^FU۽GF[kpe,&LIlvY`a<#>~_|~w A9w;k/xX5YۇC{PKY=MaI2;vd{=߽߽߽߽߽߽߽߽߽߽߽ޞ~v7f|!ӝywV[uTG9f磖~uuƅ5~_kXX+(10=Z}ә>H&zl+zXjp߽߽#ۺ2ؽcKe54-ڝa1.i\.a*KMG"ON {O?wLdzV}v~j ێo~cOQ5DG`et%7娨Z==߽߽߽߽߽߽߽߽߽߽߽i??&Zn?n쬝^g;yW{r ]x MQGOu bfX߽(5,;wM۳egqTxY+!LV>nz#$~~|9bXό7 n*u,Tt4VTbYro=fovM:{".{?rYf'86  GK2kIñ+/g,߽߿ؿG_uwtx[utlpmta}kve}e"l#d~b_{{{{{{.'\GOϏm?wXFWpE^OߛWՑSK{{?Y>d|ue?>:~nXowc%rT8l S1e*X#ΐ(+" {{Gl|!л%}_GLv>W!ӝuT2xcjyigE #}7bV_πYc{{_^WSP2/յQ|SUWUS"OMMObP|hǏeI迏xY[.ː NFYw1YAOSENd|uI[md.\c1OOjN姠j6O;sy]r ^Z%*)  {߽߽߽߽߽߽ [b em3;Ox򿡶{ndjpmn]y|e業*Z)Q]YG߽ؿG_v7,Lu>3erUlK]]ROIKR3,HB!A?Aξܛwwqi簻n5P氹:uiLl45d-~~u_uc/ȿ:{e.ީՒڵrݘ,f߬૩bx"߽_YK#lo~~v/e{,7{{;|߽߽={{yÃݻ?v;jnm϶\UE^/5b⩤ZzyRHݑ>~7.+#>a7>B=1[+GL+*<)2 ZB%wD@^}߽obV_πYc{{c]_ 6e7c7mvmu~2~uڽ*X)7+]s$/p)_*~0|au%~G/ǚ]6RhToSSPKmͿuamw^(?f-8v8 Ja)$X~~bV_πYc{{ñ+/g,߽ة;:ON]Cf4 ~o4qxOQDd]L5 ߽٫~~~d"+ E"jJ:_i*hj)iD &B+{{W0paҿ8~ ven_μ1?'Y[Oz_luE]GO ,JDf~mh)jki訨櫬:jZJZhj!P@ñ+/g,߽ر_:>|Ϙ;~C3lԝcg%{'wg31*r4RaƬ~f߽߽ج+'\&Yf2ՔV'!+$AI 4ҺGhYPO{{"_YK#lo~~v/e{,7{{;|߽߽9ȝ}?nߩ϶ϐG۽pX)amlߛ̌Mհ> M2`]o~f߽߽߽߽߽߽߽߽߽߽߽߽߽߽?!+6ȟ[4ev ,&Eq뭗2DS^DdRYH~Y6(-&ikkL3\Gdl:zü6> o/?Yc~v֝Ѵh7NF퍉ixmrM*nM!"u }߽߽߽߽߽߽߽CwKĎ|=>:/C:{s0d59-7=COGQNӪ"F߽oe?>:~~bV_πYc{{O^x.O?;wG?]uon a3 h=W]U},>v~o߽ސ%~~~~~cE|/]=gpM㷏]l̊v9'͍2ZU RGWh S~QN晲sG.oW(wꚮU,*GCwv%_IS2VC[:if{߽ y=?{ ߽߽߽r1cֿj6 Sn>mڪ%'vU DuRUoH}Gl~~{{{{Y>Q*Qnܮ{'u|xSm"qmCwl>েjUQSD4u~Z^ؿ z{;׬2ݟ+$?m=v8 ɂqdc\G{{}߽߽߽O CC4ܺl?sI*頒i)GqXqHXRSmv*eD- f.z#{L߽2{^Ȳm]r7¥E}Oc8[rufc7U[*jޥRWR{߽߽߽߽߽߽߽A7o~~@=߽߽߽ݹ'Zﭱw$Nx?E&RdoNe)hwtK6.ykXc 4)o{{@,SKMK :H)9 ~~߽߽hLY*a0nl6@ʊj ;c$?a!O0'~~~fC4`~~{{#RG~e-T]մ~J2YD8፧^ҒDP2Ojfl0UbO{{Y?aۿ̓7b2-S$tǗvJ֤4@9VWf+YC `Ā}Q?~~eow=a[W{5JԛG}lξ8DvClu~~/{{{{?| ߽߽{{{{wwGoj-+쏌!Z.~>fvdolM ֪MaB{{ {{{?lHz<{{p>oֽ[hoRMFb%'@CG[ ],HeVGS~j׮?Π[}8NAC{ TܳΑ_ЫP߽߽@߽{~?O:߽߽N߽f? ZnJ7S>՛hqur{{P{{{{{{C;c»S^J'`#VX}(KYέ {{{{{{{{{{{{{{(]|vfS:lOd7|V|f6iۖfo,|WmNiK^'6i_ij%yyiidbK,YGbY$s{^]]:9elGW=]F*o#0[S,.=Eb<ܕ@?]$~n~~~~S|؟i߽ސ^c_#:t^I;//plOՐUiF!V@I4G%w>q?My-/}llv?Tn]Çl]>KwacȮ q83=cE<f$x>~_{{{{"°?#w!=߽޸>{TO/O_c0N==F_uu-V#6<[3E>籘^JhftMD~z#{{&/;_C7]6Fx(j'Ѯn*:>S!nh}u}Ž>CwOmwcW״whbroőܹQ]t% B>{,nae>w/M0aKSO͟S9H h1hM`i1@E'%wGßRl䚧9]qpδ,F5M>S2?xmW`.)~sMhl=ٛ1KvGbmv~E9wv?rd'C4l  ؿ̳GWc{{ʋ;Ӈ{s?&ظN]evVś޸ jmQ3-TUԯ"@VV{O@bU=W& 0s _᠋n]f;SEO]%=2S'߽e.k663L~ @Y _+W 7CMi*++'HAgvr}߽ޟ[f[ {esWal>y,oc*Uee+t.q׾w'?'QCkhWÉԛ{hjw&_Y-̜;fW,Xg{j?ɯA:csl.FKιٻLKlm%H>6D U3߽8FB C`lV&Zh2حպ8,F2zJHrWB4k u{{|/]ub߽մ=M;d- F'ft^(p[QĦ6tB~{{{{H¾o#8˳U/&icD d2Ir# Jg߽߽okƛ?zǟe?n|mrI>?Sg!~ܪXGַ߽1>g|A\^>߸:ZjFn6p@m;ofA@Z)MϿ{{)|Cn5&`U[3C{scfwml io*K}Ho:W0%?E~u{hd=alͽPSͣܘܮٓטjE; K5 MƳֱ{??=`{WGďoTӛfq-6d3&eG!Bν߽߽߽jv_$ K߽߽hKO5nOfg?9LWUyQ#_s21̇{9(+VQHcŢ{_x6K!ӵ&K]WRFM]CQ%-];g̭ol]u㞢#,]M$22g *TբJ{{{6?7c|lT|X04ݣ6- vnm}N\Gnf?edӵ0j9޲=i/YΑ ߪx>X-ֽO sEyδ&ru AG$堒1t{s Y6{o2L##1Y|U\,mu4d6ԃ~{4I~Sm;E.6`un~3g%$c>MPUڭZcwu{{{{{"°?#w!=߽޸>kyO5|uX?^{7"% ~/}/軓sT=O۴ ecsJX -ٍ5f2i}~~{{dAp~ =gzmnZ,/w`GUd%tC~4GgOmV"qZWcGw.TMPle&q m. v~~G]{w_~CQ>k@tCHJn۸ A ` E׏~~t~~~8O[7@߽߽ߨ/Gδٽӟ ;zðpn 0I("mI߽~ ؿ̳GWc{{*/_ {{{~:p/z_oڬ6mvQԹj4~~U~~~~~oR{;߽`|M_v{{{{{{{{gͫRՔv6jpG~OIf K.d@б!"ʌJ/߽s?$1?-+gOIt-2I<{L.I)V#`}2Ul?1jL*%Eޚ:JIQfxe*HRUWSPTVVCIGGI 5UuU2,4=D8DD}߽ٮ5_]tGuQ&*j6#C.SZ3f3Xd>L${vڻ1!߿˪c|f:x?y*H$`G .,}߽߽߽߽߽aKf [j{|nL[{ ܹ:\. Bͽ߽߽߽jv_$ K߽߽Oy||αTn^߈:nQG,Ÿ:=1T9댞vFVR-K/߽z:*'h)ix*) u&Y!2oܷ{%sϚ:di᧧|^||RRG -,rUT;,qF@~~7#o߹O{~S~~~~H?/rWG}߽߽߽c{{=߽߽߽߽߽߽߽߽߽߽߽޻.vwV/W~Ԛ MܵRThV*jI%.|zE^{?FҐ>޻gwov6Kpnܥ> 7c_].o'SOIMXz7).SWE(7 Kv6`lmR(c3GH[/EU=vYɂKCJ?S)$~.*65pbvvfvnʜl ͗hʩe@l/o~~p>v[Kw`v殧Ň޹z*Rtn8z}sWFb~a~~~~E`~F?Cd{{p}߽ݿ9/׷~~@ Oa;'iVl=Hb̮f,Vb(eofF"`˫&߽ސ%~~~~~~~{IV//UO%N2z g(^>ݾ OYJ['z4qZ(d" y=?{ ߽݁]e}+6Uu'_}sg}{ v")%u ?\Gl{{_ N;I?Elnx*7Wv+KLUNTJėv$~c{{{{%¨g!ah>5dvenkfM9dfyF&R}\f3%cl}v_1bq8JO%_Q%?CIUյRqE4HT@~f&+߽߽9Y`) 9a6)$R^9#u!A>k/H?WyY]lTPx+gDOōŃŧC^ ؿ̳GWc{{ݏoďݗ dbuf\uAŁxBXLjil|sƍck{{Yw+/ΐ %ۛg[kv tmmdž1{!OfU2OGd" PXՁ~vC[?c_/xoo{{$#?Ϳ%?˿}ҽ K;Vڕ=ۻyq,Y R%RQZ}~~~~GyG~{,>3u (ds|e%[˯]==<3r,W[~(Πv#ܿT_a~ f6ߌ07c>Ԙhu)^s8)8IqZ(I){{W߽߽}_S߽߽߽߽߽) ܕ_~~~{d~~~~~~~~~~~~vUnGzm%m-킮ۛLO%N+#*ge!>_v+hYzwVmCUkETCIqjL^L2%45~Z'fc)G;O!W_/ᡢZ8ntĚQo~m~ ;O;So$f{NjvcڋsA}%ijR:6: U{߽ |~z{ǿ{{{{{{C]Έ|e{K;VL|tȞQ")c>^_Ӫb]?o{W{'߽߽_H70ۻ2 t)"SuUK-L?~39iY '߽3i`p[j`glm]omͽp8\]4TX>H`4U(߽߽{{{{y/['ɭf={pG|uj>Jg#X Cstؗ`8UĻIn~v4=KRTS| G-=q0[iVnݟ+)k跞ꪫ zaSd :@{߽߽߽ު+%=bbzg hq^fSzvM'e4"i j>~^_UĻIn~{{{{{{{EW>:)j#jzZ֚z$j`4Bh [~^Nlݟ̟wgr9n B+2v#Ud25rM! w6߽߽5O۴`n=MXחǏݘVG5eɜSBhUe{{߽߽?N7bRtRlV9]ÎT+O)F?iKXCՠ{߽ߺ_:':w6gg쬑߷$J-ӱ7;s৚/ztc#Fޙ##߽߽Mo'>F6}w^Tzÿj66^nMM4R4s=$ > |{oڴ{:0X=Qs4و9;C)6.M;F 7߽߽ 7䔝>9v>'}m>ɠ'ٹ5{hY *U=]|iG{{Ӫb]?o{Gޟʷkgʭ_ef'?x=m&ݰWaf>ko.wv{ؘސn-vjS窻+ >EjbkPYa*Ҕ ߽iEoXgueAwb~ߛC|Éߣ).xkj:LjAj ֱ{=߽߽߽s*Doߏ{ng:K]Y쭙ٕ;'%Sf)*b5S~zZW{'߽߽o\@9x!)7jlMo_ g*g-6V< Nl[t߽9d.a3;?=ѵQ;X]Łٸ f; nT4 _Sj%!n=&NU(^쿐ۋ]ZQl86n#0{qGd٪W?d[{O]02/M[%1Ci&*|.j횀 ~*xZ C`߽[w]=w&u&/t|l] VQ`@Ͽ{{c߽߽߽߽?8>^{OpǤOvd|Bf̫O~~a{!?<ܹ FvNc.x-Qv91RI{_~~y?~u'_;)eaU1 _|DɓٝRFmlNa2Gm7VTJ߽@:u_K?vm~~i?Y?̏=uwe~CwU,Fǣv涖fL3DUcX>+.@o{{߽߽߽߽~wow`p8:S-鶷TjH2-S.X T!VR%t{{Stؗ`8w:ڿɓȝߟ;k?xnҔ_{~~~~~~~~~~~~~ek¿?P#h+s\o_]EDT$ӿk]3bPR9R5E|5>8mMD*'gvo`fሱ=>;C֔52F*9O߽/_˿}7NQd<M=ESU"Qf v64 d~?{{{{{{C\9_01wwPdslLOL᷍16jcVv.ޞQa즕M!@X Gtؗ`8{~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ۙ6#+7W`ٜo3]KaYkrY\JX(u41#;PO{{*_?8~ Ktf?8~ Ktf?8~ KtfZꯑڣ5I]UᢨTU#047>jɋ!%N#YZ' IV߽]=Iwko[+5>GxvlUApnJn&jVI {{LkLkLk~>f~~Fޯܽ_6P(*fgje2l6;-KQ%3ȳ$519P!>~:wsKsά0Qdf}q748i(kmɌGGZZLA$&LkLkc||(q8_2Le6;|܆G![2SQoj**%X5g*H{~-[O+{C|lظ97)c?=[㿈24yO5LėwU>~\?~p@Җ}߽߿~p@Җ}߽߿~p@Җ}߽=߀}/ڝo[ %?%UL[Mej$yd'*D'ď~~V7ΏG?ڛ/ōvc'.? -l9nl'1IOSMQsA4l@{p??c_~~p??c_~~3>~l^[~J[;cwW՛%Y#o`7NC/E5D .c'v~fO߽߽߽߽WFd1Xܦvl}z!L)+T{=PDo,*$=߽WLkLkLkn3XV\nwp5u.OdbqY*)gr4SO SDH>߽߽߽߽߽߽koFq.=-ll>qKS-dٟUc֮4bDeG{{ ~p@Җ}߽߿~p@Җ}߽߿~p@Җ}ُ߽]{WiW=]?UlǷr8|: ᩂHΌ{ `V?.oM?iῊd⻏p9=$iSmNqz_pmVr 7[#Mix$,Dُ=ٽ{"aَC}ǒ2*a}-Ckn~nۯvܸ[aȻ3#SDF9*x~{`~~~~~~~~~ub+VUo]=+U:0oNߙXDޛ7v0U=-\ 6(tOK:]%@(H>TE;U'j;;'}m]ͱ 59*$es<K-<)ߑٿ4wNSnݱ*~㪠4ؼe;S%ZY*r}*B%BEH4_{r=߽߽߽߽߽߽@a?@8P>K޾:b`|pދ}߽߽߽ %|HYw/i:U~z¼[G~z{{{7ʟG,M۞n(߽߽}߽߽߽߽߽Sn_uxiiiaTi&ye(bK31 &CG}wsT=osGivc%ESv.eIif ~~~~i>|A ݝwعJU&cmAS&6|^71TF{{aÈgu\.sC(fZ,/'Kn>t%&$#>߽߽V)_w|흣ɵ~v/]"5NYE(THT}rXHieL\JXJ~{{{{{{F!kmES2I%_EVe:BeUhٯ)e&Fi51{l~~~~~OQv?'φˮ[:;%M$I]Y,n鬢FTn,4"G%-lVo#߽{{{{{{w"] K˴ΘԝմURCnOߘ\h_SqTBEN!~~~t |f@fL]?IvkCFF80o3iLlvS$&3 d1{{{{{{? _F~d߽߽߽߽(iE|U~O橲O^2Qis],Vqv^ܘWOrhi2'PoX_ň(QM,Gq24+yɕQեz ߽{{{{{{{{{{A"a7ŞFw{v _Wl̜E\Ol]CFA윅lUd6 l Ǹ+iT~]tڻ`Bj ,C"D:U{{~~~~~~~~~l[lmwݸz õwn /76)c3=fpgTPdrC4g?_prx 7!A_rTH%JZJۉ U~Ϋ7_jzn-p5?7S&#綄5]&{Xozvw_^ؽq#K${?wf3TWD؉ {0~~~~~~~~~~~~~a7qO6- piVTΫ##1p䆪l./*4Ә7>Ǡ]!8E>w_ےG~$O~~~~~~T۬~*{`^_-?{{`}߽߽߽ـeO~~x~t |f@Yw/i:U~{ 3~= ~rˎ?]ەMP=me:T=SV8c 3kiVk){g{{{{{{{{t>R]>"n|KmS{*X+m,Mu& %+|ښ>~n[[z;|+5mnMٸ*|p&mNEH-ܝ{˷WOo^[³\}ϔݛ3ū%5d}De@?rxI؟S4ğ߽7uk;vQ}=_썿M$0Ϛ{3Gcz!̥|He(vUͳ3;qvݢ|sf1-lLd4d?5L꥘PnH~]]aX=cg0R*CK{*zE$gmcAǝ)IBYjkj*6kin­=v~Eb)Qw`b1L]L M$vO{{{{{{{{{~p|1}߽߽߽߽߽߽߽{tp{߿{{ nJ;߽߽=߽߽߽߽߽Sn_uy䷧+D)~~~fo?ƏXߋ=߽߽߽*;Q-{{{{{{{"eߟW߽߽OU?o/U%8j>+ܛ(5bN{pS?3}HYWB>aF|~h(dZ;?^⵸$ME]ZQf!Qt*Q`O߽7**|pP]q5)DRߝ( &6OQ) OK $_Ix#kj[LStmm5Dyӳ6v̡Zo*Bש7߽";=ee>Ov6Wl^tQ R2ϺꥁxJQ|U{ma6F㦦v#sG(1;qlE3F<ԙU!6{{J{H#+tu!\>u~e'??]vA1ִ$@Ս۝]4{y Lps#cW>~gQ⏜l}߽߽߽߽߽߽߽߽߽دa;c?3ﲛ{Ƥjxw4iJ NrKG yD9tb1߽6yu^/Vn:ݧvػh[ubs8\K"5E bEIa}I"({?b2_]{{{{SoMP~:]ݑKKon6;6N>[n#N 1U$2jtDYh}?)_O051$枏pнV?#1Ϗ,fCrѺ{f%w]'qc%]g-ٕy'˶( L>@Mbix5+`dn3'l*,ywgmxZͬjӫ5Q,}A_|1*emo4si5yD3plg&TKF FQUO;{k_{;gdi1A]AC8|>~ˌЉD*G4<{{%~~~~~NJ_lOl+GP }{`d0jۛ?[_0Hl}ufX }`RKK7Vӱwc*7\L spiXX([߽߽߽߽߽߽߽߽߽߽߽߽u?|OʯQ#vMs[[tw>wQ |zLXl@y]h):R EDWv'h폩Vh0v*}@Xz^)##~]^߿{{{{{{{G7;srNͯ1M$nt WL\L]@k}1ڝǔ[p cGf TsM#jTs~/¯GͶ+v~3CSQӟD;ujLkn|p~"pdW jR9K]O%$}Bd2KNNch&KdF uH>b?g'^ lo>ۡhc\k;O^^ :: *xᖪ6Ce۵X>ozl^z NƊ1Y1_=;IjݒU+~oݛz';}˘1'V'nŌm\u,4T eCo+e}^F7R 䨘Rc j UB#$"s+{{mϻ?v~j˜Ox|TMIONcG˼$C`'AoǷ\gxw.ݣ#Gcn﷑i =3ڞ{,߽!K?]ߺ~^le`7f`vNv۸lF[sS˂[rlvG+xG<Q c?qOruvJq7%/hn>%P>ottԋ\L^P *{߽=߽߽@a?@8P>K޾כ;%ֽ:|tۿpm)rQGFLGҽD5C#{{?ٲOy/G/bG{|o%N]ۛmIM5fݝZ9ҪZNc3YA<1,FJH?~~~~~~T۬~*{`^_-?{{`}߽߽߽ـeO~~x~t |f@Yw/i:U~`w-Ϸ'gDSE~ConӚ :-M Pa.U^w"7/{hv`v}Dbl"|s8+~S~~~~Ls3.U#) ` ̴qu'WxQC3(k\b}߽߽߽ηxE7"ע i,uߒR8&pk|?뭗cS Oܝ͋Ʃ_FƢ;))LIUSmuY9iU^=I W/xnZ祦1O SUѻZuh}߽9{`l=͋}{{g v^4dZ'tQ ]B6%[8Mف}`76/ѹzZnBV42fG{ԝ][;]׻;zr5&wfow%VTsNͮVh$ep`Sll%v Fd1Wal>l@2SU,~Hɺ8ѹR߽ޚ?̗Qs/嫻9c7efի*=zy|vr[O$ZHUQi_W ,tW6.R>Fjm6H2-:w G(9~ {F{{( JI=iro4{Y)'؝iGz5V*.FP%!qM߰3,G<`9AL'*{>/)c1٬.F1PRe19l]]>Cd)㫠$dvH2>*ezjiY`&xh2:mw 4[v&XS|98eh3nN0׸+G>ڽ뭳9G;V &?o iq.bsM4Qv{y|'/G>DVno=F0ZJ۹Z—wEfPRK[7L+ޅM ]a(shpF Tpm|}TUI ){vFg1['f홂R6۸}0ÑM`h1X1"oK۸|VCbq}|t0KO"|u%9&+dlj)qtmɽMr؛;Q=4y-ѹN$pCHi`hНۛ7=浩pHs99.;ZJq5,I"Gu{_W'ݙ\vS*ZwluWy**|1KMQ[2$| uTVapLcߧV11+4hVy&qF~J^TBȗo4lnMŲ~8N]׭ݍ8ۚČgm-|cTT-]ecWcݍ=5M{pd0yn =s)>$4})*_߽K7~4\/LMWKgKUZڧg/],yYUN덡.ň[_OPEϊKK4SYW34iybOصW [|~ o~~~~~~~~~~~~~~~~~~T۬~*{`^_-?{{`}߽߽߽ـeO~~x~t |f@Yw/i:U~t c~t|SXjZzNU&"xh]۫[d5Ot5UHf,=K~~~~'/Yf{M:5!YCfVumW"hv\Dl[1~s:.KUARd::SD{{p)[;0TE6W@-Ttt;_ACKcE<4rF6%W߽߽r[o餂JgM?cn8c ngק1sJ!w2WHt2 ?~~~~nOЏ^δ I]&tw/1S+tY"r㾩=߽߽߽~ *6'wn)V'a4uB1ŶF֩8ޓ~~~~~`>'K1I_]՝M S)i)l&ةf >:&J̑m#~S<|eR~ӥoʎAEmUVStJƩRX{߽ȳ߽߽߽߽ؿ?-OPm=7ga E=fRɏ;7VQ]KΊ~mzzx*')iI)E6hX2mn(߽߽}߽߽߽߽߽ء]mQrt |}MJ ݁{m\ucb)7:y#r4ec~a{{5 >GkPޑ쭡{e =^Ci2.z諠ex(%ՑO߽?9b2=׮./Y#ۿ#**ď-FwS]dC<E<1߽_{{{{??AY4]/~ 5iLvF,TcQȟ7 +!j(p؟7&*veJE!~?7w&+ۏ{->psæWCd0hr4RD?uo|I=[]TJ,J̾2Ґe[]]6٧^O߽߽߽gK^ߔ5;wiKHǮhتE\hwf2 SWdRwPrvfl>ĺ eBV/LepT5,HGH~W!woS6wϐ_wnߧ,A,F*u$E!e0d&%&|Uj99w5Isso:Ɋ+IpC[*;{Cxlכ7wܛyq{h Sl}IfhC Pr-Ǻ'[b8L6vr58ܝJ[]=mdPRΗGEa=߽?F}#~5|NC$xKi=(䪩i]S<>qkA-8a{qqp2eshYLǘі?RHS0>?s?3;|uqa:=;fWnT-;UTbˤ⺾I1,kݭ9`U}>tr zM>Iff,ć~/_^V{goW3#x{oc"k(PPS*SӠURu][~s;RgM/c(!pA>r;P)wVRMa#Ws$SmY*J`l /_ugcX`en-Ԃhxʊ(lxU?`k߽_  }ٽW>wwps2TVuJ3vsL~c1OC(vAMi4ZGM)]^޴66ن;LGpT+MPkE{u/RE5 WǏ;KjjOQ=>?PDG{N $NSn:4ٸvTd2~zrL Sό}߽%ݑ{'w.fl-3yndx&X yRR#S<ܛ/mYlarۏp0,>-̰Qc=MeeLx#fc{n;|}>_n|V<[ЛI>N ]ir}xzoH 67Ei>W+& xuT{)hwNbtecPQinY%{d߽߽߽߽߽?e[ӭo= -rh(_-`\SfVQ1Ȉ&Q4 vHU{_3>1e(7F!W8-bHzQǥ\\sgvQ [|~ o~~~~~~~~~~~~~~~~~~T۬~*{`^_-?{{`}߽߽߽1EF$.?ݝUhc2ʴXh$@T}OMe(1%\CV/i> qFf]RCUo{{ {{{{{"eߟW߽߽ {k|z:UԘuMԛ*N/ܰ]6,H߽{{{#?KvXd:ۙlv{oյ7!4rCWA4$Rt;C][jh28z 9*)jj!d iWGRYA'|?n]#?#67S<ٸm2´gk"U(ir Fɵ/¿4%z+>BXQ_7%51ݩ&Scw&=6tlO{eMz&WG%KȘ9L+LGi_!mGػVlT/xλٻbu>ǵ3SA]X㒚HdQϿ{>Mth[wߴR}]u*E9y A!|Vx=)2}vv-A)lئ:Ⱶox%UEwu]:gꮱ}ޠ͓ջ zk6vƮ&$tCğvO؊\]]4|2UO)ј( sn}߽}{{{{{{{’?5/[g}nRYrElT'!m_d1߽߽@&Gw''o/_(~:m}E$t{˳ͭNj$FŇBr=߽ށYw/i:U~zi5ڝ3>$f~I,˒{״6FF" rx8Byt~^mT~{M£9ٿ0>{/{{{{{{$Nꯝ;n}ZvUIsK> uTM?tm7Qd)?{߽̏>_+wqRuNA2{+P`ګI2SO.'{{{{{{{{SoMP~IcSr5ECc5,TwHJ]T4U JD2-JjS'Q#B6ZvxMR7Tm ߽}Od|_{5MeH; )&%7"JHXjWd-M%DR W )\>#LիP"di%ELJ^nN};z6y͋_#cD*OM:qFG,xݳ++َ+!Y? #1ҟ,ouя;\׬"zEmDD0 ^/[uүfl* Hy;uxڪ3KD: 8'ɿݧ3/:荱ŝְ^GK3p+z`稄 SJA>#*51)ƿw_5f| M盢X pNDS]sRJy5j{(ΒA~@_(W%$m첕+II{7S֚+*B BwmvK7fԳI7[b"uOI7Uk[{߽ ۽߽߽߽߽߽߽@a?@8P>K޾:b`|pދ}߽߽߽ %|HYw/i:U~hY̿s|?韚[#Q7SlvRPS @w g%j}ظ,LJ*CO$g߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽ڋhm-Ϳf؛+z,&[k M%ncpmɒ`px8%OJ I,͝GԴO-p QÐi|†]"8>w2UtiΈ I{{{{{{{C6ɻffL- {w+BL*oiN1Ę{{EOkP㖃i(t´ђ8~g1@(} G߽7{{{{:w?vvWȦ۝h؟r6hÞ}߽ړ'Ǎ?ߊ; n^]gS#ۘ_T/o ok}߽_߽߽߽߽߽߽?[{gxn9Ny^>\oEv&Gk G%e {߽ޏ|E~|jW4mlӥ%N"x܆*{:1e6a~RRۻ~m >sim+wm|!-Iۻ<)J>C[HK~~)~~~~~_OKmE<ȯp RMb8I]ZPšj+Yr+Z {g S 73olO[o)ܔh+ٟZ;"螻1sTnK/Լ }LM+g&ްYLG7fsYB j"eZThJ*?{{߽߽߽߽߽߽߽߽߽߽j%"y!Qid`hG`@$aO^ d?9vmf1>?n\Y9ZcL؊%,x %DBlDu# X}J7kdl0i7iv[)!ew쬆R'D@}ß͞' M EU۽*$q)~CM4N%R-M5,H9*2߽޻o%QG<{xU2t*>/{{߽߽߽߽} Ṫϓ?~D]GK )!!E[.$uHl~Y}w[Bƴ;m6cMMlKKUb s1 QI{uf2UQE]GQEQKYI+SM pc^>PjM.[w'\б=߽ك!,p|{_߽߽?'?wǞ.=])4ܻ.h]7v?:!l˿yCMDž\G eopt}E~~~~~~ے8#~{,ꮎWV2C+b{{_) LkwOXm(>&'I; NϭT=UQ<{3) v}$A暖ǽ߽T{"*{߽#gv>z9Gn?O7[ 8=G|t>e} /8иrG??=MOW8<3r?>z{~~~syL'ar5|)b1<^OQ]G_I$5TUUPȡzJI⪤H*ij`ex%xe@C+A{&j8g'Q2Rt}6dߋOQKukC4XeHQ#ӤiN.PR|i3T*:L.]1Z7L^BpӳH*[х{߽糥2_?Sqd2fQi;&yW -U()KP#_l]k۪Tv9V:ѸGҋ1tj =:3YB?n߽Cw,{3&FÆGv~K5AmM*: mnAyfi%}R;Oq؛$-økbҏJCӻ]*0GE39fo{=~~~~~~~}OG$vvpO} vF*q)s[_+ rQd*&I *iS/?ȬBnZ8;/IIPqHڣLFbudHich~~~~~~~~~_>[u/&eG>?NZPc߮7&]]"QQɔ%,A{{!Kx=k~~C{`@9/?߽߽% M5{gF?N6KlmA%ee8)>8ܔ6k `?O{{ۣ߽߽ӯW?iߎo%u_I7 >IG{;lnTjyƥO@r}߽ށo/lZ߽߿%<_?{!Kx=k~{m?'kzF3g{ w|=;xff>j=}V//ѵeۘLw_BvSë~ʫHrs>~\>5ͳ8܏SP#26ݸ"i2WgqfO%;mz :3{߽ï'vڨgY%~ ԔJh6e QRTeB~q?!7GKڦH^]1[W^nYDl#7>ƾ;/%M%DY:Ԉե=H/7G~o/lZ߽߿%<_?{w~#/_ݕ.3ؘw%n(T|TT@P=<_[.4|ܹzM^6H겳SԦ5s6|+Ϥ]]^@9/?߽߽ r__{{w1{Wm_n3cvn[ffnmKM$SAKQwNg\."&{{w߽߽{Mٷt[;wn6WyMזۯ-n5)dlGݸ̭ɗ9BI1gRy!wBO{{PRch1hh()i訩)Xi)bH)XUG@W{{P'kw?@t;l;nvVU;s soelDS:z|l||C{{ r__{{ֿ~~7G~r:.~+h|ꞈc{T){6{!ƘcqPPQ[դo{{#_o/lZ߽߿%<_?{!Kx=k~{ "'676_a^ MiwN"=uVųfi!*ǫԗ] ƥW߽߽d](YNˤlz㹶-a?}®<|Ro~:7G~o/lZ߽߿%<_?{6ȣڽo~'ww 8zX}xj1tTl&ȳXȱ~g?fۈTͧU.pyѶn֘UΏ;@wZ?6@Iz3䐚-r Gm y%f߽ޔ^߽߽߽߽߽Y>m뿒{<|lvņu9UIڒ8#*R_C/EK37~6ZfqmJa-mL Dһ1Ue>_.N ԽyG)7wZo=(_ҥL QN%Ft)!VHF[7w6yss3znz:Ȅ$TIXUd`Hb/{{{{{{{{{{{{{{{{ת3t`vn~ەv<4R:XUesyzbӬUճO <"c|<>lt,FE@V FYuf߽?':O7۩ovWmIPuzү!MM<]sҴ:X*(OO]o7nPc,ό{Q ˨KQNK˔Yɦ%o 0{߽eOD_Nߛ_SM7^Wc0Wr-×*Y5_JtV|}ۓmqaୖ*Vi2L"E|Z"J(E<jk߽c7{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{o,cr}Ώ{?_i7'tMTxǖJfMmSk2>^\G\Y,7n4M7{s {GM{{{{{{{#ߣR?ޛHw 9]nm 8c[cBeL~T6 {v4}YY87[.R<QNɅ q~8WkrJLn3IS_GCACG U|2R0RQ޽5XR'G,mIbG"?-cWG;!':wzO&誏njBiVI|q{߽{=߽߽߽߽߽߽߽߽߽=)AC QIU==S#ι<=*;( 4MMaG@-+DdDV}o'BTDUJ߽>W߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽oaZ'&V#[Ӷ7wػ1SB@M@(Ed~:%{S _wV[X" \6WuMmf6#PT[C]EF悳W FBTE*S(jYHQVd)1J}LT44PKUY[YU*AMIIM<5:qv If*zxyH`ifiX$qEy$P ${{#'rtHvhjwjo 6FsS4jX벛S)rFȥ@cQ;<핻檓!3-nkF VeM㊡Ԕ5@+{sl=߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽zZ Zz***y+*掚6fH`.*${{-[-mt}UJIP]5Qd#EĊT~cߛ6{ xlŇؿ,rIVyX]Je {{U{{{{{{{{{{{{{{{{{{{{{{{{{{{{i¡8ƚiΆۢ(4hOR}I?rs ,}y{Sy#N)mP67+COX:}߽{{{{{{{{u"6Dub_Ọ̑;>zJҾ*|xY(9a|DŞ9ٴ~!Ux;rBcqI Hs)U:*9VH]OcC?PN잸}/j0 %$ttki'䞦fyew_l`v^-ݻthR%FҷwrH䳒ē~ w>C薟C!dd6CK*spLd R .]t%@׏;blMFuC^dj$[S?uW|MM*ε?W[֏_s|_[I8mzmw/kD*h$y.=t9.eRb4b Q[]Wg5LH}tt~wSzn>'*%n/]) lV$G0N{ <'S7k^[7vgy,Fz(ꥅG#{';M|߽߽>d|e?>E~~biϟY"c{{ñ4g,_߽٨9S70r{Ǽ:T2>E1_?pI>mm?K~,_3ȟTcwNΪ58\UAܱl]ς\V*BWxVy~z]ñ4g,_߽߿ؿoGȯ_7YK#Wlo~~"5*jWw W TZf@)H>~j:Yv]4#OF:VJZ+ilQjJz*= (-~bvD2̓zwWQw[' \KNٛ1٘VqcSci*eVU{߽Žv,=!joαo۱bKO*;$x,[߽߽ؿoGȯ_7YK#Wlo~~f?ɿ|_!n̓ؽ?;jgWR[+v>gv!i), ]-~\~~~~ k{wc1ۏί[T}OV΢){t'9vNmd{ib+娘~ue?>E~~biϟY"c{{]|7ϓ{Y`|\x]14Gz;k 'S5j# ؿoGȯ_7YK#Wlo~~/#Ƈ!h~*G==K9Շ/SiÄÎJ4a[{߽4>ꯏe{KWwOST+qf2U*țf\KmR`QRK I>~V}߽C:sQo^M{?w5*5{md1ZVIcV%Rf b0K^/NSQ֧dK,."!mQ7a246jV$C}lͩ~Qo~@0;羺}Ƚ14Y }Dz}?[#pyVeajg:я{{ñ4g,_߽߿ؿoGȯ_7YK#Wlo~~v/{,+7{{;M|߽߽4>12/SI};q_#ed-oȖʎxk띣a JrSo~~A~z8PŏGGU|[ݱbv6J*>z俺uu UGd!hKIQp{Qǒm%Q;Qu :OI}׶GknL|НG9K.S߽߽fm_ |oZ\ٞܕoH)\9ٚ! Kk rqf:sGȮUWI"W裫Y㦍%IUX#Qo~~}ZC}~3[di ~S{[lKWeK(_{{(.~Ou^,Gg) {CALn؛yPQm~Ԡdfs v]] %o,;/ O/(p6r72.NiWV ZO:k"93NEli R5*)U^r_0{Xǔ-؛[o(']?͕񿩠!>9NifR=ǽi,*L}+K0iC2>_z#i|u,7]XwA[%LQ.G5ZıSYޖ( u{p~~~~~~~~~~~~~o+S}㏢isiՌHih߬)j[l\6)A+X_FްBZ7+!4ux[o!Rsx&>G75z{{{{{{{>=? q쏎'H|u{ Ih=MA*ڊu ᨱrQKQSн5+΀i^܆<Ӭ:8RLrg <xiDv萪@UUQeUQ`X8X8{{~~~~~~~~~~~~~|^ݳ n;7GڡpcQD+YWihiUuE ߽7|S>Sw]|ɐUϋ؛&*=U8m wa9*PMS%{{{{{{{{7̯_03>_S WQήL6ŦU"syK{ֿ߽qGoo ? vaL9\wmwtsKc~T(**6{sV!QoO{{>_˳ t{{ ߽߽߽߽߽߽߽߽߽߽߽߽c0+ϟC*v]M& fP\O4I Fr\o{{| '7r=%ڛkar9U Q$Y޶ݓFܾ/((k~d߽߽Ȥi)*Yi!d &@C+A{{O3K'_TWw/G-۹')݋Dߔ" x~g'2^/LSoEjT_ƫٛȞA$Ou]qq3!rP>~wyٝس,Ėf&I~|}߽Y=y_A S;g{檌T:mF,jq/#%DqƮ}߽_>/o|Rⰸ?´X^3}Qc(@Z:H8 *(~~~{?i1?0>8E>#w-7'gMszn\tMv23e"*Ln'E,$q~!Ocql߅_辨jW=x+[tX>QENZf{~~~~~~~k[7 [3HᚢwL% 8~S_k:wŽ+~!x?&쨧g v܆)RTUS^mGv㖣mMѸq Nۏv+5Vůݵ 0%_^{꿝3*F?%k'vdh3J&I~m 29\ X7{{`on[ó{'s7`oəwn +{sn yR_T/#-`{{G{{{{{{{o?2ͣkOO>_`d-=M_k5Sb>0= Ln/??΋8ۇx\X\ȅvOVF OabG{߯b-^108fC7(l6"%rU1Q㱘uSVW+&H$y%UK=Ȥ**$Xi驩Wzp 3${ ?[;{ ޘJɬdlOt'KK<0n:g!VI<7May7e<蠗qDS>ûGSIhjP&I5X N{?>WOt+~|-$u]Im4\efɀHVh*bЀxws:Y[/=Gz T@-I E%9~x)`H'HfGheFXI# E9YՑъ0*llU~g=gU <~vfp9nnm=3Jϓ䡁 \o`2۫p`ɘ`0Vcԑ!CT" .6aToNR~X*zq{B,푱r"I D;?,G[kg['rqo41MJ" S<4gyjXj0{v}߽߽߽߽߽߽߽߽߽߽߽߽߽߽ާ}o?ujt 2X#Lc~,~~~~yneǟC/yW;{o67wcvs KqSd2<{߽uB@l읩Y 䭖Xj|E͇;: ͔zJ߽ޮ̿A?V+=ڟ5{UۿߑO?^e(;6DmچN1{-')Nnlf۳w|ޔ9Ji)tQMzΕ{O OWlFM eC>R{vo{{Y£9ٿ0>{/{{{{5?8|KulZmUƋzl,&\6z\9IȰ5L !._~~.q߽۟߿Nv KgnM{-;7v=ؘ[Ixl;jU&ϗY=yQg{]?q4g#~~{{{{Y)6]o>Pvi߅U ԙlx5-{l67/]); 6/o&~pU&;h6v?k*套OYE=e!U<~{{{{ۺΟ̟dJ)TKuPSbՃ&#*at4fوxj{{ܟ~~\G [~=YM;aeͤ`Te(m8['b~~~OFwO;GFW%9kսv_Ҽ}e㷣Z>- EDkC>.aKK;ϸ͐>粔ƶ+>ڵ1W:QO{{{{{ ?ubQ:?==Y<~Hfcoӆ~޳ME 7C:i_[7@߽߽:b`|pދ}߽݁~eGSԘ1]5C]GѽaOOhvYv}$b ߽߽߽߽߽DycYQ f&I~ws>J ~ f||y,>W7w^C)MPњ9(dT-)%YH/'߽G| Ƕ{GĮmE7aPÃN)iqulEOUy K~v 7^(~Lj\]69>ʵTa=Qm!%YnXxoTw7[7~~~~~g/yUfWyu?cl~[⪠V>%%" 6Wǿ{{tؗ`8UĻIn~{ %?ɿ;fw-w6Yu=m]~_,R|t{{ԃݹo ]bm~ԠWяwe]-\ѡuYCH@G.{{;߽߽߽߽9 Y_ ??0ff_tX]pg(q5nBh#|&8˔xg{߽ ӳve7H;NJyg0{N\ṙ- gn꾟~~1**]ŹkmwOGc2z: J ,NVVC!'4߽ӧna?ez< =>ܻZ]mYfj %ECK_9]>x$jD|CJWJ˔\(HĭI`{=`y3ͬc;70 {^ý/`{{{0Ʌ!Q=\&/_n,yL mRl"a-Só c>H^, OSyf[F Qf߽~߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽ǻx_oQQ|0"] lm,v?JދސQ)[jbu޿eWvT⚆=]p۵!Xz{zZ:B-{<=~~~w w'?@o Q?;+d?s̘lm,#Se!Ayfx樑Vh.޽3a0ɷqwTQyr٪6U`!W_{߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽ޱ[Why}CWQcU}^ţߺQUcpN?] »X{{={{{{{{gQDZwQYj̚_euU*js,ֶ߽o2L'~꟔3[hcW{+TeRooTeyV=6)~{/oQ;]c~z5&7~䦇WV6ڋW[KJhR{Gۊ>sa}~ _~~~~;zu۝;tl ;hmm]ݵ֧ۛWA1(ASK4SD20"ñ4g,_߽߿ؿoGȯ5f߿o|w ټwwݛq6n˹wb/ܽdUSKSUS++1{(q4g#~~{{{{ܣ'ёGz}lٵ}p6sUs>j .fkÔi;t'~~yR_/"v+VMs6/_x4;ۋyPd,T1RTbi`o{{{{{{'""R,}f1~Twۛ1*8}}pԻ-W`q/{{/|X)z'/;~阡92GڸKD4,eNےFis3r=z^iYm=(8hnD퍡_<2Gv㠧KYj ~~x|N{%Xmo}?i@u?mo|lV!ERG*8{{է߽߽j%"y!Qid`hG`@$a|?ş5Xo]4Ǧ}vU=LYp[=>*F"4(HV5{,?o?Tv'Z~~{{{{3Kz.~uU ̏c9uL= 8i PRg6'y Vd,n ^~z{{{_wݟ6~/yf6돊-IC2R}댪jZMŇ,Cb,f)slF;`45X1CKqн5n?%z:y9b9 ɷ_K};/-ٶdM-cpWԛOm˚ŋSUdjMsa}~ _~~~~ym:װA2S} ͚ٻlecHѷkqټ.A"MMñ4g,_߽߿ؿoGȯ5f߿o|w ټwwݛq6n˹wb/ܽdUSKSUS++1{(mM?j|m-L5weq;64Sʗl|ӿqK#$l7nlMj)a"_SIpx>a `>|`ۻ쏐i斚E`*zdW@lPgqOn:߹鮴%ſ/x%nag<2~~闫C'e|%Ƚ4x)1ۓ7һfe*iѰ6f/ vbHic5Ond#4ͱ~Na7nh;+ ݛVchtl/8 T.K:G{[|?/й밙#ݛJoXzZy{csAIPI ]3IMo{t߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽N{8<ܸnۛ f%2sc򸌮:9+* ! Q'e`A#߽߽g&k~#ݝ5Q]vڂu#+M[n 2Tn þ;pGU=37:Ͽ{{3Kv?z.~z!{{{{{{{{{{PO_~m-ݸvvo0)r;ӿ ۷OUA_`L^HbmcG+U5DqP{߽֫W>8[?Mz=սMcmX{GMURdr Uu%MeTM3;{{߽{|'dC6+WZvf? qVDiq{yۄIYO߽G{{<_/c|Jf|ɴ;btc[DRxrnM9@o~~5?oWV>PwjEd#]PL}2X`,P?{{Ng_xǝ>IgX>Qd1Y `ѯbsih႐}Sp*o;~-?{{ ߽߽߽߽{tp{*8ݱqսT#h+*i%J-ra(̲LT#y)\Y1߽п{{{{DdO}e걣w|x{ |UM 媥;:Zj):X/߽n(߽߽}߽߽߽߽߽߽߽߽߽N۬(^~b?]%_fZue$4gʕ_|m*ܾ:1?,l_?^}=WLsOzsEP:b0q;b7iLjY"c\#pSlHuE\eOا\⚺m)b9{{1=vL/^mH헵(&g+[T"$y,FzI%Y f> \m~ػ6+N? INՕSV3ņeEgvTDRB3U䟧Q II$9${{ϖ b|99,gf[|cY^GդlVRd hë9,H֛_SOEIQrUq<~kFG^{S&~ebXi:R~tsheڎjJ3Vi5vgn\.nP.k߅MGW)e{,߽ǰ ߽߽߽߽߽ݓ+k^3:Y.zn+SA;OfG, kQ+wU-N.!\}S2:MGQWKPc>2ޟ w%Qo-5Tcw>Ymʉ/25z$,R{߽_//Pi#rmǏeplI6iT^HzI%o;gewnv.foۙV+! _чeqzdMLd'F{3ğ~~~z©:t+<dch?zH/\[7UW;+7.Nzm(=h=zw*MwVu*v.UsTX߽=M^|+ _nl5݅Fc!9hg6n5a9M!$1Bנ?%}?U]5u6^]و߳ZIa4X=9(*p+;"=- >{x{O~~~~~~~~~~~~~~~~~ϸwi3rsma{?̴F E>G+Dt4K+~;QwNv.s\]Yղ76V=QP^y+K$Fc߽%>"Iw6ެ>XՐ'an=EVPdF#詥)j_𑏊 wo#Sb_Wu|W粷b`.Slml}2sÎlQ^#Ʋ"{{{{{{{:5'%/> s+Na{pɚ 1z77{{w{{{{8i^.n랯m[nvw*3#TLwR;&HYU<~{|{{{{&h ׵q^]zIԽUMKUNvc'<{?ƚm#1*O߽߽ڋhn*6줍 Jyj0*l1TJS3LAd&\{{ZꚊډ+*撦Ffyg.1$O{{gm|aUu0^hgYEGB9R/tKi]>~g{{쩾OH/~~~~!f]?ZoŬ/${GIJ$2D{;srM&Kw*hQ~~~vO)$/N}ݰ>3]%{ohcj*_ 5lsxm53P49"{Iº?el3v2[ ~ޕG1q-Ӹ^dRUV>1$CN|c7̿Z7ĝWew`<2Ë޽ISu6iAOC+ٻiePeC|Er?1 eqlD6Xٝ259͹YIUFC#"Ꚋ){<Gۊ>sa}~ _~~~~{'Oůϡ[12\V⪱:*6CqmՄ hUǤM{gS|ѧW߽߽V_>ܫқW_AtMm=?֝)][W^bXYC%l4tTPBc_{{&ˏ|xﴺ%:̑A=WG=m_GtL)4RU}W x_͟.5mJr*jXMTRl|zL Vfi Tq&{OE㶨Kly]OhNklý6j#rs{*ܐUɄ"W˯~T]QȽ:q]gTU '6xyvnx`SYC xB$bE-~~~o{wsNj'k-~ߏz/ק߽߽=߽߽M}q|9b7SOo=mlzm՚)0q9Q DjOJowGMvNJz J㺫kaqfVYdI$Kzr|k?:(;+r@|x4Qw_N'YJy# JOWRX#vM7dA~iRMSVQTʒ@G{g۹O`U|6tTʩhRDp)(jgiVxd^m$RR?~7{̿Zr$>h_ _]i%Ja _Bz21(R"J?폻N~yT`6^j$y!ZoNkVj=߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽޿/'70Fߓb,&x{F%7ePttqD'NN#߽ {*wMԻuur:I-#&rj^#).{{3 ?/Q1u]=`PYw_`j6r|eDxN2ZX7uF:9(+{{{{~!Ϟ49Q4 aw>C .]Ҥ%>X܎AӄS(>~!=ch0[I /Co]t?/><@؆%E߽߽߽߽߽ۦ9Y|nۙa 3xL^+/R y4rlSKؿ{e_^߽߽ٿ1j\ICTdnh֧ԓ<vɦW;(9?~~.N\4u*s;QʈD~~~~c\Q2߇_ͯ<{^|sE FFC^}K #R!HD\m%TD߽42,$#43#G,2$X+$n2"߽߽~c}T6.۵HdjJ/OHOl5EF7)F#M \{oԿ̷VivF';GW>9b2ryh*dTRW$kJ~~|}߽dk|xǯ#S13b"J͝Ӌ2RO߽4an7"oao< X ~jon,EH n_4/ԇ߽߽߽߽߽؍U;׶:ϥ:ٮzdTLFCuo|i੝!'HK>>l߉z/G_/OX᪞ir, &pX1+V嫩ǿ~~S|؟i߽ސ^{C/'軇߽߽?| /ڸ);CmFͥw]F*?eH{{_n[ì'lf6W`l əh 9(3{osm6R_TA+pH {{G{{{{{{{-O2OGG~E/lvUIZdM%W_v5UdrԮkJ %k(a2:+߽2Qn"_neuo_ $27pG{{{{{sO3{[9[P*9fquJScUrϿ{{?ٲOy/G/bG͗9{?~~r?c̟>0;EMr{'e}l>Kr ?<~J8H#|mzu%/HbmOdwD aidS߽}߽ٞ[Ī1n#T|gV;TmŶjm8頻R,UH{(>qfVڰC{ wd=OB] VQi!)aʯ{{{{=>wn*^a>rv~I ld-w}$RjGpSۂn@+{߽٧߽߽Wo3Pe{_=߽O}'i47wuj$YnX*g\48 daPGn}ˑ" P2U8u^ GzbP&rΔ駡j)TX08{S߽Y ݥC/i*OZ/;1x"Jlݙʬ nMi74uՊho% 1X댵^끕ܶ<%P`4l2O00{=߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽߽ގ??<ldݝ-һ't6ghezͺS9:=6>Oֵ߽G߽߽߽߽߽߽߽߽mo}ֽ_w7avS`ٸ\1VHa*k [LhQK(${߽_[,>KumlNcE5_=qU-U/3YH*w6FWiX)d{ |f@oFoſŻGWX ]5v_~t41$tOK"~z{{{;?\|vnr|?QuUjg65FȨx+~zE=U5 ߽v ~_CQy::l7%•4u5-=]]<$R̒#RA߽߽~)_V_X?G6#:ϧ mK16B!3q=3no{߽ޮ>loHOb_]+u;ƎjoO=WeDsSIJb+ jlDS/߽L߽߽߽eM{bŧ~zA{{{{4?~~;~z?NfU'~/vz >2(ej5~{{{{{{{{6 ~`]>>|Zl`>NCPm UL=4m[OTNZRESY4߽Ro??Unjgɏױ;Ywt&owF*ػ,e!uhqwzڊ=߽߽Iu26owYøsޒsUKvt]g>GU #Co3KeXf)W16oカ m&koKCVfm75{N|GcfRvG+*k~A_ w ~i.,1<6Icgyn"`DS Á8EԃǶX)Y D2FX6!CB{غ*ldty|~Y drefT0@4>c:)j葃QTO YI"ёs͇>_ wM?ܿ{{G?Cb翳?]Ϲ~~f4r= wh?>{߽߿8=߿O}{Q3Kr=,-=3h&j_4,,tI#$zYyMtGnQ3"D=^2b2F] ̷9~ls_L߽͑? ֙Sѹ``;ؒ)gv$[raT=5uۤOUs mYwܫɲj6a.C?VgmKM=um24^/sCW1~{~?OWm3^^qLodmMӁ7.-]tEL9)+p;#={Vn`w?j}Ŋe {!.sO5TI"N+x{w ѝaZmZ1f ڬ8rNv,*T,4G6P=s(T*c;m̺s%T𔎮a=]"+_#~U ]K_lUUu.e#Y}URK mzwmmM{F|EV|ybi^-Kԯɬ+Q5txw6Hdnvp{C{#?>hvSZN߹Nzku޹]&`|9+"i\7߽?~0=xF.F| kkju쎽5ȴTsԥ "߽Ņ,ѲsA &1}B^UTMU/Itct߽G">N#ḃ%>>[Ӑc7IPRfVj׫ W߽߽p=]?tc0t."B+4۴6c?ib(vЫK?߽߽쟉}Kߜ˼>?|Xۻmv_@uVWd -ؙ\šc'aJt=kz#;hdGaumTl<=r=-~&$OD)\߽݋{{q?H=]kY(zou_Wo=ݛJ}VkGnG-MB6~~$ܟ&+~~d[{~gOMgE(-*ngnq[ïN&-l,ۧ<ʬN\bZT,lo~~~~Tͤ(舗?ŚlAP{522O҃dq,: _Hu{{ɯ=f*9/nsSOV^-iiku1/y߽;i=.fq~2Ef@Bn7nɦt=}_O翷1ȤM/ߚ0߬v>"Di%|hdEc*~_m؟κ}!O^ʚj4?caY(F.wWuT ܡX#߽߽'?e|ٿ9x|~C_Gvٴꬮ[+2݋COVxdH<^~$ܟ&+~~d[{~Kr0?o߽߽_IoOm{K -o~~&?Qz ɭnWw6'56F[ dbvսK5N٢VÏ^b8`nG?Ogk/?g~}~{O:{o} ݷIYRrnG1`IBb}@Ǵīqy~[!19Sn ' >oǟ'֭M_31h> TKtGO0=A o`ط^q4SiHnM П\@'d 4~! )eʻ$f/(ƭ15ஓ ?@7[ιD Iڜg_)t ?g ?yx#Kgsi/~"][?$SĞ06qq:$nșI%vy?`2SOZS {e#HPN2rM3ٟ񇈼;7]F^ pufVߕb8WTgKmK`wW)e{z[/Կh% a+]ǟ x_Tkx Yciux^Wgjn\J Mr$[@aϙ|.OzW̟5xĚ'ѧFIhGѤڼٿb(Ov i q#A]ŗb}L=̾>D!AIO:Y$³5?\//%j6:v໲K&SЫ*Gօ~3w6v:Y? ՎX\DB,Xӿ??:/VMN#OaQХ"0}#4Ep;yk⿇.c]+u,"FvHz7a (((((((/@;-[(4mbQfcs@eOu'| lp/=xR{ ҴF=;WgtfC^'sڗ~ke %AxTӕF@ Vy ~^ nnf'/??"/xS'C;^N0XmUb<C|t|pve>Y\<~$<Zlj.ځx u?j(|3(2ҿekgX$m?NE*t)_޽_w!Mu{5bߴ8eoaA>xʤzP%NVCm9ʞ/w7Ds UhY$qY0li|Vn>׼+M6ũYU1#ҿ'6<j745ƦY&GYFr>&j~+J.7Z3Quk5;n xX%奮1ǢZ@#hG"̎`b́  | Ϗ,!X\NA`x%*}\^G qxq:5{sKIo\ZR%gfR2@&5z}'#mƥ]Za|C#*6֍ =vkU3 [;|2kx_"j$ږf+-V2A*wL >5xOZ8AIX$GFwm*IVb2?e~l>o4닓atǨ[yVE(B\޴yhd! UӜ0@퍌=T 5࠾oSx?6OM\Eoҕ~Q$`N1L`-6R=2&ZVPlPqe~6?8>#x\9rc UYtuvצ̽iJnvr hZ2<)b𔢶nu+:%#hŽһJ޶^ֿoKk藟>#E/ڭO=~PK5*@L`?\_g6]/SmcMi]QGcG=~2ݟ[c s/Mq)a<~P?7ѢҤQ pͨ۸QX2Ül7v?Q>'+[l%%xۛ][{gDW~*Ճ\AI&DA#){rۧh?|#g0WokhՖs_A~z}G޹4fZݵ=`HHV\lՑ/Zկ*RN2x曺9s̑bPjJQVZ8_m zƙp|yLȯ0ʞA<ׂ|AYxQ`񆯫ɫZæ6D6\:?W~[|X> >:>ox:`Ċmk-i/xz>nnv=64nQԜI5g`i)88]u>??''ipJ.&Aj#'kS \.?KI z7Fo_Fwu%{ !~ v}b0ε;lhǑ^хO]{C%x]?)j -lt%"p W'㹯_{Gc J~x.)>v_ɏ"Z,j|ytfVC7t7|+st./٧j4 -{ȴO@Z;UCa!X6H'z.kO_q^vm'9ʪJn捗7v[Eմ cqv7]Jy{W?t3ּW[ņiAc{}DH]v!r A~C|'3..!{@1+%䏐Ә.æG~?l2~к?E "H%nq{ʐBđE n+-eOmB)4IS2ΣCIʹ+mZs 'O[4zp>׭|;NpĶA‘3u_.xkfd㯆VSk3F ѕ# E5x@]xwd/-د% ˶DcŁ$ίy~nxh5عܴ?Ԭ"$tP0& 7V q]WSsM}/ثHVMKFԐ,9 uN/mp8# UkR~Ğ cy|w^LOٮ؃&mm ~~߃l^Zk&[Y=)H C)QEQEQE#8_u_/_w:ŇgPZWڄlt\pcFB; y.7^I>;||:Q`AyZmMʬqWߴ߃|2sw~&H2)3ht5r82XªҐ | _gź]jWM|SG$xoAL!gt.++IAQQ-wju÷7nPdn"q1I >G /5gkMi+jQy&FdYnvܺZo4owv-4̫Ҩ8Urw~ZvmVLOgZL"q_?> jx^ Vz -Xw}mqF(-z_I4#ƍ5͗-,XHd; =#J8Fk|)e|"/-:%E( 19*c%{lMV4vR]WGOQNX6m8~Li?_|N 61<甎!,x 'ۚ׽hO/-ֱjZƲJX-KAv:dG>+ڕ|)|0%4&kl^K>Q>qM|~ !!$sώS;v!~1Gȟbf|,?ݮg&m'ڕx{M i罗o#Ɩ?ko:`l5 Z y)oh 7mR9w/? 7֓_ 1Dv=]۫;y$ q:7nOtn:];s5wV2mGүv(]m<$z+RiCuu}[ z<$+{k?&RK Z\ \)U%ldWex^)[-W.c2!#!|@DK [ڦ..$SZxl]b8v[ڣ`q}q=kٷNKIn~O|Nd{X?D;ω&e}J3xPf1iw+E\dcG9qῇ.x/P4]7 [qou t`AQ_?`ߌD_?dԼyZfgۇ& Lv+~DR|4>ten!֭#;.-m ^dCTp,+'o'7CW| ?<eh%/%+nT!Œ6.hYGg? f|aŽXXړ.O8!Ï?T? G^M 9b` ḐkN]QTT:;ku04UWZKV-g>`ki͜mCyE-]eF2Ac)G~ȟRʨS/iK>Uܝd/T Iԛ\[$)BճxHտcټK^r>V4GMSǹZ:SC_5Yk_ꓨ1BT,cMS~ÿ4(w |u$_<3J 6zoM!(O$Wo8|K{3xᗍKNrlDsngۀbakJ]ꮿ!?]NYỴ;[Xe$*GATZ|Y*kwGS_ b\b|Bz $ܽ"5_\XQEW7ⶉ3WgKWNTn\ p8+̿.όuo_د|X#`9i!i7FGP~_- 㥛Cx[<ͺM3FGm%̢517Iƾ%$[иmL'6v1Db^9Qx KT~>[ oijX^Fpv\uiGv=&7=&m#mDた-:g"{K(ݟ?}jVi+4nYO+o|ewf!{4\[DN|¯@k5Ik7ֺn"=̂8.sY/}O'gp۷zb\8`TrFM?<'cm~hmI|:ywIum $jT*w*4l]jPBE?_kds |`&Ƨ} kZG\1[+% 8ޓ6~mZGTkohBcגGB2ۄZQ^~#:JIh[$zX|<(Sٯ ~9rio[K~|/ BV[8a!%j@[G 1PġmTQvVOm& 6gWMBzQF*VESGCs Ԛ,ͧj[mE5FC/5IU ޴mi"g*xu/ [Kiϫq4ׯ:Ztet[KPJmPmAnW㖟)t۬5p?ڗ*Wu ^[3 bZ%R#SRsO|Y|)şgՍf/ۏ=x`1VV6J=S] =)U_3_K6V+np‚{`gڵOq-$@I IB1IY>A~8|FesZ~4mg\K "giYݣUܣs.j_k¾4-յJ—mpc'22I*VKǣ~.<)mC F]tlRLnQh'Xyycr\^3BdM]Il-u+&+?xvok.U-*]J쀂Pƨ'ΪH+Oo<CU[V#1YG-a?7#iKE-Rii˶ V ]Aǘש]OLX浺fCʺ#IGiOkBǦ+DN#EBN t;s:U6!_RVh.$ڸ8v(+|#VIgX)(=Sp8k~& ^K~Fw]0Z:*#9ӦisK強\%5wq:Lَͤx>6/IbxTV-t;wb{s ;mYfgWS 'a%[-Ow bFXˇ%|xC?c9?~;x23<x"Q闰+.gT#`Sn0 E~QBkGOsuGmzXK5H"VE$#bI;dN_s7WZsIůEWOyRcN9IX2@ ,l|T.ŗ lH5QWzZeֿfn^`q;9u#2_vƁ )Θ5{EӘ;j<ОZ>Tgw_+ͫad#tf쮵DxٮQG)PkgL*d-֡]v_kQ)X;g$ < G?ecG>Zw:vjVF-Q(U^x c~@ mjz._z /cS;X~@9⽣C Q񅎻XYlOs.)UFʌrG5fy.P70i꡼wKEe6Wa#(`mц}V{~$kT_&ᝪh$ƜnI-JDcr)Չԟ؇+x/⟆$r+knJs޾ƚI/.o!8|MܑFiU&1?e;atyh ˗-0Hf03muك̏/O4٦4ʅze+%D▋qamχVf 2͇#_ŝiwJ>_x?[lWQgM.:_AZ7ms=ڿK%ML|z)WKe+$V׷[f_ M?鬵?X-~' >fmÒ`Ao?eς6+~!r噏,I?ok/> -cFjit>F<`8*U}zZ֗?ٵ #K-3M `Ť CO וJ˖=jaMsMA^1:~ض_޳xGI:\ [iERYREܤ/x|5wC\a[E~uޣpA+]IEJrfNgh;uIhm.ae}@`z{|1k]dtVZ8ڵ2uz7V^%vޥϊt8V!cheGɴW膥xoMn&$:zߢ3}΢0"yN}E:E\+ski7^+Kh+OY# p$ccᗑ+RKl#b\gܤ1[R)-nwc(⟶T\^׿C>#w~yjZ|OӮ.m*[͑#fU09|/>|)$|XPkT3]NK[K Lji >Lq/ bad=_[k魭Y_"v cpV` PpHmuc;jnG |[żm[\wbJU3mЬ gn$ѣ@(VDn |$_ ,~m$I0{ {k=()wߵw~)hts$m$Zss)αvT1 wQ:0-[}'kCGu5E7Kt^^7?𮣡V6[Ii{is]J: $}kH>*6JRWa+@L"0|H`p ٿKO>ۼ?KQsl6xՑfR+f[V!^ӝek^~GX<iJ״wk>X?_¶?n7:^ǘ3)wYW+xR%]k f}Su L @w2#Pڧ%6|o+3-[Iow;fE?h4O{᭻G{hYUA91Z uxgRңmb[WJ$ fxS⟇VwMot, J#8j{n NIE$e>q~ĿOx_O/ / 5i"݋x~~/O >ڞy+ͺŞ丑mK]Vnʓ1kY|_F/ Ka~> [:oxr0Qɿm.'1ٹiKޑmMŚ]e'5s`+ i_>OXHdyW~P_Oj+q13Eծ'x3ʤVHpiTȴ~O'!|b*ٿ~ ^fiiw\>}io=|y9W> >|ȶsySޮSC4|imƯַ r֑\L{GWOj\yhZG.m|eYG9y+־ osWU 5}5,3j34MVE320O)euxǟ xG޹궳7[r&m'n 겞&h<*;=}/<ۆpؚYqrW\]m]{-NpK!͟jT MwI$Nkۯ$?`?5~0jvx[}T Ϟدhj+qln^|JGQ px^8ȟ?6Ois0ܫ]KP1ZeRnmgQTJ $W?g ;z~(?Uc#ϹET*H>y¿7< Akg3\cpٷL+ {7O!]Z^Z/aPDfo5[Y5eu?a񍮹h/«4=ӣY-$ rPrcN}NQF0tgeKJ{td`} b|j᦯g\C,<Mk"ˏ65~o 5M/L[p ›9b7A7v;r8B4ohZ]bByX[0Y%kУLVZ-le)PJ]wcx_/^xvT87<=}i#[iH*D$3!8`.ڋ_PώxgjZ-m")=|&2 BVU<3k~8uxgoT?o,|2n+_O3v5!ɵw0)$VcSiiM2,g. N?zRѭwz#xDjO <|'k\MWUm&-4KIu[䀄y( o/Ɵ_o/a[[9֖Fpo5P&Ƨn@Hh6>;kx={yUvNB);;{sk TïxQ;'× 65->)] ,ە"+;~r<59g*qv\w^NLI)bjj_%tٛO٣^&x^յշw UU"=H)݀2z楨>5o'*#m`=%s_7:4)/#6eگh9):#U8~~gK}y*QIat_]'"k \Ioԅ3BI Vc#q?߲9, rgje,EBAG8Csx{OiPq 7iGus\iW]רZ%ue9m,BomW pa_^[x8#4Oϯ_5' ?5-fBB{fMy~65wMli58?epq_T 4$ _se;;pn/K~rTwQv|Y]zFom_k.~R3G 6@BM:%AC0޴(=֌6O~M>?GþY[CwԴ_oITPcRLϟ|^sٯ%o[\ʶ2܉gbQŽq#wdwg`1؏_^?>+YLˣO6w[ybfr@;Z0[E}^3NN^k۱,7hC*wNr螚-CsX|W3yi^̰=Gt?,=GG3|\jzng~uOa*WMn%Y_y_==_6NEY5++RR?5 r, #3WK#DoUj-%FO_3v}_~ l Z]&>+Dd@K:YmWdfGrAV!|K}CVү5o1Yi*Ki$aՔh'rpu~*x_ᖙQi<֒}-1oŦXݹ (Bi}ߥύI4wS(9k៉(|gwOahGvb.tw/ㆯ |=\_xS}I.9odT5mz#6c1u|{ 5[XOg4[fLak3DOԓ_ЇǿMg#A.vBTYn!|_8F_.2/fRߧYR?>k '^񧋼7w\/-uC3!pK6"gK|$V}I|g?mbNks9[x;/kG|Դ}Fo_MּgcmūȺiV*0DYq@: ˤbDL e%Гzbw~ꩣs.⋈ĖԮKG!XX`ױOV줬 7%hk-m;s\ px5_g|2N? RHn^—m)>quO$q~gxkTqCiZO|Y=vY_G]xWᮚXxRL-2E1Es?dFm4|c_Qo?Ο⫍ͺvTTk@2IA:exPĭk,4E/&-j&Kv)xwg3#}[?E_&a-S>Qy=| kۛBlOmnM+$*w'Y_^-5c~^(6;f >kۅ1@*(#{ kI͹IϾTU~2|`MjvSIލpy_?HWVޟT|н{}"yR4_NO @}}⟈ֱ'8V(ZHUgt_.f98@P<&ǍE {3?>U]4$'u~F~PvߵGs>MD/~Xic yIII[x#!؂ytx2exnԢom aܣܹ_]~U SRe7Wi|ECu=k.MZZ4߈HZ`76w~`\#ޤ*rK1#ػ/cْͶ6oeFn;T (<('5I1?enP4~Ϣ>K~0]۟64ug/74Ocf}Cot{|==_οa<7AkF%F~=h(i]ZG _3o~_~}[?eĆXs(#,d}~xv[ {xwS}BšVBK[-b3HX 4eIci+=jNmJ&[?eiᦋG>6&b=N WjFr(M;zCoۿ AOj#/jʩxCA>T >2~EP7X׽-|M-_S/K.-.wNRIio|-~n2Or^1ZʟQ\~SExx|3_y Q#B~_><'|_xNK|5 ?jqܥ+ ^90| ğco}s_&}OaAuK=7Z ARA$aV+I|FZɪ۾.`oM¼D|1*۞%_S{c5]B}cRVK_iTp BO@H eE{xX"Լ[. a\ 28elЅbI.VGRH5!^g}K ^MҍXe1IUāՙ&ˏh˸~gUNJ-ݭXgq<$5%%~fď/ǯ$kSk|/PZ:yVhDE< HqU_|Ÿt륂V] /bEbAŹsYr6GřO윲˪oonxcF5~E-.f۩mNR[DHM:ci$ τ)4d:88 ï5O)] Go#Z1ņΕ$|QufݕhO3?4{{uIk*HuY$kF_}XL&oeuOV̺nb-nѴP\YM| ό>*WIGto"H)$rVC HʞFn?~N<y:u]Z&EI?g.GnE 7z6Z'{j#?8zUyūygkчwFg}[óZh:7ty3[ȁdJ#_ ?|LO}nog]ʺgRaN3 $H`n5D&'o╸M@ 4͟2)%fc1_R-^V~ї$~d^7H̄A 0;t36~{\ N.*&+|חgo"OEܤH6qO\溏~> ~̷gkE$wM13Bq0C0|㟊\6_$@[L0-d2'ׄxt84in ˽xToB nr[>^86xjA˙;Zw>0T*<=,o#ѵş|ڧ umg}H~Qc20Q+$FxFeRi%؎H)D,4JTC8%=,.t(u巵Aq%3Čy"a;ޯ%w?/Ww^(mcฏ?'.'l"@-)U83 `'KE*h=/p~+.B{d|8z~!x_ß/k^<%Gef}'Pƈ@BWW_?]oj~!ҵ-6ҵʑyV3I R_Wtn/Z5t{'c&U[`=ʼcpo8~__6E^^${O:T{G"&EMqqKVX*U)n_ĺ{SjєS,խOұYC_ܔ?^/᷃4qiFiC 1DE Wf?$V|!}\ל2}g?fmY0u(k @J*EV7`tRG'=ZGXO1c3bx[ӍDNY]t|OO 2=wKX~~ԟ7?#EտK (NGϱi<__a?d njUh<7@{+_G׼]K>muX.@7<ɹ t9G.bqNIYuoU],-J\&iz7k<-OR Zg#4۟$׼/cYZ-iIz9I|Nq_?kƭè%ntXlZf ErJ~c>V$}~w|7="ZiΫk)V\AzRXH>uk%(ŷ?^3,EhT#+Kuc*4o~+,Ǿ.m_7W6~"rxZ;s򯊿zf|I5'M߆gݐcUGq_u >"G; TYWә5 X+6 ?_G/Ʊvb-?Jd5k ~şMK^a<>pOм7k: iykt֒gXeW0lAUPn=wQ ֵQ_Z n%a='~ |>:~џ |yg)?n *&|$h#1ٮepڿ6?໿u_~_~Z\ƃ#^oҒfՖkKQtGvFo7 A.H8c/?Gڷ0/ÿx_R?%ԡiڅv/ctWGV駭Xk mio=߷xoXOwb($ y}l3RgFC&wm"H |Yۻ:^x'l@.$Oiby &Hpf?W|!{Qly1[" d~A9\`(\_7#V1x+°Vu]]xC, ## 2+8=J+3Kݝ?nʆit{9wekogֿω>xOK5kacm=-nO $I$_gyNͤhʾ##8OjOwyuoXtTw.O9 %ӁMmnM6N-_-ɍH|!r֦?`eĶooo+Wͳ Y aՎ.v~ h #|5umA񆇨fyAmsrmI;TLc'ﺮrk6}o$qp"Q+|8 ("썭~O45 eQbc/ PGy7bN7ʴIcp9eGf7 _u$Q-kN@ҭ Ĩȗ Hc'{9p2mZZj b&y$Q. pY'^YOj o_huʫM(p7.[$׫~ͿM? .PZ#{QgD% q;Wy9 ^RU%]IE/y_ Tn[kz-[?-|6RO v9{a5*?{O1ֿ@/mMR񅎟} XmmM<~g_;c| w׍˲y$NJ_Y5Na0T$w90s_;K[CIry8|'=V2?J45GXTӛ<#γ~ϿtB4Eխk-gᓓۆ#~7lh3&:K;.,PdX9;ϏxFXg2iVO!3ʑ>Hyx W'~Ϻ}J/yGWGqj4Y,¡崄w Į0BN*ɥҔN)-s7h<VKTu$G򾇫+w |RNkw5FwV!K-V2VXZ50"2mHmnd٧]oIj=27r{?y:/y5w֮Ueg-77W$:XF1%{b(YC]pU :Q|B\_*^n-jg}m}zWm|)%|\o?G۳hx;_ ƿ~f7Uɋ+71h?~w$7Ox!4ܱ=yzϞyJ44fHs AePnb?Sc|/Kźͣǩ$on.zqx9fs@ }YqM[PpvC0)K~:?=K:OPihY$!f$>R W#ӌKW< >ΤlIbP0y7id~*:rF#F|<+ٿ y?=CX񗎼#5E.X*jz<@#r7P2"Lp _ 5K־)Y.N4pQs%ŬD 5"g `jxv}/TRbn"Kkr ǃ +ݿޯ_[O?3oKk:RK,\T*'}eè|eV23xM ֣gC˹aO!n|f: 9<ֳOrRQu'&S?23yMxIR{w {֙iP<;8¹7B0Z#s2~~4rmoᎂ~=qlT,A.79'5/񶟦Oq;%ME15̻@%.*3 E{j?|)=.\mIuhuHeJ!q!B27S$F'eqZn^׺{|GZ֛ucA?M΅y5~{ T]8}>;xB?94_W$We 8PW?(6xZkYmobcpAf z'wٟl|;?hzMGMy'y;V[&#Zl&aH~uϮN^ԛѧIqkxn,-ds=}FwZ-_.%7zM~Y1hY~"F=.GwB,$2Le!=%k\7>/;mpʯrυUȻG8,Oq3'gdKtNͻ_QhU4^ID ^x=jZmich>m,א gc#5o{l.,!Gìg )<:ӗ __rxt'&Wvs.7UvêY7I7˰8]=B|Եɨ_kRkC-ɼ̉T6w xZV?㷷0B#-ʪ(5b?T䓺=ZLմlnHB\~{[.nGQ)H]X#8+i~ZDV;c`vרlzF]Ӭ>zvnV%^teexdXc`0FM~C7Ř:Jm򖩫(ӟ[F}:Wv?h>&/o,v ʚbVCۿZ\k ٔl 0kt;~RW 6e|=<῅z]MjQU4)-i  FF Qc_wWM|.noYOiZK KKbtZ9.?1\2$aq_=lRZv+6?ʒ:K__?`ax94[}?S}+Z&;0VXݼ7c^Ww|~+vPK}ZN[]F)VEnK UH2Ϥ|I]|  nzezf)$L$[C'r#s?O?4=Zdhi ֠@jdfgako,GzN+Iԃ=^:8iEb]ѥkt,ښO›~nXEԭ6Kn W/V/ك8fxk nڍ~]0=M(dGW +O'Sx'T}aW'^bmI|Cӿi*G[ky? ~2>ѕCq!錬|g~~Ss:7O2ۛJ({?WŸد }#5m|`|@v%؞(DIQƈ Al:_B@C٢,ra$hͻ?.)c~5x_?V1Hn58Q8/Q`,@ e8|]KJRSzY'[knxy' -n=^}YkxgЙGՕrO5W*oh7;Qn;Ok㝚fp鵇׼u~76ht%Z^O$iL_j-7=Jj$ g>dI`S62!I iVtW[ݯS/EU[ednRZκշF35]>W4p꺋+ uѯ76:?hvͭu3Ǘ娐|ۻj4{`+3Y{_Qѵ;xZ[;efD(GRG_O?7s}S{qyK?iS=DW%$b8p)_Y}6 s4XO#l TQ"B"837':f=GGL]~׿MOx{o? .yw[)$cߛ~⻟FKz P= BrWy5ğ[)zī[ccǦ(G ms|NnO:/^$i5 9$]\v&tiJKmf Y{7Ӿx7 ߣ&/1xrVo4nRX<W]oZ{b':r.hwYyʊґ_=kOú׆/;U7[Oa05͸? TčĿa#kI|>/Իz|-!&HKsd .} `q2TRn*]r[kid[{<|T?$'i/ 5"[*r;Aǝn|C?J-=wx<gHm:5S"o,apkF??eVj?'-ǀ52ZwD*/])_D%eڕ_yŗ<6>< >vJ{GƿK߉O5-CIحƧ?u7[,>*#2Z\j LϛqG4\:J$_4?+ yW?1u? 'uӘCpw0ЀC 9pO^gYl<7vgޛV\[gqq}|fX$ux~|E'O~"nu 2vFGH16 Hi\`81aû[o,Y"It|\GhѣcPMx. +E|1 ,x!@# *|N[>JiQ8&[T"55H2<ƶ t%<sZľUhL?J~ڗ(⼷pMaDpWq+7Q/?jRxAY2ìZ\+16VVĪȧ̽|IIp|7r^3uyFvccqb)ٺRMfҳ4,Ŏ=CBw.e2"v5|.ƙ3ݪ #89WKJM&BӠmi0*>h~C[WvN/ﴲ֗% ,,j;1jK"64Iӽ>|euoٔ˼HԱEd^O_"k&؜h$pU a'<ܲL䳵[ ƶk4smd$0HszO״Z2ڂpx=3l/)Wvkw=;Mwޙh[T^Ea+mL\&O <`;[#~fM'G%Gl-O1˓ ,GoNmcPеokP hz8BB mW|K㟇-~xogZ| _F\mo*C N6L #k kSMkO׵jFV-VOq4dAcmY1`s?xTė,fKtgcoc#..Nf$d{%Ib)[ފS=WFJ\n٫ ||OԬm߃]]d>0Gmm,DJ>I4E.e~*xvº%}+B(`@ 0].re9b|շ'䬑iVxd|gGIfx¿ 5Tî8r4lx eJw}c%đd݂($sR~b[j~_b?EDMEi!~p^@S_8䖯sU%(~OI踑۽=}QC߂m:/swWn"\%eA澡c3\4jvg#~RM׵oimUh ,~4 YiV[[ɫ](؜;!%ccWƿ~"|~<?kmj 7Q2dIoA GnznZo{WfVƞ= 8?tT8}?dA}Evne')9IݳB*1m/]|E,fmʌ)s v*J iÿo|9Uh>0&nf:.z:6S2ڻ(HIwn??WU{(3Rxw'+]c'KH;nJ7ue`UE|upZmCǃÿPVm!y$,`TGd yeE`0bҴS|lY^RnjF+_|r-+-C}}R[?8/"[_{* q?wʧRVwoGk]kxHo%BV`EOL?v L.@~l?)9To[I?c?Cb/~#nV>|[nJACX7xI=_Muo73.IԀF [ÑϦ?P>!2ſ MDAd-R#*^!ntw: >'K9DѾd2B$05GeAŎVZ@6ws,\*He#A&]hc)u>yˊA¢3>@iyc±-3 搡(rA@g'Wtt =%pүf(ݷ23\&ÿ~&{6v3o,-stHY m," GQBqTֶ]h>iJԪ[v'yCS.j h\%DW'Wxx0_gad0jk \<1kѿ.@~>!I/h=db1>jɷ5nrW)>8M4YtHg !UDX+ô!%f{b]*4|5  kSR̳op񭝜0hnd;Gυ,! 4>zfe~^uĵ[ 'Ϣ`Og?IA43,0ǹ$G:;W/" c%_6r+[3o8e~>Z o,丸8 I#TP2I'k'|b'""Mf*' R7>P;X? |AfHeFx '"KO0nN_o]Z|$Sqj[[~vO[ĮppJOo#Ok|Ujڍ:kD a;c.~k4W~4Eo-~ӭJ]*:3جM/g^nZݶۻ龚k['ajJ1KK$V]vͳ#o:[\k߶ur}NtBs9%MGx~> _>ѬޯԵ)ys9=Nd$.z"_'S;m.k? ۬;^)v.W),z^iQ@Q@Gym$3F*tqu<Gi ?~FOf}N6Ȥd:y|`_7p~H[𿉭ZNȍ$F+UҀ?.'63\\߱OHO 'ýVl6o <6mOY'}AB@*Oa,{#rhh>G_/{/^:}hm爦mWw Gm3ƭOP7⋳ï[>.&'Xp @1V>&*xz>iTT\fNMnF_I%MkxVl47{xB;|25]ZQ5 TLco%SK84NX-4E)pʬ2Hr:^O|?e4]W%4ۧQc}e|Y4l5K0y3Y8=Ivog`YUvr~~?ˈ_Qcl\mޟsK%ww M|ͭп??m Nmzp1:-;\iON%ݾuW/t o4㸉(G 2@O_^* ^hci:F ;k{WFXV[eN\rQn+UӒO)I:mEM7;?cߊބ>,?"h~k oڭm?>o0GOTb ?  靎k-e'C>$~~wQ&y-mQ L` xۧOXkn[V4NEcKMF'(#Ot.bY#etVSAA~H1>(l ۘ!KE"-?wj~ӟ}i=H״2HvەGK2fm.#8ߎE}s?ˏ?t}'ǭgq;[hZ5T@ev"Ic1Ⱦ>yxVS[hZ{ގ1} */ %<|"Y@OXT>W,*uiNpN= pxxajvM<^@aO=?RsGv$/Iݓ:fQ~1/KA/2:䎃PdG=$Gg|1~+|7h%W;)O[VW8IŶ /6;)TeM˒? +{Eq7J4kK]/YxIhl(U4$2o> DX%uGOHat= =>"^ſ9'=Sqh~*CAح|1j3vUtO(5|im?o~)x^!_:Ѳ81O~xgďkמ,,Ri:tX]iH߹hBm_b[\k>q'٬5kDeC.q7|/iͯ~ߵ'~3wxkiiI8د.^~vsOWFD|[ȸ-pG+pee$[b8íw^4 IXt+$]lDCjҺ8X }<8aZ76a_lu7 L;q#[RWL0|˓H=GύQz2ŗŸ\=mBJt:1oIq~(C^1>OmUd=I߳_w]4ڕ֡D] Q^Ca3fj?>!xI񖩬x&*R-"9΍wqȹ$l~n~Ϻ JHk|o6?d]&@p Ru㆕kl4_ʿ?֔;]Yʘ{W\ ;R|^bGOn-S,$|Eg"ͅt50S!#g # 6 | gew]2N 9BP+=cԼ+ǃv6^eein"5 t@EQEQEQE俶UjJ^ s\B\۹IS'uH |Z?b ?cۢ|zf mE. K`/lFJbA^M˞jxgYd+M2E< zOnωmtM|f{Mvټ>r)KnF rXm_>|,|#cç<?Wki5qsmRU,_ 7_?xgǖ k{5>v*`kdO~ζ?џMi6gi\Oszeu<[2u&*F9FJSU)4c_N:t?Jφ>G$C$FzJ d8+'oƺkKfWC ~Q_b+LV2&< F=V~;-PCՆhV#+r:mp0'o^2 flmerॿ~ |"<3DPmhGRnsA_P&n'{+/BWT12^!oڿ Mkdw^n{ j;8o&9.h54!d|$`kxaqZ?>\L~7qӬw{\*m8B(_4hٗ 3"4/ bo3@m> 륱߯k<9!z6E~n ?|ii/C6>#Ik>fPko=x&~Uc*{X']e( >8|;sǧᧇ+mSXZN-.¨AP+O&_~1ԓ$^C*B`o|/Og/_T*o1|Rj?aj9V\6xTj%gLkjdW|@7?|YMV.Dzb8,$J)_I67߳$S\G "j?L# ٥G9d*w:V=?2j6 z&J5|6y|/m 4"kO}\\KݱӅQ…  7_jW«6j/.kZGrqn m!_P'?_ kχJhjI)%԰H M鱘IӼcp#-gOfa_i6ZDq= wtm|)>IᏊ |Y%;nINFl~L+/?e?Kݸ>EZ"++Wg!뺀>ൟoioxBcž#ٚżGHvAl9m?O8״%f1Wd_Znlw{.HOHaPTW>|XHφ~0|1Lu,Oe4$WizݞmY]^Bz<EZ{RJ3]O Kp?@(3b;xÝax܏l~&6sNflV>d q@o_\Y4\Ax%}pbi~ ڷ%NGxsѾ2Iuxm/+_N7 YHáY5kR?^_i=ɶX~ӫjG3\]yAE{e/:?Ï ~F[{K( {haQ@ jQEQEQEQEQEQEQEQEQEr?߄f%|es⯁49|;ԋ`m!9\ ~@Q~HD)}Yu7Bnw\(_d'Q& j-\3kOP~;&'No2_1íυ-"H[J"Esh?wۢxT{wCIrP?1u?΀>_K WrPqk^o?hxgmϊu ٷ__9tk+ #[ nB_?'jQ!еmZI2ʽ6-[ fum[AyOd?N__JP|ZٟA對j>X{2}kC_m~#x^>/|YVIewkQLc5B?~K@'oكQ|;WnI>TeϻkPEPEPEPEPEPDyK yK https://arkansas.magellanrx.com/provider/docs/rxinfo/PACriteria.pdfyX;H,]ą'cDyK yK https://arkansas.magellanrx.com/provider/docs/rxinfo/ClaimEdits.pdfyX;H,]ą'cDyK yK https://arkansas.magellanrx.com/provider/documents/yX;H,]ą'cDyK yK xhttps://medicaid.mmis.arkansas.gov/default.aspxyX;H,]ą'cr$$If!vh#v #v\#v:V l4O*++,5 5\5af4ytZr$$If!vh#v #v\#v:V l4*++,5 5\5af4ytZ ~s666666666vvvvvvvvv666>66666666666666666666666666666666666666666666hH66666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ OJPJQJ_HmH nH sH tH L`L MNormal$CJOJPJQJ_HaJmH sH tH DD z" Heading 1 $@&a$ CJ0OJQJJ@J M Heading 2 $@&a$5CJ0OJQJ\RR z" Heading 3$<@&5CJOJQJ\aJDA D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List R/R MHeading 2 Char5CJ0OJPJQJ\^JaJ4 @4 MFooter !F/F M Footer CharCJOJPJQJ^JaJH"H M Balloon TextCJOJQJ^JaJR/1R M0Balloon Text CharCJOJPJQJ^JaJL/AL z"Heading 1 CharCJ0OJPJQJ^JaJR/QR z"Heading 3 Char5CJOJPJQJ\^JaJ4@b4 z"0Header !F/qF z"0 Header CharCJOJPJQJ^JaJ6U`6 z"0 Hyperlink >*B*ph^/^ z" EmailStyle191+567>*B*CJOJQJ\]aJph<< z"ctextx<7$8$OJ QJ >> z" Footnote TextCJaJT/T z"Footnote Text CharCJOJPJQJ^JaJ@& @ z"Footnote ReferenceH*.). z" Page NumberBBB z" Body Texta$5OJ QJ aJP/P z"Body Text Char5CJOJ PJQJ ^JaJ<@< z" List Paragraph!^>"> z" listparagraph"^PJ*/1*z"Style1# FJBJ z"Default$7$8$B*OJPJQJ^JphFV QF z"0FollowedHyperlink >*B* phFPbF 'z" Body Text 2&5CJOJ QJ aJP/qP &z"Body Text 2 Char5OJ PJQJ ^JaJ>>> )z"Title(a$5CJOJ QJ aJD/D (z" Title Char5OJ PJQJ ^JaJFABF z"0Pa1 *dH$B*OJ PJQJ ^Jph8/8 z"0A25B*CJ0\^J aJ0ph.X . z"@Emphasis6]B' B z"Comment ReferenceCJaJ<< /z" Comment Text.CJaJR/R .z"Comment Text CharCJOJPJQJ^JaJ@j@ 1z"Comment Subject05\^/^ 0z"Comment Subject Char5CJOJPJQJ\^JaJ# z" Table Grid7:V20 2dCJOJPJQJ^JaJ\\\4z"0 z-Top of Form3Pa$<CJOJQJ^JaJX/AX 3z"0z-Top of Form Char<CJOJPJQJ^JaJb]b6z"0z-Bottom of Form5Na$<CJOJQJ^JaJ^/a^ 5z"0z-Bottom of Form Char<CJOJPJQJ^JaJXrX z"font57dd[$\$#5B*CJOJQJ\^JaJphXX z"font68dd[$\$#5B*CJOJQJ\^JaJphvv z"xl65/9dd9DM Q[$\$a$#5B*CJOJQJ\^JaJphnn z"xl66-:dd9DPQ[$\$a$B*CJOJQJ^JaJph z"xl67B;dd9DM NOQ[$\$#5B*CJOJQJ\^JaJph66 z"xl68<dd9D[$\$66 z"xl69=dd9D[$\$ z"xl70B>dd9DM NOQ[$\$#5B*CJOJQJ\^JaJph z"xl71B?dd9DM NOQ[$\$#5B*CJOJQJ\^JaJphJJ z"xl72@dd9D[$\$CJOJQJ^JaJxx z"xl73BAdd9DM NOQ[$\$CJOJQJ^JaJ" z"xl74@Bdd9DNOPQ[$\$B*CJOJQJ^JaJpht2t z"xl75@Cdd9DNOPQ[$\$B*CJaJphbBb z"xl76@Ddd9DNOPQ[$\$R z"xl77@Edd9DNOPQ[$\$B*CJOJQJ^JaJphb z"xl78CFdd9DNOPQ[$\$a$B*CJOJQJ^JaJph~r~ z"xl798Gdd9DNOP[$\$a$#5B*CJOJQJ\^JaJphtt z"xl80-Hdd9DNP[$\$a$#5B*CJOJQJ\^JaJphtt z"xl81-Idd9DPQ[$\$a$#5B*CJOJQJ\^JaJphhh z"xl82"Jdd9DP[$\$a$#5B*CJOJQJ\^JaJph^^ z"xl83Kdd9D[$\$a$#5B*CJOJQJ\^JaJph~~ z"xl848Ldd9DNPQ[$\$a$#5B*CJOJQJ\^JaJphzz z"xl85CMdd9DNOPQ[$\$a$CJOJQJ^JaJzz z"xl86CNdd9DNOPQ[$\$a$CJOJQJ^JaJ z"xl87POdd9DM NOPQ[$\$a$#5B*CJOJQJ\^JaJph z"xl88CPdd9DNOPQ[$\$a$#5B*CJOJQJ\^JaJph z"xl89CQdd9DNOPQ[$\$a$#5B*CJOJQJ\^JaJph" z"xl90CRdd9DNOPQ[$\$a$B*CJOJQJ^JaJphn2n z"xl918Sdd9DOPQ[$\$a$CJOJQJ^JaJxBx z"xl928Tdd9DOPQ[$\$a$B*CJOJQJ^JaJphxRx z"xl938Udd9DOPQ[$\$a$B*CJOJQJ^JaJph~b~ z"xl948Vdd9DNPQ [$\$a$#5B*CJOJQJ\^JaJphr z"xl95PWdd9DM NOPQ[$\$a$#5B*CJOJQJ\^JaJphnn z"xl968Xdd9DNOQ[$\$a$CJOJQJ^JaJxx z"xl978Ydd9DNOQ[$\$a$B*CJOJQJ^JaJphxx z"xl988Zdd9DNOQ[$\$a$B*CJOJQJ^JaJphvv z"xl995[dd9DNOQ[$\$B*CJOJQJ^JaJphxx z"xl1005\dd9DNOQ[$\$B*CJOJQJ^JaJphll z"xl1015]dd9DNOQ[$\$B*CJaJphZZ z"xl1025^dd9DNOQ[$\$xx z"xl1035_dd9DOPQ[$\$B*CJOJQJ^JaJphxx z"xl1045`dd9DOPQ[$\$B*CJOJQJ^JaJphll z"xl1055add9DOPQ[$\$B*CJaJphZ"Z z"xl1065bdd9DOPQ[$\$2 z"xl107@cdd9DNOPQ[$\$B*CJOJQJ^JaJphB z"xl108Mddd9DM NOPQ[$\$#5B*CJOJQJ\^JaJphvRv z"xl109@edd9DNOPQ[$\$B*CJaJphb z"xl110Mfdd9DM NOPQ[$\$B*CJOJQJ^JaJphr z"xl111Pgdd9DM NOPQ[$\$a$B*CJOJQJ^JaJph z"xl112Phdd9DM NOPQ[$\$a$B*CJOJQJ^JaJphZZ z"xl113"idd9DP[$\$a$CJOJQJ^JaJ|| z"xl114Cjdd9DNOPQ[$\$a$CJOJQJ^JaJ z"xl115Ckdd9DNOPQ[$\$a$B*CJOJQJ^JaJphpp z"xl1168ldd9DOPQ[$\$a$CJOJQJ^JaJ|| z"xl117Cmdd9DNOPQ [$\$a$CJOJQJ^JaJpp z"xl1188ndd9DNOQ[$\$a$CJOJQJ^JaJzz z"xl1198odd9DNOQ[$\$a$B*CJOJQJ^JaJph|| z"xl120Cpdd9DNOPQ[$\$a$CJOJQJ^JaJ z"xl121Mqdd9DM NOPQ[$\$CJOJQJ^JaJ" z"xl122Mrdd9DM NOPQ[$\$#5B*CJOJQJ\^JaJph2 z"xl123Psdd9DM NOPQ[$\$a$#5B*CJOJQJ\^JaJphB z"xl124Mtdd9DM NOPQ[$\$#5B*CJOJQJ\^JaJphpRp z"xl1258udd9DNOP[$\$a$CJOJQJ^JaJfbf z"xl126-vdd9DNP[$\$a$CJOJQJ^JaJprp z"xl1278wdd9DNPQ[$\$a$CJOJQJ^JaJDD yz" No Spacingxm$OJQJ_H aJR/R xz"No Spacing CharCJOJPJQJ^J_H aJP Px0Revisionz$CJOJPJQJ_HaJmH sH tH  qsup  quboldB B fJ0Placeholder Text B*phPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VvnB`2ǃ,!"E3p#9GQd; H xuv 0F[,F᚜K sO'3w #vfSVbsؠyX p5veuw 1z@ l,i!b I jZ2|9L$Z15xl.(zm${d:\@'23œln$^-@^i?D&|#td!6lġB"&63yy@t!HjpU*yeXry3~{s:FXI O5Y[Y!}S˪.7bd|n]671. tn/w/+[t6}PsںsL. J;̊iN $AI)t2 Lmx:(}\-i*xQCJuWl'QyI@ھ m2DBAR4 w¢naQ`ԲɁ W=0#xBdT/.3-F>bYL%׭˓KK 6HhfPQ=h)GBms]_Ԡ'CZѨys v@c])h7Jهic?FS.NP$ e&\Ӏ+I "'%QÕ@c![paAV.9Hd<ӮHVX*%A{Yr Aբ pxSL9":3U5U NC(p%u@;[d`4)]t#9M4W=P5*f̰lk<_X-C wT%Ժ}B% Y,] A̠&oʰŨ; \lc`|,bUvPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!R%theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] _:_b>:<A< ^^^? I r os,mD W!$%&''h*+,n.2367:;C>@BEHJLMNUQ%SU0VYZ^`vbeklnqtvw|HEb?W:GIJKMNOPRSUVWXY[\]^_abcdeghijlmnoqrsuvwxy{|} QpS%9,D3<DMTZab}=S7:HLQTZ`fkptz~Ijll mst3twww:XXXXXLSU! ?R$i0 ̤%-qm< R$8'0BvS ;YܣVA R$M~"Text Box 4C"î?PK!8[Content_Types].xmlAN0EH%N@%邴K@`dOdlyLhoDX3'AL:*/@X*eRp208J妾)G,R}Q)=HiҺ0BL):T뢸WQDY;d]6O&8* VCLj"󃒝 yJ.;[wIC_ :{IOA !>Ø4 p;fɑ3׶Vc.ӵn(&poPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK!p@drs/e2oDoc.xmlTn0 ?Nd͌:E"À-=+\EARcw_'9NnaIujvP7d >p1aJɨ*ϯW?\u6W3I11>lle^֪20VZtCVgs֑+#` UU`x[HK>JNغgxE+P7"?Bt ڌ*ՀjwjaU&ʻÃcMY9gFQ}cw:sv,rm;zm &r\N` goMQˢPpROև:Bb6CFD6Cr<<馌ֈ>A`Zȟ{M43|(~1{*_GO#i|8"݀ޮ_LľDӞ(:nf\s=PK!Zdrs/downrev.xmlLN0DHH\P4 ITq ѣ/IDl5rێf4;^';08Rg Zgmg5=:B`\^Ժ2LxNp J+c*)Cۣa&$>:4^܎2ϲ[i@>~VS%Ǘ'|.7v(u}W "<tpG2A fw,X>QȦPK-!8[Content_Types].xmlPK-!8! /_rels/.relsPK-!p@.drs/e2oDoc.xmlPK-!Zdrs/downrev.xmlPK   A6?6"Suzette Bridges - initialsPicture 3Suzette Bridges - initials#" ?B S  ?FvY:Zt0c$T^ t@t@ _Toc4010576579;09;08;DV^ Y b & ?EKT06 8>)1U\bi4:=Fou9!?!!!!!"""""""#D$L$j$r$%%&&''6)>)*%*(*+*,*2*D*K*++',.,`-g-H.N.Q.Z.../&/'/////m0q022223333335586@6'8/899 992999;;>>????AAAAOBVBCCsGGHHHH#I-IUJ\J_JmJJJJJKKKKLLMMM'M\McMMMSNUNNNNNOOPPQR RR=RERMRZR[SqSSSSSSS%T1TETMTjTrT2V:Vvl m mmww?ABDEGHJK؃ك8;fn++h^o^vw~~?ABDEGHJK؃ك8;3333FG,5JMVk9#f#)*.E.U3388}<<%JRJLMQQWW0Y]YvYwY__ ``/c\ccch:hvlll mTvTvwwww>?;G>PWItkt"> ̇ mpHAcc)U6@Hi*biF~f79G&Ӭu|^H ddJlr YT# ZvU1@'W ?>e™~j'py||nCDM}( ^`OJQJo(p^p`OJ QJ ^J o(o @ ^@ `OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(P^P`OJ QJ ^J o(o  ^ `OJQJo(h^h`5.8^8`.L^`L. ^ `. ^ `.xL^x`L.H^H`.^`.L^`L.^`5o()^`56. pL^p`LOJQJo(@ ^@ `.^`.L^`L.^`.^`.PL^P`L.8^8`)^`. L^ `L. ^ `.x^x`.HL^H`L.^`.^`.L^`L. ^`OJQJo(p^p`OJPJQJ^Jo("  @ ^@ `OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(P^P`OJ QJ ^J o(o  ^ `OJQJo(8^8`5)^`. L^ `L. ^ `.x^x`.HL^H`L.^`.^`.L^`L. ^`OJQJo( ^ `OJ QJ ^J o(o  ^ `OJQJo( x^x`OJQJo(H^H`OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo( p^p`OJQJo(@ ^@ `OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo( P^P`OJQJo( ^ `OJ QJ ^J o(o ^`OJQJo(h^h`)^`)8^8`)^`()^`()p^p`() ^ `.@ ^@ `. ^ `.8^8`5)^`. L^ `L. ^ `.x^x`.HL^H`L.^`.^`.L^`L.0^`0o(.^`. L^ `L. ^ `.x^x`.HL^H`L.^`.^`.L^`L.^`.p^p`.@ L^@ `L.^`.^`.L^`L.^`.P^P`. L^ `L. ^`OJQJo(p^p`OJ QJ ^J o(o @ ^@ `OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(P^P`OJ QJ ^J o(o  ^ `OJQJo(8^8`)^`. L^ `L. ^ `.x^x`.HL^H`L.^`.^`.L^`L.^`o(. ^ `. L^ `L.x^x`.H^H`.L^`L.^`.^`.L^`L. ^`OJQJo(p^p`OJ QJ ^J o(o @ ^@ `OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(P^P`OJ QJ ^J o(o  ^ `OJQJo( ^`OJQJo( ^ `OJ QJ ^J o(o  ^ `OJQJo( x^x`OJQJo(H^H`OJ QJ ^J o(o ^`OJQJo( ^`OJQJo(^`OJ QJ ^J o(o ^`OJQJo(|^HGy||"> I@Hi*Acc)CDM} ?>eddJ~j'p79GiF@'WZvU YT         6]D         2F                 *f       J                          衬                                           t0                          N:ispJ1^4E%`O%>^1 ^- ^1  scRR\ :i`ObQf|RT ^/ E%ChnJA7+ ` T)*\>R{^ T){`{`Ccx ^5FC w\!{=(_$Js&"V(w])VR*,-1^4>h.3 !03<7jJ6<74Q4DJA7<.Qk;8y|N:-4h8B8n9+ `"K9y|N:rLh%>B8/ TAu!zbA)2CAm4Q4Db/ }Ee+G OTA<.Q)2CscR}E/ ~1U$4Y O]Evw6^R{^jJ6/ {=(_,-w` bfrLh]ChV-|/ KllbAAmcuqsp\>4Hq>h.cuqf/ SvlBvEvn/ ww`Ccx5/ u!zRTOR{ JB|V-| -}Ur $7T/fk2f1V_]  ~ *2EJk_q78 gH g  / j  2 D7<9qa&p+{3A&,cw-kEY //Xn0 2ppir4? ~M_es1|.@y|*||oem&ve+r-U@b+!Et!!z"/#84#6#'=#=#b#l#z#$$d$:$>$SN$f$^}$ %u%T%n%-w%& U&K.'5I'(6(z(~()* *H*V* +9++10+m,;,-L-T-W//U/]/d11fC1E1P1T1&2S!2<2J3 55=5I5K5Cc5`6k6[n6p78;8%O8[8Nn8Pn8uI9#:p:p:;*;+;N;^;w;~;&<=L<kK=U>?;R?@OQ@~R@ @AwB]UBCC;CIUCD8FDcDEqE FFFVF2FLFMFOFjF?oFO"GBIfIk/I;I PIYmIi^J_J$KK%KiGK }KOMUMOZM>nM22N<O2OrfOPesP*QR4R*RWd6 *C8ZMbYX0"7>Chiu$)(6[mWQoxdy;|<||ExUMex56#2BK`bp"1JwKZ]gw\iK,l9W\vzz'{>Ha%9 =?`guj^hlUnp(z8A,QeDhz/PLJX-g9}UeNo^+,L>RgPD RgbvMF* ef 0J\eh'l:MD^W hhx !8;"?nz}VYq*r,S$(| tLhmGfJ"W[g=BpDhQ|32bor^+py,PU`Hc?/T'X/oy@#4/,[lz\4=%{zQK'x|KO^{V#c<AH[j]1451?sBHc2&8Y.f6L>m)>zNOTyEB_WIGW7+0eLrK Q!bY UW#eJ%y^z1}&UqkIZilt07MqN kBM2D`[_$/bz'Y*;AOZx,{F|?A@(:p@pp@@UnknownG*Ax Times New Roman5Symbol3. *Cx ArialQ. Franklin Gothic DemiEAGaramond Bold7.@Calibri7@Cambria5. .[`)Tahoma7Georgiaa LLBKHM+ArialTimes New RomanCN@Comic Sans MSK,Bookman Old Style=* Myriad Pro?= *Cx Courier New;WingdingsA$BCambria Math"1h+*8gcpn B~ o B!20\JQX $PM xx DAR Medicaid DUR Board Edits Approved at the October 15, 2014 MeetingP        #    Oh+'0 $0 P \ ht|HAR Medicaid DUR Board Edits Approved at the October 15, 2014 Meeting Normal.dotm1Microsoft Office Word@@@^o pn՜.+,D՜.+,\ `hpx  B EAR Medicaid DUR Board Edits Approved at the October 15, 2014 Meeting Title 8@ _PID_HLINKSA$-" 0https://medicaid.mmis.arkansas.gov/default.aspxZ9 .http://www.uams.edu/cdh1/peds_guidelines.aspx,|4https://arkansas.magellanrx.com/provider/documents/coDhttps://arkansas.magellanrx.com/provider/docs/rxinfo/ClaimEdits.pdfmfDhttps://arkansas.magellanrx.com/provider/docs/rxinfo/PACriteria.pdfD "https://www.medicaid.state.ar.us/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%'()*+,-4Root Entry Fஓ6Data 1Table2WordDocumentɎSummaryInformation(DocumentSummaryInformation8&CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q